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ABSTRACT
Staphylococcus aureus is known to cause severe systemic infection with high
mortality rates. Antibiotics are the only approved therapy for patients, but the
widespread prevalence of antibiotic-resistant strains limits treatment efficacy, and many
patients succumb to the disease. Many probiotic agents are commercially available, but
the mechanisms by which they benefit are not known. Understanding these mechanisms
will help develop novel therapeutics that can improve healthcare, including systemic
infections by S. aureus.
Bacillus subtilis is a probiotic bacterium that produces an exopolysaccharide
(EPS) that induces anti-inflammatory macrophages (MΦ). We tested if EPS could be
used for systemic S. aureus infections in mice and found that EPS-treated mice had
improved outcomes, reducing bacterial load and inflammation. We tested for the
mechanism behind this protection and found that EPS-induced MΦ, while they
resemble anti-inflammatory M2 MΦ, restrict the growth of internalized S. aureus
through reactive oxygen species like that of pro-inflammatory M1 MΦ. In addition, EPSinduced MΦ retained their anti-inflammatory capacity to limit T cell activation in
response to S. aureus superantigens, suggesting that EPS-induces a “hybrid” MΦ
population with both M1- and M2-like qualities, limiting S. aureus growth. In vivo, we
found that S. aureus induces interferon gamma (IFN-γ) production through natural
killer (NK) cells, a way to manipulate the host immune system for its own pathogenesis.
Furthermore, EPSxx

treated mice did not make IFN-γ in response to S. aureus, suggesting that EPS protects
hosts from S. aureus also by limiting IFN-γ production.
We suggest that EPS primes the host immune system to bolster its antimicrobial
activity and also limit inflammation, which prevents S. aureus from manipulating the
host response for its own pathogenesis, leading to reduced disease burden and
improving outcomes. By our understanding of EPS mechanism for protection, we have
identified a potential strategy to help patients with systemic S. aureus infection.

xxi

CHAPTER ONE
REVIEW OF LITERATURE
A Brief History of Probiotics
Human beings come in contact with microbes ubiquitously throughout their
daily lives. A common way by which people encounter microbes is through consumption
of fermented food products, depicted even in ancient Egyptian hieroglyphs. Many
cultures have adopted fermented food products in their diet, probably due to
fermentation being used as a method for food storage. Today, a variety of different
fermented food products are readily available due to extensive globalization. In addition,
recent advances in our knowledge of the microbes that mediate fermentation have
pointed to the potential health benefits of fermented food products, and with the
emergence of the wellness industry, microbial encounter through consumption of
fermented food products is more widespread than ever.
While the story of fermentation through microbes originates from early human
history, the microbes that mediate host benefits were not appreciated until more
recently. The first probiotic, microbes that benefit the host, was not conceptualized until
Élie Metchnikoff associated lactic acid-producing bacteria, termed Bulgarian bacillus at
the time, in yogurt with longevity of life in 1908 (Metchnikoff, 1908). The first accepted
trial with probiotics was reported in 1922 when Leo Frederick Rettger and Harry A.
Cheplin observed apparent improvements in chronic constipation, diarrhea, and eczema
in 30 patients through administration of Lactobacillus acidophilus
1
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(Rettger and Cheplin, 1921), though it should be noted that randomized clinical trials
using placebos were not standard until about the 1950s. Since then, the number of
publications and randomized clinical trials related to probiotics has surged, especially
since the 2000s (McFarland, 2015). Today, a variety of probiotic products are readily
available to the public commercially, behind an industry with an estimated value of $87
billion (Stanton et al., 2001). Despite widespread use for apparent health benefits, the
specific mechanisms that underlie these benefits are generally not clear, limiting the use
of probiotics in mainstream healthcare settings since measuring efficacy and predicting
potential adverse effects are difficult. Therefore, understanding the underlying biology
of probiotics and their interactions with the host is critical for transforming beneficial
microbes into a novel sector of healthcare innovations.
Probiotic Mechanism of Action: Colonization Resistance
Microbial Colonization of the Gastrointestinal Tract
Most studies of probiotics and their mechanisms of action focus on the
gastrointestinal (GI) tract, as many probiotic organisms have been isolated from the GI
tract and are administered orally such as Henry Tissier’s Bifidobacterium bifidum,
Alfred Nissle’s Escherichia coli Nissle 1917, and Minoru Shirota’s Lactobacillus casei
subspecies Shirota. The GI tract hosts a significant number of microbial cells, a number
estimated to equal the number of human cells in the entire body (Sender et al., 2016).
However, different sections within the GI tract provide diverse environmental
conditions for which microbes must adapt. In the oropharyngeal lumen, salivary
secretions contain a variety of digestive enzymes that dictate the kinds of nutrients that
are available. In addition, saliva contains antimicrobial molecules such as lysozyme and
peroxide, dictating what kind of microbes can survive within the oropharyngeal mucosa.

3

In the gastric tissue, parietal cells produce hydrochloric acid that lowers luminal pH to 1,
a major adaptive barrier for microbes. In fact, a major quality of what is considered a
“good” probiotic is the ability to survive passage through the acidic gastric lumen, so
they could efficiently colonize the lower GI tract (Hill et al., 2014). The small intestine is
subject to many digestive enzymes and molecules such as pancreatic secretions, bile
secretions, and brush border enzymes intrinsic to the small intestines. Like in the
oropharynx, these enzymes dictate the types of nutrients available and subsequently put
selective pressure on microbes to adapt. In addition, bile acids can have antimicrobial
activities (Binder et al., 1975), which put additional selective pressure on microbes. Also,
the lower GI tract is under massive immune surveillance that the microbes must deal
with to avoid elimination from the GI mucosa. As for the colon, a key distinguishing
environmental feature is the low oxygen content, measured at below 1 millimeter
mercury (mmHg) (Albenberg et al., 2014). Consequently, anaerobic bacteria are
enriched in the microbiome of the colon (Hugon et al., 2015; The Human Microbiome
Project Consortium, 2012). While the lower GI tract is the most densely colonized, it
should be noted that microbes are not limited to the GI tract. In fact, the microbiome
exists within other organs as well, including skin, upper and lower respiratory tracts,
and genitourinary tract, each with its own environmental factors that require their own
specific adaptations for microbial survival (The Human Microbiome Project Consortium,
2012). The diversity of the microbiota is further enhanced because each organ harbors
specialized spaces with distinct environments. While one would typically assume an
oxygen-rich environment in the oropharyngeal mucosa as it shares space with the upper
airways, certain places such as the deep crypts of tonsils harbor a robust community of
anaerobic microbes (Brook, 1981), indicating an anaerobic microenvironment within the
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tissue. In the gastric tissue, the lumen generally measures at low pH as discussed above,
but it is thought that the pH may be less acidic in spaces juxtaposed to the gastric
epithelium due to bicarbonate secretion by the non-parietal cells, assumed to be a
mechanism to protect gastric epithelium from acidic damage (Flemström, 1977). This
creates a microenvironment distinct from the lumen of the gastric tissue, where the pH
is relatively less acidic and allows for bacteria to survive and colonize. These
microenvironments are also subject to modulation by host physiology and behavior
since neutralization of gastric acid often occurs in patients given proton pump inhibitor
therapy which can cause a 104-fold increase in gastric luminal pH with just a single dose
(Laine et al., 2008). Therefore, while a vast number of microbes colonize a variety of
different parts of the human body, they do so specifically within given
microenvironments, termed niches, with specific adaptations to the nutrients and other
factors particular to that niche. As such, microbes must compete with other microbes, as
well as with the host, for limited space and nutrients to survive. To this end, many
probiotics have adapted specific strategies to outcompete other microbes, and through
many of these mechanisms, probiotics can limit colonization of host by pathogens. The
ability of the host and its microbiota to not allow colonization by pathogens is termed
colonization resistance, the very first mechanism by which probiotics were thought to
benefit the host as conceptualized by Metchnikoff, to prevent colonization by microbes
that promoted putrefaction of the GI tract (Metchnikoff, 1908).

5

Direct Competition of Microbes
Today, there are many mechanisms described by which microbes compete
against other microbes. Lactobacilli are the prototypic probiotic bacterium studied early
on in the field, aptly named for their production of lactic acid through their metabolic
processes, which gave the sour taste associated with probiotic-containing foods. Lactic
acid production reduces pH, as low as pH 4.5 in the female genitourinary tract in
humans (Andersch et al., 1986), which limits the growth of other bacteria not adapted
for acidic conditions; presence of Lactobacilli and low pH in the female genitourinary
tract was associated with reduced risk for bacterial vaginosis (Spiegel et al., 1980). This
acid production or “souring” quality in milk was originally the quality associated with
the beneficial activity (Rettger and Cheplin, 1921). Still, acid production is not the only
mechanism by which Lactobacillus species can compete against other bacteria.
Lactobacilli can use oxygen as the terminal electron acceptor for its metabolism through
flavoproteins that catalyze the formation of hydrogen peroxide (H2O2) that can be toxic
to other microbes (Eschenbach et al., 1989). The spent culture medium of Lactobacilli
was demonstrated to have antibacterial activity on Staphylococcus aureus in vitro
(Dahiya and Speck, 1968). This effect was ameliorated by treating the spent medium
with catalase, an enzyme that converts H2O2 to water and oxygen, indicating that H2O2
was responsible for the antibacterial activity of Lactobacilli. Though the specific
molecules and modifications affected by H2O2 in target microbes are not known, it is
generally thought that the oxidative damage from superoxide radicals derived from the
peroxide disrupts cellular processes, leading to bactericidal or bacteriostatic activity
(Dahiya and Speck, 1968; Thomas et al., 1994).
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Lactobacilli also produce other factors that confer a broad antibacterial activity
in vitro, as L. acidophilus LA1 was shown to secrete molecules that inhibit growth of
many gram positive and gram negative pathogens such as Listeria monocytogenes, S.
aureus, Salmonella typhimurium, and Pseudomonas aeruginosa, though the molecules
that mediate this antibacterial activity have not been identified (Bernet-Camard et al.,
1997).
Within the niche, microbes compete for nutrients against each other and against
the host as well. The fiercest competitions occur over trace nutrients such as metals that
serve as cofactors in many biological processes. Iron is the best studied of these and is
actually one of the most abundant elements on Earth (Morgan and Anders, 1980),
though most are inaccessible to biological entities. Many forms of life require relatively
high concentrations of iron, but iron is quite insoluble under physiologic conditions.
Ferric iron, the free aqueous form, have an estimated solubility at attomolar (aM, 10-18)
concentrations. The host also requires iron for many physiologic processes, and
therefore absorbs much of the dietary iron in the proximal small intestine and tightly
regulates circulating iron levels to avoid toxicity. Therefore, iron is very limited in the
extracellular space, which also serves as a host defense mechanism to limit bacterial
overgrowth and virulence, and patients under iron overload conditions often fare worse
during infection (Barry and Reeve, 1977). Bacteria have developed many iron acquisition
systems designed to scavenge iron from the environment, with the best-characterized
system being the siderophores. Siderophores are essentially metal-binding chelators
secreted by the bacteria, with an affinity for iron that generally thought to exceed host
iron chelators like transferrin (Fetherston et al., 2010). Once the iron-siderophore
complex is formed, bacteria take up the iron through active transport using specific
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transporter systems (Bäumler et al., 1998). By sequestering the trace iron from the
environment, uptake of iron by a probiotic bacterium can contribute to iron limitation
within the niche, potentially limiting the growth of pathogens. An example of this is
demonstrated in E. coli Nissle 1917, a probiotic strain of E. coli isolated from a soldier
who was thought to be resistant to an outbreak of diarrhea by Alfred Nissle in 1917.
Administration of E. coli Nissle 1917, but not a mutant defective in iron-acquisition,
reduced colonization by the enteric pathogen S. typhimurium in a murine model (Deriu
et al., 2013), demonstrating an ability of a probiotic to outcompete an already
established pathogen through iron sequestration. As discussed above, iron is not the
only trace metal for which the bacteria compete. In the case of Campylobacter jejuni, a
commensal bacterium in the GI tract of chickens, successful colonization depends on its
zinc acquisition system in normal chickens but not in germ-free chickens, indicating
that C. jejuni uses its zinc acquisition system for colonization when zinc is limited due to
microbial competition (Gielda and DiRita, 2012). It should be noted that metal
acquisition can have effects beyond the context of microbial competition, since in many
pathogens the levels of intracellular metals dictate expression of virulence factors
(Fetherston et al., 2010; Kirienko et al., 2013; Martin et al., 2013; Peralta et al., 2016).
Therefore, one way probiotics could benefit hosts through metal sequestration may also
be through suppressing virulence of pathogens by limiting their acquisition of metals.
There are also more direct mechanisms by which bacteria compete with others,
such as bacteriocins that directly kill other bacteria. Bacteriocins are a broad group of
peptides secreted by bacteria that kills targets but not the producer, due to the presence
of immunity proteins. Due to their heterogeneous nature, the mechanisms of action for
bacteriocins are quite diverse, though many mechanisms resemble those of current
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antimicrobial agents such as inhibition of peptidoglycan synthesis, pore formation,
inhibition of deoxyribonucleic acid (DNA) gyrase, and inhibition of protein synthesis
(Diep et al., 2007; Kobayashi et al., 2010; Parks et al., 2007; Piper et al., 2009).
Lactobacillus salivarius subspecies salivarius UCC118 is a probiotic that produces the
bacteriocin ABP-118 that has antibacterial activity against L. monocytogenes in vitro
(Flynn et al., 2002), demonstrating the potential for probiotic bacteriocin-mediated
inhibition of a pathogen. Still, the most interesting aspect of bacteriocins is that they are
genetically amenable for engineering, due to their proteinaceous nature. This potential
is best demonstrated in heterologous expression of ABP-118 in other bacteria such as
Lactobacillus plantarum and Lactobacillus lactis (Flynn et al., 2002), showing that
probiotics could be engineered to produce bacteriocins to target specific pathogens. Still,
the direct antibacterial activities of bacteriocins could give rise to resistant pathogens
through mutations, primarily the same concern with any novel antimicrobial agents. In
summary, probiotic bacteria use a variety of mechanisms to compete within the niches,
and through these mechanisms, contribute to host resistance to colonization by
pathogens.
Competition in the Context of the Microbiota
Lactobacilli were the first probiotic embraced by the mainstream scientific
community and have been studied for more than a century (Lee et al., 2019; Metchnikoff,
1908; Rettger and Cheplin, 1921). The principal mechanism by which they benefit is
thought to be by directly limiting the growth of pathogenic microbes through the ways
described above. Under this scenario, orally administered Lactobacillus probiotic would
survive the harsh conditions of the upper GI tract and colonize the lower GI tract with
great efficiency where it would mediate its beneficial effects; this trait of a probiotic is
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stressed even in the most recent definition of what constitutes a “good” probiotic (Hill et
al., 2014). Initially, Lactobacilli were reported to represent the majority of the culturable
bacteria from human feces (Rettger and Cheplin, 1921). Of course, anaerobic culture
techniques were not developed until the 1960s, and studies after this era demonstrated
that orally administered Lactobacilli species only form marginal populations within the
human GI tract, at best estimated to be 0.01% of culturable bacteria (Dal Bello et al.,
2003; Finegold et al., 1974). This observation from multiple studies accounting for
anaerobic bacteria seemed inconsistent with the idea that Lactobacilli exclude
pathogens in the GI tract through direct competition, given that other bacteria made up
the dominant population. Since then, many probiotics have been screened for
colonization efficiency (Jacobsen et al., 1999). For example, specific strains of
Lactobacillus probiotics with high colonization efficiency such as Lactobacillus
rhamnosus GG have been identified, and have been the focus of probiotic studies
(Canani et al., 2015; Jacobsen et al., 1999; Yan et al., 2016).
The GI tract harbors a complex community of microbes, collectively termed the
microbiota, that in recent years gained appreciation for its ability to affect host
physiology in virtually every organ system (Abrams and Bishop, 1967; Atarashi et al.,
2011; Furusawa et al., 2013; Mazmanian et al., 2008; Al Nabhani et al., 2019; Sharon et
al., 2010; et al., 2015; Tyagi et al., 2018). The underlying mechanisms by which the
microbiota affect host physiology are not entirely clear, but it is well accepted that the
different composition of the microbiota correlates with the different physiologic
conditions or processes, including colonization resistance against pathogens. Likely,
host environmental contact plays a great role in the composition of the microbiota, as it
would dictate what microbes are introduced into the system. Once exposed, host factors
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such as barriers, nutrient availability, already existing microbes within the host, and
immunity would select certain microbes for colonization in various niches. Within
niches, individual microbial members compete with one another to dictate which would
successfully occupy the niche, forming the microbiota. Some members of the microbiota
could indirectly affect the microbial composition by affecting host physiology, altering
the niche microenvironment. Therefore, a vast number of relatively simple mechanisms
from individual microbes combine to form a complex network of interactions that likely
dictate the overall composition of the microbiota within the host. In turn, this may
suggest that the introduction of a relatively minor member such as a Lactobacillus
probiotic into the GI tract could have profound downstream effects on pathogen
exclusion through the change in microbial composition in response to Lactobacilli or
other probiotics. Of course, the exact composition of the microbiota responsible for
pathogen exclusion is not known, and how probiotics specifically alter the composition
of the microbiota has not been extensively studied. For now, there is an interest in using
a combination of probiotic organisms to benefit hosts such as VSL#3 (Gionchetti et al.,
2000) that is commercially available, with the idea that by providing multiple agents of
supposedly “good” bacteria, more beneficial mechanisms could be deployed, and better
host colonization resistance against pathogen could be achieved. Understanding the
dynamics of microbial composition in the context of host resistance to pathogens will be
needed to understand better the full range of ways probiotics could promote exclusion of
pathogens.
Ironically, the most successful form of microbial therapy designed to alter the
microbial composition is one of the oldest: fecal transplantation. Fecal transplantation
involves the transfer of fecal matter and its microbial content from a healthy donor to a
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recipient in an attempt to treat disease and is supposedly documented in a 4th-century
traditional Chinese medicine textbook (Zhang et al., 2012). In the modern era, fecal
transplantation is most often used to treat Clostridium difficile infection (CDI), a severe
diarrheal disease in patients after antibiotic use due to GI dysbiosis. CDI patients are
initially treated with antibiotics which is efficacious, but this perpetuates the GI
dysbiosis that allows for C. difficile colonization in the first place, and many patients
experience recurrent infections (McDonald et al., 2018).
In a clinical trial, fecal transplantation was attempted on patients suffering from
recurrent CDI with the idea that resolving the dysbiosis by the transfer of a “healthy”
microbiota will restore colonization resistance to the pathogen and cure disease.
Compared to vancomycin, the standard therapy, fecal transplantation was so much
more efficacious that the study, although controversial, was stopped early with the
conclusion that fecal transplantation is the superior therapy (Van Nood et al., 2013).
Currently, fecal transplantation is recommended for patients with more than two
recurrent CDI episodes (McDonald et al., 2018). Still, what constitutes a “healthy”
microbiota is unclear, let alone the methods to standardize the criteria for selecting
“healthy” donors for obtaining transplant material. In addition, fecal transplantation
has been extensively used in animal models to transfer physiologic traits to demonstrate
the role of microbiota in host processes, including obesity (Ridaura et al., 2013). Thus,
fecal transplantation has the potential to be therapeutically useful in many conditions,
but without a complete understanding of how specific microbial compositions affect
physiology, unintended consequences such as transfer of metabolic syndromes could
occur (Alang and Kelly, 2015). Nevertheless, a key mechanism by which probiotics could
benefit the host is through competition for nutrients and niches for survival, which can
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directly or indirectly limit colonization of the host by pathogens. Probiotics also possess
these mechanisms to outcompete pathogens, and the potential to use microbes directly
for therapy is demonstrated in one of the oldest therapies. A better understanding of
how members of the microbiota confer host colonization resistance to pathogens will
help develop specific microbial therapies that are efficacious and result in adverse
effects that are predictable and manageable.
Probiotic Mechanism of Action: Manipulation of the Host Barrier
The Gastrointestinal Epithelial Barrier, the Host-Microbe Interface
The key feature of the host immune system is the ability to selectively respond
against foreign pathogenic antigens but not innocuous self- or non-self-associated
antigens. This challenge is perhaps best represented within host mucosal surfaces,
especially the GI tract, where the host is in perpetual contact with the members of the
commensal microbiota. Here, mounting an inappropriate response against food or
commensal antigens would result in an inflammatory response that could impede
normal functions of the GI tract essential for life. Such dysregulation of GI immune
homeostasis is thought to cause GI disorders such as inflammatory bowel disease (IBD)
and colon cancer (Feng et al., 2015; Al Nabhani et al., 2019; Willing et al., 2009). The
immune system harbors a complex array of mechanisms to maintain immune
homeostasis, especially at mucosal sites (Chung et al., 2011; Coombes et al., 2007; Craig
and Cebra, 1971; Gabanyi et al., 2016; Sakaguchi et al., 1995). However, failure to
respond to potentially invasive pathogens can lead to dissemination of the pathogen.
Thus, the mucosal immune system must harbor mechanisms to tightly regulate
immunity and strike a delicate balance to ensure host survival. This process generally
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starts at the point of contact between the host and microbes, the intestinal epithelial
barrier.
The GI tract is the most significant barrier surface, lined by a single layer of
columnar epithelial cells that are designed to absorb nutrients while restricting
translocation of microbes from the lumen. To prevent inappropriate triggering of
immune responses against commensals within the lumen, intestinal epithelial cells
generally sequester some of their pattern recognition receptors (PRR) to surfaces in
deep crypts or on the basolateral side of the cell, especially in the colon where microbes
most heavily colonize (Chabot et al., 2006; Vamadevan et al., 2010).
The intestinal epithelial cells are supported by an array of immune and nonimmune cells within the GI mucosa and within the gut-associated lymphoid tissues
(GALT) that play important roles such as excluding luminal pathogens, suppressing
inappropriate inflammation, responding against invading pathogens, and promoting
wound healing to maintain the intestinal barrier functions (Cario et al., 2007; Coombes
et al., 2007; Kim et al., 2018; Lycke et al., 1987; Silvey et al., 2001). Loss of this barrier
function leads to increased non-specific translocation of GI luminal contents including
the microbes, which could trigger PRRs on epithelial cells and mucosal immune cells to
induce inflammation, leading to GI tract disorders such as IBD. Because of their nearly
ubiquitous presence amongst many host organisms from Drosophila to humans, GI
tract commensals are thought to have co-evolved with the host and are thought to
harbor many mutually beneficial processes such as promoting gut barrier functions and
maintaining immune homeostasis. This is highlighted by the observations that immune
disorders such as IBD are associated with dysbiosis (Willing et al., 2009), although the
mechanism behind the phenomena is not clear. While there are a lot of mechanisms by
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which commensals probably do this, the majority of the studies on probiotics have
focused on three major mechanisms the host utilizes to maintain the gut barrier that
commensals are able to reinforce: strengthening the epithelial tight junctions,
promoting mucus and antimicrobial secretions, and modulating IgA responses as
described in Table 1.

Table 1: Major Mechanisms by which Probiotics can Exclude Pathogens in
the GI Tract.
Modulation of Epithelial Cell Barrier Functions
As previously described, the GI lumen is lined by a single layer of intestinal
epithelial cells that are joined together by tight junctions, adherens junctions, and
desmosomes. Desmosomes, or macula adherens, are cell-cell junction plaques that
anchor intracellular intermediate filaments between cells, providing structural integrity
for the epithelial monolayer. Adherens junctions, or zonula adherens, are actinanchoring cell-cell junctions that utilize calcium-dependent cadherin-catenin
interactions that not only join neighboring cells together but also promote apical and
basolateral polarization of the intestinal epithelium. Lastly, tight junctions, or zonula
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occludens, are the most apical of the cell-cell adhesions that facilitate selective transport
of ions and solutes and also prevent translocation of microbes and toxins. Of the
adhesive junctions, tight junctions are the best characterized and have been the subject
of studies related to probiotics. Probiotics can enhance the functions of tight junctions,
which would strengthen the epithelial barrier integrity. Overall functions of tight
junctions can be estimated in vitro by measuring electrical resistance across the
epithelial monolayer, or transepithelial resistance (TER). For example, probiotic strains
of L. acidophilus and Streptococcus thermophilus slightly increased TER in Caco-2 cells,
a human colonic epithelial cell line (Resta-Lenert and Barrett, 2003). In the same study,
the probiotics helped HT-29 cells, another human colonic cell line, maintain TER levels
during infection with enteroinvasive E. coli (EIEC), which normally results in a 3-fold
loss in TER within 24 hours. This correlated with a reduction in the number of EIEC
colony forming units (CFU) that passed through the epithelial cells, suggesting that the
probiotics help keep the invasive pathogen at bay by strengthening the epithelial tight
junctions (Resta-Lenert and Barrett, 2003). Tight junctions consist of four families of
proteins: occludins, claudins, junctional adhesion molecules, and tricellulins (Furuse et
al., 1993; 1998; Ikenouchi et al., 2005; Stevenson et al., 1986). Occludins are regulated
through phosphorylation that helps localize these proteins to the tight junctions to link
the junction to the actin cytoskeleton (Andreeva et al., 2001). Treatment of HT-29 cells
with L. acidophilus and S. thermophilus resulted in an increase in occludin and zona
occludens protein 1 (ZO-1) phosphorylation suggesting that the probiotics function
through modulation of tight junction proteins (Resta-Lenert and Barrett, 2003). Live
probiotics were required for these effects implying that there are some effector
molecules produced by the probiotics, but the molecules remain unidentified. In
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addition, these probiotics induced phosphorylation of extracellular signal-regulated
kinases 1 and 2 (ERK1 and ERK2) (Resta-Lenert and Barrett, 2003), but how the
probiotics influence this pathway and what other pathways are influenced remain to be
elucidated. It should be noted that there is no evidence yet for these probiotics
influencing tight junctions in vivo. One concern for these probiotics is that spent
medium from L. acidophilus and S. thermophilus cultures were unable to influence tight
junctions in vitro, suggesting a requirement for close contact of live bacteria to the
epithelial cells (Resta-Lenert and Barrett, 2003). In the GI tract, the majority of
commensals are thought to be spatially separated from the epithelium with a layer of
mucus secreted by the goblet cells (Johansson et al., 2008), and it is unclear if probiotics
could come in close contact with the epithelial cells and affect tight junctions in vivo. A
mucus-producing clone of HT-29 cells (HT-29-MTX) is available (Gagnon et al., 2013)
and could be used to determine if a probiotic could affect tight junctions in the presence
of host mucus.
Barrier dysfunctions have been well-documented in many inflammatory
conditions of the mucosa (Johansson et al., 2014; Meddings et al., 1999), and
inflammatory mediators such as interferon gamma (IFN-γ) and tumor necrosis factor
alpha (TNF-α) have been demonstrated to increase epithelial monolayer permeability
and decrease TER in many epithelial cell lines (Fish et al., 1999; Madara and Stafford,
1989; Schmitz et al., 1999). Bifidobacterium infantis is a probiotic present in the VSL#3
formulation and B. infantis-conditioned medium prevented TER loss induced by IFN-γ
and TNF-α in T84 cells, another human colon cancer cell line (Ewaschuk et al., 2008). B.
infantis-conditioned medium did this using a similar mechanism as L. acidophilus:
increase in TER, increased levels of claudins and occludins, and phosphorylation of
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ERK1 and 2. Ewaschuk and colleagues were able to assess the effects of B. infantis in
vivo by measuring ex vivo tissue permeability of colons isolated from mice treated with
B. infantis. They found that B. infantis reduced intestinal permeability and that these
effects correlated with beneficial effects, as B. infantis reduced colitis due to interleukin10 (IL-10)-deficiency (Ewaschuk et al., 2008). However, splenocytes from B. infantistreated mice produced reduced levels of IFN-γ, and colonic IFN-γ levels were indeed
reduced as well, making it difficult to know if the reduction in colitis by B. infantis
administration was due to direct improvement on tight junction functions or due to a
decrease in inflammatory cytokines. Modulation of immunity by probiotics is a subject
of further discussion, but this study demonstrates that a probiotic can reinforce tight
junction functions in vivo to benefit hosts during inflammation-induced colitis
(Ewaschuk et al., 2008).
Some mechanisms by which probiotics reinforce the intestinal barrier functions
do not necessarily involve the tight junctions. The intestinal epithelial cells are subject to
high rates of turnover, constantly being shed from the luminal surface, and then
replaced by proliferation and differentiation of the stem cells found in the crypts
(Bjerknes and Cheng, 1981). Noxious stimuli such as inflammation can cause death of
GI epithelial cells to disrupt the barrier and trigger an inflammatory reaction that
further increases intestinal permeability. Specifically, TNF induces epithelial cell
apoptosis, a programmed form of cell death, in cell lines and in mouse colon explants
which can be prevented by conditioned medium from L. rhamnosus GG (Yan et al.,
2007). L. rhamnosus GG does this by activating protein kinase B (Akt) that mediates
cellular pro-survival signals, and this activity was attributed to two unidentified proteins
of 75 and 40 kilodaltons (kDa) in size (Yan et al., 2007). There are many mechanisms by
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which probiotics can limit epithelial permeability, and through these, probiotics can
help exclude pathogens from invasion. Still, the specific molecules that mediate these
effects remain mostly unidentified, and elucidating the mechanisms, especially the
signaling pathways by which epithelial barriers are reinforced, would help identify
targets for therapies in many inflammatory GI conditions.
Modulation of Epithelial Secretions
It is essential to recognize that the epithelium is not just a physical barrier, but
also an active participant in regulating the intestinal microbiota. To this end, the
epithelial layer hosts specialized cell types that serve specific functions. Goblet cells, first
noted by Friedrich Henle in 1837 and noted for mucus production by Franz von Leydig
in 1857, are one such cell type, forming a gel-like layer that covers the luminal surface of
the GI epithelium. In the colon, the mucus layer is divided into the inner and outer
layers. The inner layer is anchored to the goblet cells and is generally thicker, with
estimated pore sizes around 0.5 μM, which prevent penetration by most bacteria
(Johansson et al., 2008). About 50 μM (mice) or 200 μM (humans) away from the
epithelium, the mucus is converted, through proteases, into a thinner outer layer that
allows penetration by bacteria. This two-layer system is thought to prevent most
bacteria from coming in direct contact with the epithelium, preventing intestinal
inflammation. The mucus layers consist of about 50 proteins, and mucin 2 (Muc2) is the
most critical, as Muc2-deficient mice lack colonic mucus (Johansson et al., 2014). Muc2
is heavily polymerized and glycosylated, eventually forming a massive web-like structure
that gives mucus the sticky nature with pore sizes designed to limit bacterial penetration
(Ambort et al., 2012). Muc3 is another mucin protein of the small intestine thought to be
large and heavily glycosylated as well (Gum et al., 1997), though the exact function is not
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known. Germ-free mice have inner mucus layers that are penetrated by microbe-sized
beads (Johansson et al., 2015), demonstrating that commensals are essential for proper
formation of the mucus layer. Probiotics can reinforce this mucus layer, which would
help exclude pathogens from invading the intestinal mucosa. Multiple probiotic
Lactobacillus species have been shown to increase expression of Muc3 in HT-29 cells,
which correlated with reduced enteropathogenic E. coli (EPEC) adherence to the cells
(Mack et al., 2003). VSL#3, a probiotic formulation of multiple organisms, including
several Lactobacilli (Gionchetti et al., 2000), also increased expression of multiple
mucin components by HT-29 cells (Otte and Podolsky, 2004). In this study,
pharmacologic inhibition of mitogen-activated protein kinase (MAPK) prevented this
increase, indicating that the probiotic mixture affects mucin production through specific
signals. However, it is not clear how VSL#3 activates the MAPK pathway, and it is not
clear if any other pathways are involved. It should be noted that no probiotics to date
have been assessed for their ability to influence goblet cell functions. While intestinal
cell lines are notorious for being heterogeneous and mucus-producing clones of these
cell lines have been identified (Gagnon et al., 2013), the major mucus-producing cell
type is the goblet cell, and this warrants further study. In addition, the ability of specific
probiotics to influence the mucus layer in vivo has not been assessed. Goblet cells are
known to be heavily regulated by the immune system (Oeser et al., 2014; Turner et al.,
2013), and given the influence of commensals on immune homeostasis, it would not be
surprising if probiotics can modulate goblet cell functions through immune modulation
in vivo.
Mucus is not the only secretion at the GI epithelial barrier. Antimicrobial
peptides (AMP) are oligopeptides with antimicrobial activity, produced by members
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from all kingdoms of life. Since their discovery (Dubos, 1939), more than 5,000 AMPs
have been discovered or synthesized (Zhao et al., 2013), and a variety of mechanisms
exist by which they exhibit antimicrobial activity. In the human colon, β-defensins are
the best characterized AMPs. The human genome encodes 33 β-defensins, of which βdefensin 1, 2, and 3 are the most extensively studied. β-defensins are small cationic,
cysteine-rich peptides of about 4 to 5 kDa in size with multiple disulfide bridges between
the cysteine pairs (Klüver et al., 2005; Schibli et al., 2002). Because of their cationic
nature, β-defensins preferentially bind to microbial membranes that are negatively
charged; mammalian cell membranes tend to be more electroneutral. Once bound to the
microbial surface, β-defensins penetrate through the lipid bilayer, forming a pore
through which intracellular contents leak, resulting in cell death (Lehrer et al., 1989).
Probiotics could act by inducing host secretion of AMPs to reinforce antimicrobial
defenses at the gut barrier. E. coli Nissle 1917 and other probiotic strains of E. coli have
been demonstrated to increase fecal levels of β-defensin 2 in humans after 3 weeks of
probiotic administration, and also induced expression of β-defensin 2 messenger RNA
(mRNA) in Caco-2 cells in vitro (Möndel et al., 2008). While this demonstrates that
probiotics have the potential to reinforce host antimicrobial defenses through AMPs, it
is not clear if AMP secretion is responsible for the exclusion of pathogens from the GI
tract in vivo. In addition, probiotic strains of E. coli are also susceptible to β-defensins,
and the induction of β-defensin in humans by probiotics is transient, as β-defensin
levels in feces start to return to baseline by about 9 weeks after treatment (Möndel et al.,
2008). Still, probiotics have the ability to promote host secretions, including mucus and
AMPs, and through these mechanisms, they can help exclude pathogens from invading
the mucosal surfaces.
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Modulation of Secretory IgA
The third major mechanism by which probiotics can promote gut barrier
functions involves a major component of the mucosal immune system, secretory IgA
(sIgA). In the serum, IgA is primarily in its monomeric form. In the mucosa, IgA is
primarily in its dimeric form: two monomers joined together by the J chain (Halpern
and Koshland, 1970; 1973). IgA is the most abundant antibody class, representing about
70% of antibodies made by mammals (Chodirker and Tomasi, 1963). To this end, the GI
tract is lined ubiquitously with GALT such as Peyer’s patches in the ileum important for
the development of IgA-producing cells (Craig and Cebra, 1971). The IgA-secreting
plasma cells then populate the GI lamina propria, where they are thought to produce
IgA. The dimeric IgA is bound by the polymeric Ig receptor (pIgR) expressed on
epithelial cells that mediates basolateral to apical transcytosis of dimeric IgA
(Brandtzaeg, 1974; Brandtzaeg and Prydz, 1984; Tomasi et al., 1965; Tourville et al.,
1969). Close to the luminal surface, IgA is then released from the pIgR and secreted
from the epithelium as sIgA, associated to a part of the pIgR known as secretory
component (Brandtzaeg, 1974; Tourville et al., 1969). Canonically, it is believed that
sIgA serves as the first-line defense against mucosal pathogens, neutralizing microbial
toxins and contributing to pathogen exclusion by binding to microbes and limiting their
penetration through the mucus layer (Boullier et al., 2009; Lycke et al., 1987; Silvey et
al., 2001). Commensals are important for the production of IgA since germ-free mice
had no detectable serum IgA and slightly reduced cecal sIgA levels that was restored to
levels found in conventional mice once commensals were introduced (Benveniste et al.,
1971). Germ-free mice also had reduced numbers of IgA plasma cells in the duodenum
that were also restored to conventional levels by introducing certain microbes (Moreau
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et al., 1978), indicating that the microbes stimulate sIgA production by promoting the
development of IgA-producing cells. Certain probiotics such as L. casei have been
demonstrated to increase IgA levels in the GI tract by increasing the number of IgA+
cells in the small intestines after about a week (Galdeano and Perdigón, 2006). However,
this IgA was not specific to the administered probiotic, suggesting that L. casei generally
increases IgA levels rather than inducing an antigen-specific antibody response
(Galdeano and Perdigón, 2006). By reinforcing sIgA production in the GI tract,
probiotics have the potential to protect hosts from invading pathogens.
While it is important to note that sIgA mediates important canonical functions
within the GI tract such as neutralization of microbial toxins and exclusion of
pathogenic microbes (Boullier et al., 2009; Lycke et al., 1987; Silvey et al., 2001), how a
non-specific increase in sIgA levels would benefit hosts is not immediately clear. In
addition, it is not clear what mechanisms actually drive increased sIgA levels in
response to commensals or probiotics. A potential explanation for how probiotics could
protect hosts through IgA stems from a recent appreciation for how commensals
influence the IgA repertoire. The diversity of antibody specificities is generated in large
part by the action of activation-induced cytidine deaminase (AID) in activated B cells
(Muramatsu et al., 2000). AID functions by converting deoxycytidines to deoxyuracil in
DNA of the Ig variable (V) genes, which results in the introduction of a transition
mutation from a cytidine-guanine pair to a thymine-adenine pair, or error-prone
excision repair of the deoxyuracil, that introduces mutations, diversifying the V gene
pool as B cells proliferate (Petersen-Mahrt et al., 2002); this process is called somatic
hypermutation (SHM). AID is also responsible for class switch recombination, which is
required to generate different antibody classes, including IgA (Muramatsu et al., 2000).

23

Commensal microbes increase the levels of sIgA in the gut (Benveniste et al., 1971), but
this is only one aspect of what commensals do to influence sIgA production. In germfree mice, the level of sIgA is decreased, but also decreased is the frequency of SHM,
indicating that commensals also influence the generation of sIgA diversity (Lindner et
al., 2012). The ability to diversify the sIgA repertoire is likely more important than
increasing sIgA levels to maintain gut homeostasis, since AID mutant mice that have
defective AID functions had levels of fecal sIgA comparable to that of wild-type (WT)
mice but had reduced sIgA diversity that correlated with expanded intestinal bacterial
population and increased invasion by Yersinia enterocolitica during infection (Wei et al.,
2011). The reduction in SHM frequency is also observed in T cell-deficient mice in
conventional housing, indicating that commensals drive sIgA diversification through T
cells (Lindner et al., 2012). Generally, microbes are sampled through specialized
epithelial cells called microfold (M) cells that bring in luminal microbes through
transcytosis to the associated immune cluster (Bockman and Cooper, 1973; Owen and
Jones, 1974). Here, antigen presenting cells such as dendritic cells (DC) take up the
microbe and activate T cells that coordinate germinal center reactions to give rise to
antibody responses (Alpan et al., 2001).
Activated T cells can differentiate into T follicular helper (TFH) cells that are
critical for selective survival of high-affinity B cells and the maintenance of germinal
centers (Breitfeld et al., 2000). The germinal center also is home to T follicular
regulatory (TFR) cells that regulate the germinal center reactions (Chung et al., 2011).
These follicular T cells help shape the sIgA repertoire against intestinal microbes, as
evidenced by the change in the profile of IgA-coated intestinal microbes by the transfer
of follicular T cells into immunodeficient mice (Kawamoto et al., 2014). Therefore,
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probiotics could promote the development of antigen-specific sIgA responses that could
target pathogens for exclusion. An example of this is observed with B. bifidum and B.
infantis that reduce rotavirus-induced diarrhea in mice which correlates with increased
levels of virus-specific mucosal sIgA levels (Qiao et al., 2002).
The specific mechanisms for how the administration of probiotics leads to the
generation of antibody responses against seemingly unrelated pathogens are not clear,
but two possibilities seem feasible. For one, the probiotics could harbor some antigens
that bear a resemblance to those found on pathogens, therefore driving a probioticspecific sIgA response that also targets pathogens with similar epitopes, a phenomenon
that could be described as molecular mimicry. However, probiotics do not usually
induce a sIgA response targeting itself, as the administration of L. casei increased sIgA
responses but none that targeted L. casei itself (Galdeano and Perdigón, 2006). Another
possibility is that, by stimulating GALT immune cells including DCs and follicular T cells,
overall mucosal antibody responses may be heightened, increasing the likelihood of
generating antigen-specific antibody responses against others, perhaps pathogens like
rotavirus. Unfortunately, the increase in sIgA by probiotics is a generally accepted (and
marketed) benefit that needs further mechanistic understanding, and how it would
actually be beneficial remains to be studied.
A recent observation about sIgA is that a part of the sIgA repertoire is innate-like,
enriched for polyreactive antibodies, and thought to serve as a first-line defense
mechanism (Bunker et al., 2017). The natural sIgA arises through a T cell-independent
process and is not affected by the absence of germinal center reactions or SHM (Bunker
et al., 2015). The natural IgA coats specific members of the commensal microbiota
(Bunker et al., 2015; 2017), though what functional outcome this has on host physiology
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is not clear. However, sIgA can enter the Peyer’s patches in both in vitro and in vivo
models, where they can be internalized by DCs (Rey et al., 2004), though functional
outcomes on DCs or germinal center reactions were not assessed in this study. This
suggests that sIgA-coated commensal microbes could selectively be transported to the
GALT where they could interact with immune cells to affect host physiology. IgA-coated
probiotic L. rhamnosus can stimulate DCs isolated from Peyer’s patches to induce
regulatory T cells (Treg) through IL-10 and transforming growth factor beta (TGF-β)
(Mikulic et al., 2016). While the ability of IgA-coated L. rhamnosus to enter Peyer’s
patches in vivo or ex vivo was not assessed, this study suggests that sIgA, given that a
part of its repertoire selectively binds to commensals, could mediate uptake of
probiotics into the GALT where it can influence immune homeostasis. A similar
phenomenon has been described for invasion-deficient Salmonella as well. While
invasion-deficient Salmonella is avirulent, it is generally not considered a probiotic. Still,
in vivo administration of IgA-coated invasion-deficient Salmonella by direct injection
into the duodenum of mice resulted in increased presence of bacteria within the Peyer’s
patches compared to injection of uncoated bacteria, and this led to the generation of an
antigen-specific IgA response (Fransen et al., 2015), demonstrating that IgA can
mediate selective uptake of GI bacteria to promote antigen-specific IgA responses.
Further investigation into the relationship between sIgA, commensals, and the overall
IgA repertoire will be needed to understand the basis by which probiotics can protect
hosts from pathogens through sIgA.
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Probiotic Mechanism of Action: Immune Homeostasis
Microbes and Immune Homeostasis
While a substantial number of studies have focused on ways probiotics confer
protection against pathogens through exclusion, it is essential to note that this is not the
only way probiotics can benefit hosts. In fact, probiotics are currently marketed with
claimed health benefits that span the entire human body: improved digestion,
strengthened immune system, reduced allergy, improved cardiovascular functions, and
even improved psychological health. One particular benefit that is becoming a major
focus of multiple research disciplines is the effect of the microbiota on immune
homeostasis. Mucosal surfaces, especially the GI tract, are in constant contact with
microbes that need to be regulated by host immunity. Failure to regulate the intestinal
microbes can leave the host vulnerable to pathogenic invasion (Wei et al., 2011).
However, inappropriate activation of immunity has detrimental effects for the host, as
evidenced by inflammatory diseases caused by dysregulation of host immunity such as
IBD (Hugot et al., 2001; Kühn et al., 1993). Therefore, a delicate balance between the
need to restrict microbes and to limit inflammation must be achieved. To this end, many
host mechanisms exist to regulate immune responses tightly. We have already discussed
the influence of the microbiota on host physiology, but the relationship between host
and commensal microbes is suspected to be more intertwined. One evidence for this is
the observation that the development of the different arms of the immune system,
especially adaptive immunity, coincides with the evolutionary appearance of organisms
that host a complex microbiota (Pancer et al., 2004; Zuo et al., 2017). Therefore, it is
perhaps not surprising to see that the microbiota exerts its influence on just about every
major host immunoregulatory mechanisms. Probiotics also target these
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immunoregulatory mechanisms, mainly those described in Table 2. By reinforcing the
immunoregulatory mechanisms, probiotics have the ability to promote immune
homeostasis and prevent inflammatory diseases.

Table 2: Major Mechanisms by which Probiotics Promote Immune
Homeostasis

Modulation of Regulatory T Cells
The major immune cell type that mediates regulation of immunity is the Treg cell,
generally defined by the expression of the master transcription factor, forkhead box
protein P3 (Foxp3) (Fontenot et al., 2003; Hori et al., 2003). Foxp3 expression by Treg
cells is critical to maintain tolerance to self-antigens, as Foxp3-deficient mice experience
systemic autoimmune disease and die by about 4 weeks of age (Fontenot et al., 2003).
In humans, mutations in FOXP3 gene are linked with the systemic autoimmune disease
known as immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome
(IPEX) (Bennett et al., 2001). There are two main subtypes of Treg cells, natural Treg
(nTreg) cells and inducible Treg (iTreg) cells. nTreg cells develop from the thymus through
the host-intrinsic mechanism and generally mediate central tolerance against selfantigens upon release into the periphery. Certain peripheral naïve T cells can be induced
into iTreg cells, which then can mediate tolerance against both self- and foreign-antigens.
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Unlike nTreg cells, iTreg cells are heavily influenced by the local cytokine milieu, especially
TGF-β, which is thought to help maintain Foxp3 expression in Treg cells (Zheng et al.,
2010). The canonical anti-inflammatory cytokine IL-10 is also known to potentiate iTreg
differentiation (Hsu et al., 2015). The GI tract is perhaps the most critical place to
maintain immune homeostasis, and the balance of effector T cells and Treg cells is critical.
This was experimentally demonstrated by the transfer of naïve T cells, defined by the
expression of cluster of differentiation (CD) markers as CD4+CD45RBhigh, to
immunodeficient mice which recreated a Treg cell-deficient host and resulted in pan-GI
tract inflammation (Read et al., 2000), assumed to be due to unchecked T cell activation.
In this model, co-transfer of the CD4+CD25+CD45RBlow compartment, known to be
enriched for Treg cells, ameliorated inflammation in the GI tract (Read et al., 2000),
suggesting that Treg cells are important to maintain homeostasis in the GI tract. In the
colon, the majority of the Treg cells are iTreg cells (Atarashi et al., 2011; Geuking et al.,
2011; Lathrop et al., 2011), and since they are influenced by environmental signals, they
are thought to be the cells interacting with the microbiota to maintain immune tolerance.
The microbiota is known to play a role in promoting or maintaining Treg cell population
within the GI tract since germ-free mice harbor reduced numbers of Treg cells in the
colonic lamina propria (Geuking et al., 2011). Not surprisingly, a significant way
probiotics are thought to function in homeostasis is to reinforce the Treg cell
compartment. Chronic administration of Bifidobacterium breve Yakult strain to mice
ameliorated colitis in the naive T cell transfer model, and this is thought to be due to an
increase in the number of colonic Treg cells that produce IL-10 (Jeon et al., 2012). It
should be noted here that B. breve-induced IL-10+ Treg cells did not express Foxp3, a
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phenotype consistent with a subset of Treg cells called type 1 Treg cell (Tr1) (Groux et al.,
1997).
The effect of microbes on immune homeostasis and Treg cells is often studied in
the context of the GI tract, but the effects are not necessarily confined locally. Certain
Clostridium species of the GI tract microbiota are known to be sufficient to induce IL10-producing, Foxp3+ Treg cells in the colon in germ-free mice (Atarashi et al., 2011).
Supplementation of these Clostridia species to normal mice under specific pathogenfree (SPF) conditions limited colitis induced by the chemical irritant, dextran sodium
sulfate (DSS) (Atarashi et al., 2011), indicating that the local induction of Treg cells by the
microbe helps limit inflammation. However, mice supplemented with these Clostridia
species were also resistant to allergic sensitization as well, as these mice had reduced
serum levels of ovalbumin- (OVA) specific IgE following systemic immunization with
OVA (Atarashi et al., 2011).
The mechanisms by which microbes in the GI tract can have systemic
immunomodulatory effects are not clear, but two main possibilities exist. For one,
locally induced Treg cells, or any other immune cell, could mediate systemic effects either
by the production of systemic immunoregulatory mediators or by redistribution to other
tissues. The other possibility is that the mediator molecules of microbes drain into the
circulation and directly affect immune cells in other tissues. In Clostridia-supplemented
mice, splenocytes produced higher levels of IL-10 upon stimulation, which suggests that
IL-10+ Treg cells are present systemically (Atarashi et al., 2011). Still, it is not clear if this
increased IL-10 production even comes from Treg cells, nor is it clear if these cells
originated from the GI tract. However, there is compelling evidence for microbial
products directly affecting tissues outside the GI tract.
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Short chain fatty acids (SCFA) are byproducts of microbial fermentation of
carbon sources, often those that cannot be processed by the mammalian hosts such as
dietary fiber. Administration of SCFAs to germ-free mice resulted in an increase in
intestinal Treg cells and protected mice from colitis in the T cell transfer colitis model
(Smith et al., 2013), indicating that microbes promote immune homeostasis by inducing
Treg cell differentiation through SCFAs. SCFAs are known to directly promote Treg cell
differentiation in vitro through G-protein coupled-receptors (GPCR) (Smith et al., 2013),
and SCFAs can be detected in the human circulation (Cummings et al., 1987), suggesting
that, by getting into the circulation, SCFAs could directly engage T cells for Treg cell
differentiation in distant tissues. Indeed, one study demonstrated that administration of
L. rhamnosus GG to mice resulted in an expansion of SCFA-producing Clostridia, which
increased Treg cells in the bone marrow to promote bone homeostasis (Tyagi et al., 2018).
Therefore, by enhancing the Treg compartment, probiotics can help maintain immune
homeostasis within the local environment and beyond.
While probiotics promote Treg cell differentiation, they do not necessarily target
T cells directly. In fact, the best-characterized probiotics have been found to exert their
functions through a mediator cell type, generally of the myeloid lineage, which can
promote Treg cell differentiation. The classic example is an anaerobic member of the
microbiota, Bacteroides fragilis. B. fragilis is known to ameliorate colitis in multiple
murine models, and as in many other probiotic agents, this is mediated through the
induction of IL-10-producing Treg cells (Mazmanian et al., 2008). This protective effect
requires polysaccharide A (PSA), a zwitterionic polysaccharide that forms the bacterial
capsule that recapitulates protection from colitis when administered as purified PSA
(Baumann et al., 1992; Mazmanian et al., 2008). PSA inhibits the production of TNF-α
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induced by infection with Helicobacter hepaticus in in vitro co-cultures of bone
marrow-derived DCs (BMDC) and T cells in a Toll-like receptor 2 (TLR2)-dependent
manner (Mazmanian et al., 2008). In vivo protection from colitis also requires TLR2
(Mazmanian et al., 2005; Round and Mazmanian, 2010; Wang et al., 2006), indicating
that PSA exerts its effects in part through TLR2 on DCs. Other probiotics also go
through mediator cells to induce Treg cells. B. breve Yakult strain induces Tr1 cells in the
colon and in vitro during co-culture of intestinal CD103+ DCs and splenic CD4+ T cells, a
process that requires TLR2 signaling in the DCs (Jeon et al., 2012). Non-immune cells
can also be the mediator cell type for promoting Treg cell differentiation. In the case of
SCFA-producing microbes, SCFAs can act on pancreatic β cells, the insulin-producing
cell, to induce production of cathelicidin-related AMP (CRAMP) which promotes antiinflammatory polarization of macrophages (MΦ), leading to increased Treg cell
differentiation that correlates with protection from autoimmune diabetes (Sun et al.,
2015).
Modulation of Macrophages
Other immune cells can also be targeted by microbes to promote immune
homeostasis. In particular, MΦs are a diverse group of cells of the mononuclear
phagocyte (MNP) system and tissue resident cells that perform homeostatic functions in
virtually all tissues (Broug-Holub et al., 1997; Fox et al., 1987; Gautier et al., 2012;
Geissmann et al., 2003; Mackaness, 1962; Nahrendorf et al., 2007; Nimmerjahn et al.,
2005; Udagawa et al., 1990). Classically, MΦs can be characterized in two major
categories, classically activated M1 MΦs that mediate pro-inflammatory type I responses
and alternatively activated M2 MΦs that mediate pro-fibrotic type II responses (Mills et
al., 2000). Under in vitro conditions, MΦs can be polarized into M1 and M2 MΦs in
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response to the type I cytokine IFN-γ and a microbial ligand or type II cytokines IL-4
and IL-13, respectively (Doherty et al., 1993; Held et al., 1999; Murray et al., 1985; 2014;
Stein et al., 1992). M1 MΦs are best known for their antimicrobial functions and their
expression of inducible nitric oxide synthase (iNOS). M1 MΦs phagocytose microbes
and kill them by producing toxic molecules like reactive nitrogen species (RNS) through
iNOS and reactive oxygen species (ROS) through the action of nicotinamide adenine
dinucleotide phosphate hydrogen (NADPH) oxidase, a process characterized as the
respiratory burst (Sbarra and Karnovsky, 1959; Segal, 1987; Xie et al., 1992). M2 MΦs
are typically associated with immunoregulation and anti-parasite responses, typically
defined by the expression of arginase 1 (Arg-1) (Munder et al., 1998). M2 MΦs have been
studied often in tumor environments, specifically designated tumor-associated MΦs
since these cells are now recognized as a distinct subtype, with robust suppressive
activity against tumor-specific T cells (Curiel et al., 2004; Kuang et al., 2009; TorroellaKouri et al., 2009). M2 MΦs are thought to suppress T cell functions by three different
mechanisms: inhibitory cytokines, inhibitory cell surface ligands, and local depletion of
arginine (Curiel et al., 2004; Huber et al., 2010; Modolell et al., 2009; Pesce et al., 2009;
Taylor et al., 2006). Both iNOS and Arg-1 use arginine as the substrate, and this is
thought to drive polarization of MΦs since these enzymes mutually exclude the action of
the other by competing for the same substrate (Munder et al., 1998). However, it is not
known how these enzymes contribute to differential polarization of MΦs, and there are
other processes known to influence this polarization such as β-oxidation of fatty acids, a
process important for M2 polarization (Huang et al., 2014). The designation of MΦs into
M1 and M2 originally fit well with the two classes of T cell responses (Mills et al., 2000),
but this likely represents an oversimplified view of MΦs. In fact, other signals that
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activate MΦs such as IL-10, TGF-β, and glucocorticoids did not fit with the original
descriptions of M1 and M2 MΦs, and since these signals induced mostly
immunoregulatory functions like that of M2 MΦs, the M2 MΦs were proposed to be
further subdivided into subsets based on activating signals (Anderson and Mosser, 2002;
Edwards et al., 2006; Ehrchen et al., 2007). Still, the factors that affect MΦ phenotypes
are a seemingly endless list, including salt concentrations (Binger et al., 2015) and even
cell shape (McWhorter et al., 2013), and attempts to subdivide MΦs into more subsets
would be equally complex. This is further complicated in vivo due to the different
developmental ontogeny of MNPs, including MΦs in vivo. The circulating MNP
progenitors, monocytes, arise from the bone marrow and differentiate into MΦs and
DCs upon being recruited to tissues (Tamoutounour et al., 2013; Volkman and Gowans,
1965). However, different tissues harbor resident MΦs that are thought to arise from
progenitors during fetal and yolk sac lymphopoiesis (Ghosn et al., 2010; Ginhoux et al.,
2010; Hoeffel et al., 2012; De Schepper et al., 2018; Tamoutounour et al., 2013). Given
the recent appreciation of the complex nature of MNPs in vivo, the most appropriate
view is likely that MΦs exist in a dynamic spectrum of specialized cells with differing
ontogeny that constantly modulate their functions in response to environmental cues.
The GI tract harbors many MΦs, typically expressing C-X3-C chemokine receptor
1 (CX3CR1) (Geissmann et al., 2003). The mucosal layer receives constant input from
the circulating monocytes that replenish the MΦ pool while the deeper muscle layers
have tissue resident MΦs that self-renew (De Schepper et al., 2018). Based on
localization, it is thought that the mucosal MΦs mediate interactions with the
microbiota while MΦs in the muscularis layer interact with the enteric neurons to
support digestive functions of the GI tract (Gabanyi et al., 2016; De Schepper et al.,
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2018). In fact, ablation of GI tract MΦs resulted in increased GI tract transit time,
indicative of decreased GI motility (De Schepper et al., 2018). Intestinal MΦs play an
important role in coordinating immune responses against microbes in the GI tract, as
depletion of CX3CR1+ MNPs resulted in increased T cell responses against intestinal
pathogens (Kim et al., 2018), indicating that these cells limit inflammation under
homeostatic conditions. The microbiota is known to influence these MΦs, since
depletion of the same CX3CR1+ MNPs resulted in decreased T cell responses against
intestinal pathogens in antibiotic-treated mice (Kim et al., 2018), suggesting that under
certain conditions, intestinal MΦs promote antimicrobial responses instead. Specific
microbes can exploit MΦs to promote homeostasis as well. We already discussed SCFAs
that induce pancreatic CRAMP to modulate MΦs and promote Treg cell differentiation,
preventing autoimmune diabetes. CRAMP-induced pancreatic MΦs take on an
immunoregulatory phenotype with high TGF-β production and expression of aldehyde
dehydrogenase (ALDH), an enzyme involved in retinoic acid (RA) production, which is
linked with Treg cell differentiation (Sun et al., 2015). Still, it should be noted that this
study did not assess if CRAMP-induced regulatory MΦs were responsible for Treg cell
differentiation, and the mechanism by which CRAMP confers this MΦ phenotype is not
known. Another example is H. hepaticus, which was demonstrated to produce large
polysaccharides that modulate MΦs to express an anti-inflammatory gene expression
profile through TLR2, which prevented exacerbation of colitis (Danne et al., 2017). This
study assessed signaling pathways needed for H. hepaticus polysaccharide in vitro, but
these pathways were not confirmed in vivo. Nonetheless, these studies demonstrate that
microbes target MΦs to reinforce their homeostatic functions and prevent inflammatory
disease.
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Modulation of Invariant Natural Killer T Cells
Another cell type of interest is invariant natural killer T (iNKT) cells, tissue
resident lymphocytes that recognize lipid antigens presented by the major
histocompatibility complex (MHC) class I-like molecule, CD1d (Bendelac et al., 1995;
Kawano et al., 1997). iNKT cells are distributed across many tissues, but they have been
best characterized in mucosal tissues and adipose tissues. Like the T helper cell
compartment, iNKT cells develop from the thymus and differentiate into IFN-γproducing iNKT1, IL-4-producing iNKT2, IL-17-producing iNKT17, follicular helper
iNKT, and IL-10-producing regulatory iNKT10 compartments to coordinate different
immune responses (Georgiev et al., 2016). In the liver, the site where iNKT cells are the
most frequent, iNKT cells continuously patrol the liver sinusoids (Geissmann et al.,
2005). During infection, the patrolling iNKT cells get activated and become stationary at
the infective focus, producing pro-inflammatory mediators like IFN-γ (Velázquez et al.,
2008). iNKT cells are thought to then coordinate antimicrobial responses by other cells
like Kupffer cells, the liver resident MΦs, and help clear pathogens (Lee et al., 2010).
However, one study demonstrated that during sterile focal liver injury induced by heat,
iNKT cells get to the injury site but make a 180° turn from the injured focus and settle at
the edge of injury site (Liew et al., 2017). There, iNKT cells produce IL-4 and not IFN-γ,
supposedly in response to self-lipid antigens. This was proposed to coordinate the
differentiation of recruited monocytes to wound healing MΦs through IL-4, as IL-4
blockade prevented wound healing (Liew et al., 2017). This suggests that under certain
circumstances, iNKT cells promote wound healing in response to lipid antigens.
In the GI tract, iNKT cells represent about 1% of the lymphocyte population
(Matsuda et al., 2000). Microbes have been suggested to influence the iNKT population
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within the GI tract, as germ-free mice had increased numbers of colonic iNKT cells
compared to mice in SPF conditions (Olszak et al., 2012). Specific microbes can have
similar effects, as the administration of B. fragilis to germ-free mice was sufficient to
reduce colonic iNKT cell numbers to levels found in mice under SPF conditions (An et
al., 2014). B. fragilis does this through a specific sphingolipid molecule, GSL-Bf717,
which limits iNKT cell activation in vitro and is required for reduced iNKT cell numbers
in vivo (An et al., 2014). iNKT cells are known to drive allergic inflammation in the gut
through the production of IL-13 in a chemical-induced allergy model (Heller et al.,
2002), and SPF mice and B. fragilis monocolonized mice had reduced inflammation
during oxazolone-induced colitis compared to germ-free mice (An et al., 2014; Olszak et
al., 2012), suggesting that microbes reduce inflammation by modulating the gut iNKT
cells. On the other hand, iNKT cells from germ-free mice are hyporesponsive, and
exposure to Sphingomonas yanoikuyae was sufficient to restore iNKT maturity
(Wingender et al., 2012), suggesting that certain microbes instead promote proper
maturation of iNKT cells to reinforce host defenses. It should be noted that for common
probiotic organisms, their effects on iNKT cells have not been explored. Since iNKT cells
play roles in both host defenses and immunoregulation in response to microbes, they
represent prime targets for probiotic therapy that remains to be explored.
Bacillus subtilis, the Probiotic
Exposure to Bacillus subtilis
B. subtilis is a gram positive, spore-forming bacterium ubiquitously found in the
environment, in particular in the soil (Siala et al., 1974). Human exposure to B. subtilis
is thought to occur through contact with soil and as a part of the diet in many cultures.
Fermented soybean food products contain B. subtilis, the most widely recognized being
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natto, a Japanese dish prepared by fermentation of cooked soybeans with a pure culture
of B. subtilis var. natto (Ashiuchi et al., 1998). As a spore-forming bacterium that has
been extensively studied by the scientific community, B. subtilis possesses qualities that
give significant advantages as a potential probiotic product. Bacterial endospores are a
dormant form of the cell that are generally formed under nutrient-depleted conditions.
Once formed, spores can persist indefinitely, and can withstand a variety of extreme
conditions including heat in excess of 100°C and even ultraviolet radiation (Alderton
and Snell, 1969; Nicholson et al., 2005), which makes long-term storage of B. subtilis as
a product fairly simple. Upon oral administration of spores, B. subtilis is known to
complete its life cycle within the GI tract, from germination into a vegetative state to
endospore formation prior to passage from the gut (Hoa et al., 2001). To date, oral
administration of B. subtilis has not been associated with any adverse outcomes in
immunocompetent individuals (Hoa et al., 2001), and B. subtilis has been safely
consumed as part of fermented soybean products for a long time in certain regions of
the world, making B. subtilis a durable probiotic easily administered orally, and safe for
human consumption.
As an orally administered probiotic, B. subtilis-containing products have been
tested for their potentially beneficial effects, though the specific mechanisms have not
been elucidated. Like many other probiotics, some have suspected that B. subtilis can
alter colonization of pathogens through competitive exclusion. One study tested if oral
administration of B. subtilis PY79 spores could alter colonization by the murine enteric
pathogen, Citrobacter rodentium, and found that B. subtilis-colonized mice had
reduced the number of C. rodentium CFU by 75% and reduced diarrheal disease
(D’Arienzo et al., 2006). A more recent study observed in a study in rural Southeast Asia
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that people colonized with B. subtilis were not colonized with the opportunistic
pathogen, S. aureus (Piewngam et al., 2018). This study then tested if B. subtilis
prevents colonization by S. aureus by orally administering spores of B. subtilis NCIB
3610 to mice and found that this prevented intestinal colonization by S. aureus. This
exclusion activity was attributed to B. subtilis production of fengycin, a cyclic
lipopeptide, which interfered with S. aureus accessory gene regulator (Agr) quorum
sensing critical for expression of various virulence factors (Ji et al., 1995; Piewngam et
al., 2018).
Immune Modulation by Bacillus subtilis
Another way B. subtilis is thought to benefit hosts is through immune
modulation. One study treated RAW264.7 MΦs with B. subtilis PY79 spores and found
that the spores were taken up by the MΦs, which had slightly increased IL-6 gene
expression (Duc et al., 2004). The authors also administered spores to mice orally and
found an increase in gene expression of IFN-γ and TNF-α in intestinal tissues and in
GALT, suggesting that B. subtilis spores stimulate the immune system. In another study,
B. subtilis A109 spores orally administered to mice were shown to result in increased
MΦ oxidative burst activity when stimulated, and increased natural killer (NK) cell
killing activity (Kosaka et al., 1998), indicating that B. subtilis stimulates multiple
immune cells in vivo. Rhee and colleagues investigated the role of microbes in GALT
development in rabbits and found that specific members of the microbiota, including B.
subtilis, promote GALT development that is important for antibody repertoire
diversification (Rhee et al., 2004). For the development of rabbit GALT, factors
associated with stress responses in B. subtilis were required, though the mechanism
behind this was not clear. In fact, how B. subtilis stimulates immune cells in all of the
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studies discussed above is not known. Understanding how B. subtilis modulates the
immune system, by identifying bacterial immunomodulatory factors and the
corresponding host response pathways, will be critical for developing B. subtilis into a
therapy that could be used in many clinical settings.
Bacillus subtilis Exopolysaccharide
Our group was interested in understanding the mechanism by which B. subtilis
benefits hosts, especially in the context of disease processes. The group initially chose
the C. rodentium-induced murine colitis model where B. subtilis had been
demonstrated to be protective (D’Arienzo et al., 2006), and confirmed the beneficial
effect of B. subtilis in C. rodentium infection using an undomesticated, biofilm-forming
strain of B. subtilis, NCIB 3610 (Jones and Knight, 2012). Bacterial biofilms are a
community of bacterial cells encased within a self-produced extracellular matrix
composed of carbohydrates, proteins, and nucleic acids. B. subtilis biofilms are also
composed of a complex matrix, and the two major components are the protein TasA and
the polysaccharide EPS produced by the products of the 15 gene eps operon, encoding
epsA through epsO (Branda et al., 2001; 2006). Administration of a B. subtilis epsH
mutant that fails to produce EPS could not protect mice from C. rodentium-induced
colitis, suggesting that EPS is required for protection (Jones and Knight, 2012). Biofilmassociated bacteria are thought to be more persistent (Anwar et al., 1992), and it may be
that biofilm formation by B. subtilis is needed to prevent C. rodentium pathology by
better excluding the pathogen through competition. However, pre-treatment of mice
with B. subtilis PY79 only mildly reduced the number of C. rodentium CFU in the colon
in the original study (D’Arienzo et al., 2006), and no difference in C. rodentium CFU or
any alteration in colonization in B. subtilis NCIB 3610-treated mice was observed in the
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studies by Jones and colleagues (Jones and Knight, 2012; Jones et al., 2014), indicating
that the assumption that B. subtilis protects through exclusion of C. rodentium from the
GI tract may not be correct. It should be noted that a few key differences between
studies by the two groups could explain the differences observed. One is that B. subtilis
PY79 is a domesticated laboratory strain that does not form robust biofilms as B. subtilis
NCIB 3610 does under in vitro conditions (Branda et al., 2001), which may affect the
way B. subtilis colonizes the GI tract. Another is that D’Arienzo and colleagues infected
suckling NIH Swiss mice with 103 CFU C. rodentium while Jones and Knight used
C57BL/6J mice infected with 5 x 108 CFU C. rodentium, so perhaps with the increased
pathogen inoculum, B. subtilis was not able to compete against C. rodentium as well in
the study by Jones and Knight. Also, the sIgA repertoire is known to be different
between different strains of mice, which leads to differences in microbial composition
(Fransen et al., 2015) that could affect how B. subtilis and C. rodentium interact within
the GI tract. The other possibility is that B. subtilis exerts its protective effect through
modulation of host processes through EPS. Jones and colleagues tested if B. subtilis
reinforces host barrier integrity during C. rodentium infection, which would reduce
pathogen translocation into host tissues and reduce triggering of inflammatory
responses that drive disease. However, B. subtilis-treated mice did not have reduced gut
leakiness during C. rodentium-infection, as measured by the translocation of orally
administered fluorescein isothiocyanate (FITC)-labeled dextran into serum (Jones et al.,
2014), indicating that B. subtilis did not alter host barrier functions. The pathology of C.
rodentium-induced colitis depends on CD4+ T cells recruited to the GI tract, which
mediate pro-inflammatory responses that drive IBD-like pathologies such as crypt
hyperplasia, loss of goblet cells, and increased pro-inflammatory cytokine levels
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(Higgins et al., 1999). When assessing C. rodentium-induced disease in B. subtilistreated mice, it was observed that B. subtilis reduced crypt heights and levels of proinflammatory cytokines and that the goblet cells were left intact (Jones and Knight,
2012; Jones et al., 2014), suggesting that B. subtilis protects hosts by altering host
inflammatory processes. Jones and colleagues hypothesized that B. subtilis EPS might
have immunomodulatory properties that mediate protection, and indeed, systemic
administration of purified EPS from B. subtilis recapitulated protection from C.
rodentium-induced colitis by B. subtilis spores (Jones et al., 2014). This suggested that
B. subtilis exerts protection by producing EPS, an immunomodulatory polysaccharide
that prevents inflammation. (Jones et al., 2014).
Host recognition of microbial molecules generally starts with PRRs. Studies of
other probiotics that work through immunomodulation found that signaling through
TLR2 was required for their beneficial effects (Danne et al., 2017; Jeon et al., 2012;
Round and Mazmanian, 2010). Based on this, it was hypothesized that EPS also alters
the immune system by first engaging a PRR. Indeed, EPS failed to protect TLR4deficient mice from C. rodentium-induced colitis as well as mice deficient in myeloid
differentiation primary response protein 88 (MyD88), the adaptor protein critical for
multiple TLR signaling pathways (Jones et al., 2014), indicating that EPS exerts its
effects through TLR4 signaling. TLR4 is best characterized as the mediator of signaling
induced by lipopolysaccharide (LPS), a microbial ligand found mostly on Gram-negative
bacteria (Hoshino et al., 1999). However, the process by which the signal initiates is
quite complex. Upon release from the microbe, LPS is first bound to LPS-binding
protein, an acute phase protein in the serum (Tobias et al., 1986). LPS is then delivered
to CD14, a glycosylphosphatidylinositol (GPI)-anchored glycoprotein found on the
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surface of MNPs (Hailman et al., 1994). Originally, CD14 was thought to be crucial for
the recognition of LPS since CD14-deficient mice were insensitive to lethal challenge
with LPS and cells from these mice failed to produce pro-inflammatory cytokines TNF-α
and IL-6 in response to LPS, though limited production could be detected at high LPS
concentrations (Haziot et al., 1996). However, CD14 does not mediate intracellular
signaling, and further studies suggested that CD14 brings LPS to TLR4 where signaling
is initiated. Transfer of LPS from CD14 to TLR4 was recently confirmed (Ryu et al.,
2017). Myeloid differentiation factor 2 (MD-2) is the major protein that binds LPS when
complexed with TLR4 (Akashi et al., 2003), and this complex initiates signaling through
the intracellular Toll-IL-1 receptor homology (TIR) domains of TLR4 (Poltorak et al.,
1998). The signal is amplified by the adaptor protein, MyD88, and leads to downstream
activation of the transcription factor nuclear factor kappa light chain enhancer of
activated B cells (NF-κB), which drives gene expression of pro-inflammatory cytokines
(Kawai et al., 1999). It is not clear how TLR4 signaling contributes to EPS-induced
protection from C. rodentium-induced colitis, given that the activation of TLR4 is
generally associated with pro-inflammatory responses while EPS decreased
inflammation during disease. Nonetheless, understanding both in vitro and in vivo
pathways of EPS-induced activation of TLR4 signaling, and the resulting host responses
will be key to understanding the therapeutic potential of B. subtilis EPS.
Anti-Inflammatory Effect of Bacillus subtilis Exopolysaccharide
Intraperitoneal (i.p.) administration of EPS is sufficient to confer protection in
murine C. rodentium-induced colitis (Jones et al., 2014). Under homeostatic conditions,
the peritoneal cavity myeloid compartment is dominated by MΦs. There are two subsets
of peritoneal MΦ: large peritoneal MΦs (LPM, defined by CD11bhighF4/80high) that
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represent the majority, and small peritoneal MΦs (SPM, defined by CD11b+F4/80+) that
represent the minority (Ghosn et al., 2010). Upon stimulation with i.p. LPS injection,
the peritoneal cavity becomes dominated instead by SPMs, which show enhanced
antimicrobial nitric oxide (NO) production compared to the LPM counterparts (Ghosn
et al., 2010). LPMs are thought to be the long-term residents of the peritoneal cavity but
disappear after i.p. LPS injection; LPMs are hypothesized to be recruited to different
nearby tissues for various purposes. For example, it was recently demonstrated that
during sterile liver injury, LPMs, defined by their unique expression of GATA-binding
factor 6 (GATA-6), were recruited directly from the peritoneal cavity to the liver surface
through the mesothelium to mediate wound healing (Wang and Kubes, 2016). Since
LPMs are the major innate immune cell within the peritoneal cavity and MΦs are well
known to sense microbial products to mediate various functions, EPS was hypothesized
to alter the functions of LPMs to exert its protective functions. Indeed, EPS failed to
protect mice from C. rodentium infection when mice were depleted of peritoneal MΦs
through the administration of clodronate-loaded liposomes, indicating that MΦs are
required for protection by EPS (Paynich et al., 2017). MΦs are described in a spectrum
between two polarization states ranging from pro-inflammatory to anti-inflammatory
functions. Since EPS reduces inflammation during C. rodentium infection that is
primarily thought to be driven by T cells (Higgins et al., 1999), EPS was proposed to
drive an anti-inflammatory polarization of MΦs that limit inflammation during C.
rodentium-induced colitis. Paynich and colleagues compared the CD11bhighF4/80high
LPM compartment between phosphate buffered saline solution (PBS)- and EPS-treated
mice 3 days after i.p. injection and found that the LPMs resembled M2 MΦs in EPStreated mice, showing increased expression of M2 markers, including CD206 and Arg-1
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(Paynich et al., 2017). These EPS-induced MΦs limited splenic T cell activation in vitro,
suggesting that EPS induces anti-inflammatory M2 MΦs that suppress T cell functions
(Figure 1A) (Paynich et al., 2017).
Although M2 MΦs can inhibit T cell activation by depletion of arginine through

Figure 1: Established Model for the Anti-Inflammatory Effect of B. subtilis
EPS. A. EPS drives anti-inflammatory M2 polarization of MΦs. B. EPS-induced M2
MΦs limit T cell activation and promote Treg differentiation. C. EPS limits systemic T
cell activation, limiting disease due to inflammation. Adapted from Paynich and
colleagues, Journal of Immunology, 2017.
the action of Arg-1 expressed by EPS-induced M2 MΦs, supplementation of L-arginine
did not restore T cell activation in co-cultures with EPS-induced M2 MΦs. However,
neutralization of the inhibitory cytokine TGF-β and blockade of the inhibitory cell
surface molecule programmed death-ligand 1 (PD-L1) using antibodies in vitro restored
T cell activation, suggesting that EPS-induced M2 MΦs inhibit T cells through TGF-β
and PD-L1 (Paynich et al., 2017). In addition, co-cultures of EPS-induced M2 MΦs with
splenocytes resulted in an increase in CD4+CD25+Foxp3+ Treg cells, and there was an
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increased percentage of Foxp3+ T cells in the peritoneal cavity of EPS-treated mice in
vivo, which suggests that EPS-induced M2 MΦs promote Treg cell differentiation
(Figure 1B) (Paynich et al., 2017). Also, cells from the mesenteric lymph nodes (mLN)
of EPS-treated mice were hyporesponsive to stimulation with phorbol 12-myristate 13acetate (PMA) and ionomycin, indicating that EPS limits T cell functions in vivo
(Figure 1C) (Paynich et al., 2017). Finally, transfer of these EPS-induced MΦs to
recipient mice was sufficient for protection from C. rodentium-induced colitis (Paynich
et al., 2017), indicating that B. subtilis EPS protects hosts from colitis in large part
through these anti-inflammatory M2 MΦs that modulate T cell activation during disease
in vivo, limiting inflammation and improving disease outcomes.
Administration of EPS results in anti-inflammatory M2 MΦs in the peritoneal
cavity, but it is not known if EPS has similar effects in other tissues; after all, i.p.
injection is considered a systemic route of administration (Turner et al., 2011). EPStreated mice had reduced levels of T cell effector cytokines in the serum after in vivo
administration of anti-CD3ε antibodies that activate T cells (Paynich et al., 2017),
indicating that i.p. administration of EPS affects T cells systemically. Consistent with
this view, orally administered B. subtilis spores, but not the epsH mutant spores,
prevented allergic inflammation in the lung in a house dust mite-induced eosinophilic
inflammation model (Swartzendruber et al., 2019), indicating that the antiinflammatory effect of EPS is systemic, and can reduce inflammation in tissues beyond
the GI tract. To date, the structure and composition of EPS remain unknown.
In summary, B. subtilis is a probiotic bacterium that produces EPS, a component
of its biofilm that has systemic anti-inflammatory properties. B. subtilis has been
consumed by humans for many years and is not known to cause disease in
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immunocompetent individuals. Additionally, it can be easily administered as durable
spores by the oral route, and there is a potential to use purified EPS as a pharmacologic
agent. This anti-inflammatory property of B. subtilis is likely to benefit many patients
suffering from various diseases with inflammatory pathophysiology, and to this end, the
specific mechanisms by which EPS modulates host responses in other inflammatory
disease conditions remain to be elucidated. Here, we present our study on exploring the
potential to use EPS for one such disease with a systemic inflammatory pathology,
sepsis, one of the most severe manifestations of systemic infection.
Sepsis and Staphylococcus aureus
Sepsis Epidemiology and Pathophysiology
Sepsis is defined as a life-threatening organ dysfunction caused by a
dysregulated host response to infection (Singer et al., 2016). Sepsis is one of the most
severe manifestations of ongoing infection with mortality rates approaching 50% in
some cases (Angus et al., 2001). Sepsis accounted for about 6% of all US adult
hospitalizations in 2014, estimated to be over a million cases a year (Rhee et al., 2017).
While controversial, sepsis is considered the most expensive condition to manage in the
US (Torio and Andrews, 2006). Sepsis is generally thought to start when microbial
ligands engage host immune cells, setting off a pro-inflammatory response designed to
clear microbial pathogens: activation of innate immune cells, production of cytokines
and chemokines to recruit and activate additional immune cells, and activation of
complement cascades to further support pro-inflammatory responses. While many
processes are thought to contribute to the pathophysiology of sepsis, the most clinically
concerning is the loss of endothelial integrity. Recruitment of additional immune cells to
tissues generally occur from the circulation. Initially, the local pro-inflammatory
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mediators activate the nearby endothelial cells and induce their expression of leukocyte
adhesion molecules such as vascular cell adhesion protein 1 (VCAM-1) (Bevilacqua et al.,
1987; Osborn et al., 1989). Circulating immune cells are captured by leukocyte adhesion
molecules and start rolling along the endothelial surface until activated by chemokines
through GPCRs (Atherton and Born, 1972; Kim et al., 2003). This leads to the
expression of integrins such as intercellular adhesion molecule 1 (ICAM-1) on
endothelial cells that mediate adhesion between immune cells and the endothelium
(Dustin and Springer, 1988; Dustin et al., 1986). Finally, the adhered immune cell
crawls to a junction between endothelial cells (Phillipson et al., 2006) where it squeezes
through to the basolateral side to enter the tissue, a processes defined as diapedesis.
This process is accommodated in part by the loosening of the endothelial junctions by
the increase in intracellular free calcium ions in response to cross-linking of adhesion
molecules, which activates myosin light chain kinases and subsequent actin-myosin
fiber contractions (Hixenbaugh et al., 1997; Huang et al., 1993). This results in a small
separation of endothelial cells that immune cells can squeeze through, which increases
vascular permeability. Increased leakiness of the endothelium is generally maintained
locally, but under severe systemic conditions such as sepsis, vascular permeability is
increased systemically, and intravascular fluid is lost into the tissues. This makes
maintaining blood pressure difficult, and perfusion of organs can become limited due to
cardiovascular collapse, leading to multi-organ failure. Another major complication
during sepsis that stems from endothelial dysfunction is related to the coagulation
system. Coagulation is mediated by a complex cascade involving plasma coagulation
factors and platelets, designed for deposition of fibrin at sites of tissue damage to
prevent leakage of blood contents. Many aspects of inflammation are known to activate
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the coagulation cascade, but the most prominent way sepsis is thought to initiate the
coagulation cascade is the tissue factor that is produced as a result of tissue and
endothelial damage (Osterud and Rapaport, 1977). It should be noted that microbial
ligands like LPS have been shown to directly activate platelets as well (Andonegui et al.,
2005), though the contribution of such activation to sepsis is not clear. Due to the
systemic nature of the disease, sepsis can initiate widespread activation of coagulation
cascades within the vasculature, a condition known as disseminated intravascular
coagulation (DIC). DIC is thought to precipitate two major issues: widespread
microvascular thrombosis that blocks blood flow resulting in organ dysfunctions, and
rapid depletion of platelets that further complicates endothelial dysfunction and
maintenance of blood pressure for organ perfusion (Akca et al., 2002; Toh and Alhamdi,
2013). DIC is a common complication of severe sepsis and is often associated with
mortality (Ogura et al., 2014). Despite extensive clinical studies, sepsis remains an often
lethal challenge that is difficult for physicians to identify, diagnose, and manage.

Table 3: Evaluation of Sepsis in Patients. As recommended by Singer and
colleagues, Journal of the American Medical Association, 2016.
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Clinically, patients suspected of sepsis are evaluated using a sepsis-related organ
failure assessment (SOFA) score. SOFA score system evaluates functions of major organ
systems, determining a score for estimated organ damage (Singer et al., 2016). For
example, mean arterial pressure (MAP) greater than or equal to 70 mmHg, considered
relatively normal in terms of overall cardiovascular function, is given a score of 0 while
MAP less than 70 mmHg would be given a score of 1. Higher scores would be given if
pharmacologic agents had to be used to maintain MAP. Functions of other systems such
as renal, hepatic, respiratory, and coagulation systems are evaluated and given scores,
and a cumulative score is determined to diagnose sepsis, along with microbiologic
evidence of infection. Increased serum lactate levels in patients, a sign of metabolic
acidosis due to severe illness, with hypotension resistant to fluid resuscitation has been
associated with much higher mortality rates, so these criteria are used additionally to
diagnose septic shock (Singer et al., 2016). Since many patients often present with vague
symptoms, and since sepsis is a rapidly developing condition, physicians are encouraged
to use a broad screening tools such as quick SOFA (qSOFA) scoring, a much simpler
version of the SOFA score, to identify suspected patients and subsequently evaluate for
sepsis, as outlined in Table 3. However, many patients with modest dysfunctions
according to SOFA scores can rapidly deteriorate, and the diagnostic criteria for sepsis
remain controversial (Singer et al., 2016), making the diagnosis of sepsis a challenge.
Treatment of sepsis patients focuses on two primary approaches.
The best highlighted is antimicrobial therapy to reduce inflammatory stimuli.
The other is to limit host responses, especially on maintaining MAP and preventing
platelet depletion. Due to high mortality rates, sepsis patients are often aggressively
treated: broad-spectrum antimicrobial therapy initiated within one hour, aggressive
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testing to identify the infectious source, immediate intravascular fluid resuscitation,
vasopressors, and more invasive interventions such as blood or platelet transfusions and
mechanical ventilation if necessary (Rhodes et al., 2017). Despite aggressive
management, mortality rates for sepsis remain high (Angus et al., 2001; Rhee et al.,
2017), highlighting a critical need for novel strategies to manage and treat sepsis
patients. For a majority of sepsis cases, the causative organism is not identified, though
some of this is presumably attributed to early initiation of broad-spectrum antimicrobial
therapy that could impede detection of organisms through traditional culture methods
(Vincent et al., 2009). Of the cases for which the causative organism is documented, S.
aureus remains the top etiologic agent of sepsis, accounting for about 20% of all cases
(Vincent et al., 2009).
Clinical Considerations for Staphylococcus aureus Infections
S. aureus is a gram positive bacterium found on the skin and anterior nares of
colonized individuals. About 30% of the general population is thought to be colonized
with S. aureus without apparent disease, and S. aureus is considered a part of the
healthy microbiota of the skin (Gorwitz et al., 2008). However, upon breaching
epithelial barriers, S. aureus can seed into underlying soft tissue and cause disease
generally described by a cutaneous abscess; S. aureus is the primary cause of skin and
soft tissue infections (SSTI), estimated to be about 3.4 million emergency visits in 2005
(Pallin et al., 2008). While SSTIs are the most common form of S. aureus infection, S.
aureus can penetrate into deeper tissues and cause severe diseases including necrotizing
fasciitis, necrotizing pneumonitis, osteoarthritic infections, infective endocarditis, and
bacteremia, to name a few.
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Like many infectious diseases, S. aureus bloodstream infections are aggressively
managed with antibiotics designed to reduce the inflammatory stimuli (Liu et al., 2011).
Historically, penicillin was introduced in the 1940s, that successfully reduced case
fatality rates due to S. aureus bacteremia (Blair and Carr, 1960; Fleming, 1929).
However, penicillin resistance was reported only a few years later, and within a decade,
antibiotic-resistant S. aureus, harboring a plasmid-encoded penicillinase, became
widely prevalent (Blair and Carr, 1960). A penicillinase-resistant β-lactam antibiotic,
methicillin, was introduced in the late 1950s to combat these resistant S. aureus strains,
but the medical community was met with methicillin-resistant S. aureus (MRSA) by
1961 (Barber, 1961), which limited treatment efficacy. Antibiotic resistance continues to
be a significant problem today, where strains resistant to a variety of standard
antimicrobial agents are reported, including vancomycin-resistant strains (Hiramatsu et
al., 1997; Liu et al., 2011; Weigel et al., 2003), making treatment of S. aureus infections
a challenge. Several novel antimicrobial agents are in the development pipeline
(Holubar et al., 2016), but resistance can and will likely arise as resistance is often
conferred through mobile genetic elements that are easily acquired, and that will
perpetuate the process of developing antimicrobials and resistances. Therefore, novel
strategies to combat S. aureus infections are critically needed. A major goal of
antimicrobial therapy during sepsis is to reduce the inflammatory stimuli by targeting
the pathogens for removal. However, an alternative approach may be to target the host
to limit overt inflammation and promote survival. To this end, understanding host
responses against S. aureus during bloodstream infection is critical.
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Host Responses to Staphylococcus aureus Infection
As in other bacterial infections, the initial host response against S. aureus is
induced through recognition of microbial molecules through PRRs: for S. aureus,
recognition of lipopeptides through TLR2 is the primary sensor mechanism (Hashimoto
et al., 2006; Takeuchi et al., 2000).

Figure 2: Histology of S. aureus-Induced Murine Renal Abscess. A female
C57BL/6J mouse was systemically infected with S. aureus USA300 (LAC) and kidneys
were assessed 2 days post infection (d.p.i) for histopathologic features. A. Hematoxylin
and eosin (H&E) stained section of a S. aureus renal abscess. 400x magnification. B.
Schematic representation of histopathologic features of the S. aureus renal abscess 1.
Surrounding renal tissue. 2. Fibrous capsule surrounded by additional immune cells like
macrophages and T cells. 3. Damaged tissue with necrotic cells and neutrophils. 4.
Infected focus of S. aureus. Image by Paik and colleagues.
This recognition results in the production of signals and chemokine gradients to recruit
neutrophils to the site of infection, which is critical for initial containment of the
pathogen. Depletion of neutrophils results in increased mortality in an animal model of
S. aureus bacteremia (Alonzo III et al., 2012), and patients with defective neutrophil
functions are predisposed to infections, predominantly S. aureus (Marciano et al., 2015).
Once at the site of infection, neutrophils phagocytose S. aureus and try to kill the
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pathogen through a complex intracellular process involving endosomal acidification,
production of RNS and ROS, and release of AMPs. In addition, neutrophils can release
DNA and toxic granules known as neutrophil extracellular traps as they undergo cell
death (NETosis) which traps bacteria for killing (Brinkmann et al., 2004). S. aureus
harbors many mechanisms to withstand the actions of neutrophils, requiring additional
host mechanisms for immunity such as MΦs and T cells. Monocytes, which differentiate
into MΦs within tissues, are generally the first cell type recruited after neutrophils to
augment anti-bacterial immunity (Volkman and Gowans, 1965). MΦs use similar
mechanisms as neutrophils to contain pathogens but have the additional capacity to
present antigens and coordinate subsequent immune responses mediated by the
adaptive arm of immunity. T cells of the adaptive immune system can then augment
bacterial killing through the production of pro-inflammatory cytokines, which help
recruit more neutrophils and monocytes and increase their killing capacities (Held et al.,
1999). These cells typically constitute the classical pathological feature of S. aureus
infections characterized as abscesses. Abscesses form as neutrophils arrive at the
infected site and employ its antimicrobial defenses. S. aureus withstands neutrophils
while tissue damage occurs, creating a core containing bacteria, necrotic debris, and
neutrophils. The additional immune cells recruited are thought to contain the infection
by promoting the development of the fibrous capsule at the edge of the infected foci,
forming a mature abscess structure, as outlined in Figure 2.
Staphylococcus aureus Evasion of Host Immunity: Recognition
Unfortunately, S. aureus has numerous mechanisms to interfere with the host
immune response at multiple levels, as described in Table 4. For one, S. aureus can
interfere with host recognition, mainly by counteracting TLR2 signaling. One way S.
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aureus does this is through a lipoylated E2 subunit of the pyruvate dehydrogenase (E2PDH), an essential metabolic enzyme complex, which is also secreted.

Table 4: Major Mechanisms of Immune Evasion by S. aureus.
The lipoylated protein has structural similarities with TLR1-2 agonists and is thought to
limit TLR2 signaling through direct antagonism, interfering with TLR2 signaling
induced by S. aureus lipopeptides, resulting in limited host response in vivo and
promoting bacterial survival (Grayczyk et al., 2017). S. aureus can also do this by
Staphylococcal superantigen-like protein 3 (SSL3), which binds to TLR2 and
antagonizes signaling induced by TLR2 agonists in cells in vitro (Bardoel et al., 2012).
By limiting activation by TLR2, S. aureus evades recognition by the host to promote
bacterial survival. Another mechanism by which S. aureus can subvert host responses is
by impairing immune cell recruitment, that depends on immune cell recognition of
chemokine ligands through chemokine receptors. Chemotaxis inhibitory protein of S.
aureus (CHIPS) is a protein secreted by S. aureus that binds to phagocytes to interfere
with chemokine-induced migration (Haas et al., 2004). Similarly, Staphopain A is a
protease that cleaves C-X-C motif chemokine receptor 2 (CXCR2) on the surface of
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neutrophils, limiting neutrophil homing to infective tissues. (Laarman et al., 2012).
Through these mechanisms, S. aureus limits immune cell recruitment to infected sites,
promoting bacterial survival.
Staphylococcus aureus Evasion of Immunity: Withstanding the Killing
Once the host recognizes pathogens and recruits MNPs to the infected site,
bacterial clearance is thought to occur through phagocytosis of bacteria for intracellular
killing. One mechanism by which the host enhances phagocytosis of pathogens is
through antibody- and complement-mediated opsonization. Opsonization is the process
by which antibodies and complement deposit on bacterial surfaces, enhancing uptake by
phagocytes that recognize the deposited antibodies or complement through antibody
fragment crystallizable region (Fc) receptors and complement receptors, respectively
(Caron and Hall, 1998). Protein A is a molecule produced by S. aureus that binds
immunoglobulins and blocks their opsonic activity (Forsgren and Quie, 1974), which
would reduce Fc receptor-mediated phagocytosis of bacteria. On the side of complement,
Staphylococcal complement inhibitor (SCIN) is a C3 convertase inhibitor that prevents
complement activation and subsequent deposition on bacterial surfaces, limiting
opsonization and uptake by human neutrophils (Rooijakkers et al., 2005). Even when S.
aureus is taken up by phagocytes, S. aureus harbors mechanisms to resist phagocytemediated killing. Staphyloxanthin is a carotenoid pigment that gives S. aureus the
hallmark golden color, but it is also an antioxidant that allows S. aureus to withstand
neutrophil-mediated killing through the production of RNS and ROS (Liu et al., 2005).
S. aureus also encodes two superoxide dismutases, SodA and SodM, which inactivate
superoxide radicals to resist phagocyte-mediated killing (Karavolos et al., 2003).
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Through these mechanisms, S. aureus subverts the host phagocytic responses,
promoting its persistence within hosts.
Staphylococcus aureus Evasion of Immunity: Killing Immune Cells
S. aureus also harbors more sinister mechanisms to counteract the host immune
response, a deleterious challenge to the immune system through toxins. S. aureus
produces seven different pore-forming toxins, some of which target immune cells. These
leucocidins bind to a specific host cell receptor and subsequently recruit another subunit
for oligomerization on the cell surface, forming a pore through the host cell membrane
and killing it (Finck-Barbançon et al., 1993; Noda et al., 1982; Woodin and Wieneke,
1963; 1967). The most notorious leucocidin is Panton-Valentine leucocidin (PVL), which
recognizes human complement C5a receptor (C5aR) to kill neutrophils (Spaan et al.,
2013). Neutrophils are not the only cells to be targeted by leucocidins, as leucocidin ED
(LukED) had been demonstrated to have a broad repertoire of cells it kills by targeting
C-C motif chemokine receptor 5 (CCR5), CXCR1, and CXCR2 on T cells, NK cells,
neutrophils, monocytes, and DCs (Alonzo III et al., 2012a; 2012b; Reyes-Robles et al.,
2013). In the context of abscesses, monocytes are additionally recruited to reinforce
neutrophil-mediated antimicrobial defense, but S. aureus also harbors ways to target
MΦs for killing. A study demonstrated that S. aureus could produce deoxyadenosine
from extracellular DNA released by neutrophils during NETosis to kill U937 cells, a MΦ
cell line (Thammavongsa et al., 2013; Winstel et al., 2018). S. aureus mutants deficient
in nuclease and adenosine synthase, nuc and adsA respectively, failed to exclude F4/80+
MΦs from the core of renal abscesses (Thammavongsa et al., 2013), suggesting that S.
aureus utilizes DNA released by neutrophils through NETosis to kill MΦs, promoting
bacterial survival within abscesses. It should be noted that the killing of U937 MΦs by S.
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aureus-produced deoxyadenosine was very mild, and that stressing the DNA processing
system using pentostatin, a purine analog, was required for robust killing of MΦs. It is
not clear if such stress would occur in vivo, but S. aureus mutants incapable of
producing deoxyadenosine could not exclude MΦs from the abscesses, indicating that
the killing of MΦs likely occurs in vivo. By targeting multiple immune cells for killing, S.
aureus is able to evade a variety of host responses to establish itself within various host
tissues.
Staphylococcus aureus Evasion of Immunity: Superantigens
The cells of the adaptive immune system can additionally be targeted for killing
through activation-induced cell death, which is mediated by superantigens (SAg)
produced by S. aureus. Staphylococcal enterotoxins and enterotoxin-like proteins (SE
and SEl) and related SAgs are secreted proteins that bind to both the Vβ region of the T
cell receptor (TCR) complex and MHC class II on antigen presenting cells, activating up
to 20% of the T cell repertoire (Fraser, 1989; Peavy et al., 1970; White et al., 1989). This
polyclonal activation of T cells results in massive production of pro-inflammatory
cytokines, which can cause a phenomenon called cytokine storm that causes toxic shock
syndrome, an often fatal complication (Todd et al., 1978). Concurrently, the
inappropriately activated T cells can impede proper adaptive immune responses, either
by activation-induced cell death that removes specific T cells from the repertoire and by
limiting activation of T cells through presented antigens (White et al., 1989; Xu et al.,
2014; Ziegler et al., 2011). Similarly, the other arm of adaptive immunity can be targeted
by protein A which has SAg activity against B cells that results in apoptotic removal of B
cells from the repertoire, limiting antibody responses (Goodyear and Silverman, 2004).

58

By targeting different immune cells for destruction, S. aureus is able to impede immune
effector cell functions directly, promoting its survival.
Concluding Remarks
During infection, S. aureus utilizes many mechanisms to perturb the immune
response at multiple levels, resulting in a suboptimal host response not sufficient for
bacterial clearance. This allows the pathogen to persist and, in the case of systemic
infection, overt systemic inflammation occurs as a prolonged attempt to clear the
pathogen. This perturbed inflammation can often result in the manifestation of sepsis
and lethality, despite aggressive antimicrobial therapy to reduce bacterial burden.
Therefore, an optimal approach to managing patients with systemic S. aureus infections
is to bolster host antimicrobial defenses to reduce the bacterial burden while limiting
inflammation to reduce the tissue damage and prevent the development of lethal
complications such as sepsis. B. subtilis EPS is a probiotic-derived agent with potentially
systemic anti-inflammatory properties. We reasoned that this anti-inflammatory agent
could be used to limit inflammation during S. aureus bloodstream infections, reducing
the host burden of disease. Herein, we focused our studies on tests of the protective
potential of EPS against S. aureus bloodstream infection using a murine model, and to
elucidate the specific mechanisms by which protection occurs, with the hope that these
insights will help develop novel strategies to manage sepsis and reduce patient suffering.

CHAPTER TWO
MATERIALS AND METHODS
Mice
All studies utilizing animals were reviewed and approved by the Institutional
Animal Care and Use Committee at Loyola University Chicago Health Sciences Division
(Maywood, IL). Unless otherwise specified, all mice were bred in house at the
Comparative Medicine Facility at Loyola or purchased from Jackson Laboratories (Bar
Harbor, ME). ND4 Swiss Webster mice were purchased from Envigo (Indianapolis, IN).
Founder mice for in house breeding were purchased from Jackson Laboratories. All
mice were housed at the Comparative Medicine Facility at Loyola and fed standard
sterile chow. All mice used for this study is listed in Table 5. Unless otherwise noted,
C57BL/6J mice were used.

Table 5: Mice Used in This Study.
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Common Reagents
All bacteriologic media were purchased from BD Biosciences (San Jose, CA). All
cell culture media components were purchased from Thermo Fischer Scientific
(Waltham, MA). Fetal bovine sera (FBS) for cell culture were purchased from Atlanta
Biologicals (Flowery Ranch, GA). Modified Roswell Park Memorial Institute (RPMI)
medium was used for all cell culture experiments (RPMI base medium supplemented
with 2.4 mM L-glutamine, 1x minimal essential medium (MEM) vitamins solution, 50
U/mL penicillin, 50 μg/mL streptomycin, 0.5 μg/mL amphotericin B, 0.5x non-essential
amino acids, 0.5x essential amino acids, 10 mM 4-(2-hydroxyethyl)-1piperazineethanesulfonic acid (HEPES), 1 mM sodium pyruvate, 0.195 % sodium
bicarbonate (NaHCO3), 30 μg/mL gentamicin, 3.5 x 10-4 % 2-mercaptoethanol, 10%
heat-inactivated FBS). For antibiotic-free RPMI medium, penicillin, streptomycin, and
gentamycin were excluded. All antibodies were purchased from BioLegend (San Diego,
CA) unless otherwise specified. All chemical reagents were purchased from
MilliporeSigma (Burlington, MA) unless otherwise specified.
Preparation of B. subtilis-Derived EPS
EPS was isolated from culture supernatants of B. subtilis DS991 (overproduces
and secretes EPS) or DK4623 (DS991 derivative with lytic genes (Wang et al., 2014)
deleted) grown to stationary phase in 1% tryptone phosphate broth (1% tryptone, 25 mM
phosphate, 0.1 M sodium chloride (NaCl)) or minimal salts glutamate glycerol (Msgg)
medium. Alternatively, EPS was prepared from B. subtilis DK6251 (Isopropyl β-D-1thiogalactopyranoside (IPTG)-inducible eps operon with gamma-polyglutamic acid (γPGA) deficiency) grown as a lawn on Luria Bertani (LB, Miller formulation) agar (1.5%)
plates with 1 mM IPTG. For ΔEPS, B. subtilis DS5187 (DS991 derivative that cannot
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make EPS) was used. All bacterial strains used in this study are listed in Table 6. EPS
was extracted by precipitation with 75% ethanol at -20°C. The precipitate was pelleted
by centrifugation at 13,700 x g at 4°C for 30 min, resuspended in 0.1 M pH 8 Tris buffer,
and treated with 67 μg/mL DNase and 330 μg/mL RNase at 37°C for 2 hours (hr),
followed by digestion with 40 μg/mL proteinase K at 55°C for 2 hr. EPS was then
purified on diethylaminoethyl (DEAE)-cellulose (GE Healthcare, Chicago, IL) ion
exchange column chromatography or gel filtration on Sephacryl S-500 (GE Healthcare).
Carbohydrate-positive fractions were identified, and total carbohydrate content was
estimated using a modified phenol sulfuric acid assay (Albalasmeh et al., 2013; Masuko
et al., 2005). All EPS preparations were assessed for the lack of protein and nucleic acid
content by spectrometry and also for their ability to induce peritoneal M2 MΦ as
previously described (Paynich et al., 2017) prior to use. All three strains of WT mice in
this study were capable of generating peritoneal M2 MΦs in response to i.p. EPS
administration as described previously (Paynich et al., 2017).
Preparation of S. aureus Cultures
Starter cultures of all S. aureus strains were prepared in tryptic soy broth (TSB)
medium, cultured at 37°C overnight. S. aureus LAC and AH1263 (plasmid-cured
derivative of LAC (Boles et al., 2010)) were used in many studies interchangeably, but
we did not observe noticeable differences in outcomes. Transposon (Tn) insertion
mutant library strains from the University of Nebraska Transposon Mutant Library (Fey
et al., 2013) were used for SAg studies. For bloodstream infection experiments, starter
cultures were freshly diluted 1:100 into TSB and cultured at 37°C to exponential phase
for 3 hr. Inoculum was prepared by washing the subculture three times in 10 mL PBS,
normalized to an inoculum of 108 CFU/mL in PBS on the day of infection using optical
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density (OD) measurements on Genesys 10S UV-Vis spectrophotometer (Thermo
Fischer Scientific), to OD600 nm ~ 0.323.
Statistical Analyses
Data were analyzed using GraphPad Prism 5 (GraphPad Software, San Diego,
CA). Unpaired, two-tailed Student’s t-test was used to determine statistical significance
unless otherwise noted.
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Table 6: Bacterial Strains Used in This Study. All B. subtilis strains were
generously provided by Dr. Daniel B. Kearns of Indiana University. S. aureus LAC was
from Dr. Victor J. Torres at New York University. AH1263 is from Boles and colleagues,
PLoS ONE, 2010. All the Tn library strains are from Fey and colleagues, mBio, 2013.
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Murine Model of Bloodstream Infection by S. aureus
Four to eight week-old C57BL/6J mice were treated with 3 to 6 mg/kg EPS in
PBS by i.p. injection one day prior to and one day after systemic infection with S. aureus.
For infection, mice were first anesthetized by i.p. injection with 250 mg/kg Avertin
(MilliporeSigma), then injected with 107 CFU S. aureus in 100 μL PBS through the
retro-orbital venous plexus. Mice were monitored for signs of disease daily. For survival
analysis, any mice that lost more than 20% body weight were considered dead to avoid
utilizing any subjective criteria for assessing mortality. To assess bacterial burden,
tissues were harvested from euthanized mice into 5 mL PBS and homogenized using a
Polytron Brinkmann PT 10/35 homogenizer (Brinkmann Instruments, Westbury, NY).
The homogenates were plated on tryptic soy agar (TSA, 1.5% agar) plates for 12 hr at
37°C to enumerate bacteria. Cleared tissue homogenate supernatants were collected by
centrifugation at 3,000 x g to assess levels of local cytokine and chemokine levels. Blood
samples were collected from submandibular facial veins to determine bacterial burden
or to determine serum levels of cytokines and chemokines.
Cytokine and Chemokine Measurements
Levels of cytokines and chemokines were determined using the cytometric bead
array (CBA) flex set for IL-1α, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12p70, IL-13, IL17A, keratinocyte-derived chemokine/C-X-C motif chemokine ligand 1 (KC/CXCL1),
monocyte chemoattractant protein 1/C-C motif chemokine ligand 2 (MCP-1/CCL2), MΦ
inflammatory protein 1 alpha (MIP-1α/CCL3), MIP-1β/CCL4, regulated on activation,
normal T cell expressed and secreted (RANTES/CCL5), granulocyte-MΦ colony
stimulating factor (GM-CSF), granulocyte CSF (G-CSF), IFN-γ, and TNF-α (BD
Biosciences), according to manufacturer’s specifications. Samples were analyzed using
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LSRFortessa or FACSCantoII flow cytometers (BD Biosciences) and data were analyzed
using FCAP array v3.0 or FlowJo V10 (BD Biosciences).
S. aureus Growth Assay
Starter cultures of S. aureus were subcultured 1:100 into 200 μL TSB containing
EPS at various concentrations in a Falcon 96-well flat bottom tissue culture plate
(Corning, Corning, NY). The plate was incubated at 37°C on a 250 round per minute
(rpm) shaker. Growth was monitored at various time points by measuring OD550 nm
using a BioTek ELx800 absorbance microplate reader (BioTek, Winooski, VT).
S. aureus Uptake and Growth Restriction by Immune Cells
Starter culture of S. aureus was washed three times in 10 mL PBS then
normalized to 108 CFU/mL by OD600 nm ~ 0.323. S. aureus inoculum was serumopsonized for 30 min using 10% fresh mouse serum at 37°C. Four- to eight-week-old
mice were treated with 3 to 6 mg/kg EPS by i.p. injection and peritoneal cells were
harvested by lavage with 300 mL/kg RPMI medium. For MΦ depletion studies, 200 μL
clodronate- or PBS-loaded liposomes (VU Medisch Centrum, Amsterdam, Netherlands)
were administered to ND4 Swiss Webster mice by i.p. injection 1 day prior to EPS
administration. F4/80+ and F4/80- peritoneal cells were purified from mice 3 days after
EPS injection using the BD IMag cell separation system (BD Biosciences) according to
manufacturer’s specifications after incubation with anti-CD16/32 (93, BD Biosciences)
and biotinylated anti-F4/80 (BM8) antibodies for 15 min on ice. F4/80+ macrophages
or F4/80- cells (5 x 105), or total peritoneal cells (106) were infected with opsonized S.
aureus at MOI 1 in antibiotic free RPMI medium and incubated in rotating microfuge
tubes at 37°C for 30 min. To enumerate internalized S. aureus, cells were washed three
times with 1 mL PBS then lysed with 0.1% saponin (MilliporeSigma) and plated on TSA
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plates for 12 hr at 37°C. Restriction of S. aureus growth was assessed by culturing the
washed cells for 2 to 6 hr followed by quantifying S. aureus CFU after lysis with 0.1%
saponin and plating on solid medium. For ROS experiments, 2 μM
diphenyleneiodonium (DPI, MilliporeSigma) was included in medium during the assay.
To assess peritoneal cell composition, cells were first incubated with anti-CD16/32 (93)
antibody for 15 min then stained with anti-CD11b-allopyocyanin (APC, M1/70), antiF4/80-APC/cyanine 7 (APC/Cy7, BM8), anti-Ly6C-pycoerythrin (PE, HK1.4), antiLy6G-FITC (1A8) antibodies for flow cytometric analysis using FACSCanto II. Data were
analyzed using FlowJo V10.
Measurement of Reactive Oxygen Species Levels
Total peritoneal cells from PBS- or EPS-treated mice were harvested by lavage
with 300 mL/kg RPMI medium 3 days after i.p. EPS injection. Cells (106) were infected
with opsonized S. aureus at MOI 1 for 30 min at 37°C in rotating microfuge tubes in the
presence of 1.25 μM CellROX Green (Thermo Fischer Scientific). For mitochondrial ROS
(mtROS) measurements, 2.5 μM MitoSOX Red (Thermo Fischer Scientific) was used
instead. Cells were washed three times in 1 mL PBS then incubated with anti-CD16/32
(93) antibody for 15 min. Cells were subsequently stained with anti-CD11b-APC (M1/70)
and anti-F4/80-APC/Cy7 (BM8) for flow cytometric analysis using LSRFortessa
(CellROX Green) or FACSCanto II (MitoSOX Red). Data were analyzed using FlowJo
V10, and median fluorescence intensity (MFI) of ROS indicators were determined after
gating on CD11bhighF4/80high LPMs.
Preparation of S. aureus Culture Supernatants
Overnight starter cultures of S. aureus AH1263, JE2, sek::erm, seq::erm,
sex::erm, USA300_1559::erm were prepared in 5 mL antibiotic-free RPMI medium.
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Starter cultures were diluted 1:100 into antibiotic-free RPMI medium and cultured for 9
hr at 37°C on a 250 rpm shaker. Supernatants were harvested by centrifugation at 3,000
x g and sterilized by passing it through a 0.2 μm filter.
Measurement of Reactive Nitrogen Species by Griess Test
Peritoneal F4/80+ cells from PBS- and EPS-treated mice were harvested and
purified using BD IMag cell separation system 3 days after i.p. EPS injection. Cells (105)
were seeded into Falcon 96-well flat-bottom tissue culture plate in 200 μL RPMI
medium per well and stimulated with 10% S. aureus AH1263 culture supernatant for 24
hr. Supernatant (50 μL) from the stimulated cultures were mixed with equal volume 1 %
sulfanilamide (Thermo Fischer Scientific) and equal volume 0.1 %
naphthylethylenediamine dihydrochloride (MilliporeSigma) and OD550nm were
measured using a BioTek ELx800 absorbance microplate reader (BioTek, Winooski, VT).
RNS levels were estimated using a sodium nitrite standard.
Superantigen-Induced Splenic T Cell Proliferation
Total splenocytes from naïve, PBS-treated, or EPS-treated mice were labeled
with 5 μM CellTrace Violet (CTV, Thermo Fischer Scientific) according to
manufacturer’s specifications. CTV-labeled cells (3.5 x 105) were seeded into a Falcon
96-well flat-bottom tissue culture plate in 200 μL RPMI medium per well. Cells were
stimulated with 33% S. aureus culture supernatants for 4 days. For peritoneal MΦ cocultures, F4/80+ cells (5 x 104) from PBS- or EPS-treated mice, purified using the BD
IMag cell separation system, were added to the wells. To assess for T cell proliferation
and activation, cells were stained with anti-CD4-APC (GK1.5), anti-CD8a-PE/Cy7 (536.7), anti-CD25-APC/Cy7 (PC61), and anti-CD44-PE (IM7) and analyzed using
LSRFortessa or FACSCanto II. Data were analyzed using FlowJo V10.
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Analysis of Peritoneal Macrophage Phenotype by Flow Cytometry
Peritoneal cells were harvested from PBS- and EPS-treated mice by lavage with
300 mL/kg RPMI medium 3 days after i.p. EPS injection. Cells were incubated with
anti-CD16/32 antibody for 15 min on ice and stained with anti-CD11b-APC (M1/70),
anti-F4/80-APC/Cy7 (BM8), and anti-CD206-Brillian Violet 421 (BV421, C068C2).
Cells were fixed and permeabilized using BD Cytofix/Cytoperm solution (BD
Biosciences) and stained with anti-iNOS-PE/eFluor 610 (CNXFT, Thermo Fischer
Scientific) and anti-Arg-1-FITC (polyclonal Sheep IgG, Bio-Techne, Minneapolis, MN).
Cells were analyzed using a LSRFortessa and the data were analyzed using FlowJo V10
by first gating on CD11bhighF4/80high cells.
Stimulation of Splenocytes with Heat-Killed S. aureus
Starter cultures of S. aureus strains were washed three times in 10 mL PBS then
normalized to 109 CFU/mL by OD600 nm ~ 1.200. S. aureus was then diluted in PBS to 3.5
x 108 CFU/mL and heat-killed at 65°C for 1 hr. Splenocytes from naïve WT or MyD88
KO mice were harvested and seeded (3.5 x 105 cells per well) into a Falcon 96-well flatbottom tissue culture plate in 200 μL RPMI medium. For cell depletion experiments,
target cells were incubated with anti-CD16/32 antibody for 15 min on ice, then stained
with biotinylated anti-CD3ε (145-2C11), biotinylated anti-NK1.1 (PKC136), or
biotinylated anti-CD11b (M1/70) antibodies prior to cell separation using the BD IMag
cell separation system. Cells were stimulated by adding 10 μL heat-killed S. aureus
preparation to MOI 10 for 24 hr. For SAg-based stimulation, cells were stimulated with
33% S. aureus culture supernatant for 24 or 96 hr. For neutralization experiments, 1
μg/mL anti-IL-12p40 (17.8), 10 μg/mL anti-IL-18 (YIGIF74-1G7, Bio X Cell, West
Lebanon, NH), or 10 μg/mL Rat IgG2a κ isotype control (RTK2758) antibodies were
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included in the medium during stimulation. Culture supernatants were collected and
assessed for cytokines and chemokine levels by CBA using LSRFortessa.
EPS Stimulation of Peritoneal Macrophages In Vitro
Peritoneal cells from naïve BALB/cJ mice were harvested by lavage with 300
mL/kg RPMI medium. Cells were incubated with anti-CD16/32 (93) antibody for 15 min
on ice, then stained with biotinylated anti-F4/80 (BM8) antibody prior to purification
using BD IMag cell separation system. F4/80+ cells (5 x 105) were seeded into a Falcon
96-well flat-bottom tissue culture plate in 200 μL RPMI medium and stimulated with 1
or 5 μg/mL EPS or 10 ng/mL S. enterica LPS (MilliporeSigma). At 24 hr, supernatants
were assessed for levels of cytokines and chemokines by CBA using LSRFortessa.
Measurement of NF-κB Activation
RAW 264.7 NF-κB/AP-1-secreted embryonic alkaline phosphatase reporter cell
line (RAW-SEAP) was obtained from Dr. Jay Radke at Idaho Veterans Research and
Education Foundation in Boise, ID. RAW-SEAP cells (105) were seeded into Falcon 24well tissue culture plate (Corning) in 500 μL RPMI medium 1 day prior to stimulation
with 0.1-1 μg/mL EPS, 0.5-5 μg/mL ΔEPS, or 10 ng/mL S. enterica LPS. At 24 hr,
culture supernatants were collected, and the endogenous alkaline phosphatase activity
was heat-inactivated at 68°C for 30 min. The SEAP activity in supernatants were
measured by mixing the supernatant with equal volume (50 μL each) 1-step paranitrophenyl phosphate (PNPP) substrate solution (Thermo Fischer Scientific) and
measuring absorbance at 405 nm using a BioTek ELx800 absorbance microplate reader.
Analysis of IL-4Rα Expression by Peritoneal Macrophages
Total peritoneal cells (3 x 105) from C57BL/6J mice were seeded into Falcon 48well tissue culture plate (Corning) in 400 μL modified RPMI and stimulated with 5
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μg/mL EPS or ΔEPS in the presence or absence of 5 μg/mL neutralizing anti-IL-10
(JES5-16E3) antibody or Rat IgG1 κ isotype (RTK2071) antibody. Cells were scraped 24
hr later and incubated with anti-CD16/32 (93) antibody for 15 min on ice. Cells were
then stained with anti-CD11b-APC (M1/70), anti-F4/80-APC/Cy7 (BM8), and anti-IL4Rα-PE (I015F8) antibodies and analyzed by flow cytometry using FACSCantoII or
LSRFortessa. Data were analyzed using FlowJo V10.
In Vivo Cytokine Neutralization
For IL-10 and TNF-α neutralization experiments, mice were treated with 250 μg
neutralizing anti-IL-10 (JES5-2A5, Bio X Cell) or 500 μg neutralizing anti-TNF-α
(XT3.11, Bio X Cell) antibodies by i.p. injection 1 day prior to EPS i.p. injection.
Flow Cytometric Characterization of Splenic Myeloid Compartment
WT or TLR4 KO mice were treated with PBS or EPS by i.p. injection. Splenocytes
were harvested the next day and incubated with anti-CD16/32 (93) antibody for 15 min
on ice. Cells were stained with anti-CD11b-APC/Cy7 (M1/70), anti-CD11c-APC (N418),
anti-Ly6C-PE (HK1.4), and anti-Ly6G-FITC (1A8). Cells were analyzed using
LSRFortessa. Data were analyzed using FlowJo V10.
Stimulation of Bone Marrow Neutrophils
Mouse tibias and femurs were flushed with 3 mL RPMI medium to harvest bone
marrow cells. Bone marrow cells were layered over a Histopaque gradient established
using Histopaque 1077 layered over Histopaque 1119 (MilliporeSigma). Neutrophils
were isolated by centrifugation at 800 x g for 30 min at room temperature without
brakes. The interface layer containing bone marrow neutrophils (BM-PMNs) were
carefully collected and washed twice in 10 mL modified RPMI medium. BM-PMNs (105)
were seeded into Falcon 96-well flat-bottom plate in 200 μL modified RPMI and
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stimulated with 5 μg/mL EPS or ΔEPS, or 10 ng/mL S. enterica LPS for 24 hr. Culture
supernatants were collected and assessed for cytokine and chemokine levels using CBA.

CHAPTER THREE
RESULTS
B. subtilis-derived EPS Attenuates Bloodstream Infection by S. aureus
To test our hypothesis that EPS could limit inflammation during systemic
infections to improve outcomes, we administered EPS to mice one day prior to, and one
day following infection with S. aureus USA300 LAC, a clone of an epidemic communityacquired (CA)-MRSA strain from Los Angeles County (Miller et al., 2005), through the
retro-orbital venous plexus. This mimics direct seeding of the bloodstream as it could
occur during invasive surgical procedures or intravenous (IV) drug use. We found that
whereas all PBS-treated mice died by 3 d.p.i., more than 50% of EPS-treated mice
survived (Figure 3A).

Figure 3: Effect of EPS on S. aureus Bloodstream Infection Outcomes in
Mice. Mice were treated with EPS on -1 and 1 d.p.i. and infected systemically with S.
aureus. A. Survival analysis. Any mice with more than 20% body weight loss were
considered dead. Data analyzed using Mantel-Cox test. B. % body weight. Error bars
represent standard deviation (SD). N = 19 (PBS), 21 (EPS). Data pooled from 6
independent experiments. ****P<0.0001. Adopted from Paik and colleagues, Infection
and Immunity, 2019.
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We also found that EPS-treated mice lost less weight compared to PBS-treated mice
(Figure 3B), suggesting that the overall burden of disease was reduced.

Figure 4: Effect of EPS on Systemic Inflammation During S. aureus
Bloodstream Infection at 1 d.p.i. Serum levels of cytokines and chemokines were
measured in PBS- or EPS-treated mice after systemic S. aureus infection on 1 d.p.i. using
CBA. Each triangle represents one mouse. Bars represent mean. N = 12. Data pooled from
3 independent experiments. *P<0.05. **P<0.01. ***P<0.001. ****P<0.0001. Adopted
from Paik and colleagues, Infection and Immunity, 2019.
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We could notice the beneficial effect of EPS even with a single dose early during disease,
since even at 1 d.p.i., before the second dose of EPS was administered, EPS-treated mice
had lost less weight compared to PBS-treated mice (Figure 3B). This suggests that pretreatment with EPS reduces the burden of disease induced by systemic S. aureus
infection, increasing host survival.
Given that EPS has anti-inflammatory properties (Paynich et al., 2017), we
assessed the levels of serum cytokines and chemokines in EPS-treated mice. Indeed,
serum levels of IL-1α, IL-12p70, IFN-γ, MCP-1, MIP-1α, MIP-1β, and TNF were reduced
in EPS-treated mice compared to PBS-treated mice at 1 d.p.i. (Figure 4), indicating
that EPS limits systemic inflammation early during disease. We did not observe any
differences in serum IL-6 and KC levels, and we could not detect IL-2 at this time (data
not shown). At 3 d.p.i., time-point representing peak disease, the serum levels of KC
and TNF were reduced while serum levels of MCP-1 trended lower as well (Figure 5).
No differences in serum levels of IL-6, IL-12p70, MIP-1α, and MIP-1β could be observed,
and IFN-γ was not detectable at this time (data not shown). This suggests that a
single dose of EPS reduces systemic inflammation during systemic S. aureus infection.

Figure 5: Effect of EPS on Systemic Inflammation During S. aureus
Bloodstream Infection at 3 d.p.i. Serum levels of cytokines and chemokines were
measured in PBS- and EPS-treated mice after systemic S. aureus infection on 3 d.p.i.
using CBA. Each dot represents one mouse. Bars represent mean. N = 10 (PBS), 11 (EPS).
Data pooled from 3 independent experiments. *P<0.05. **P<0.01. Adopted from Paik
and colleagues, Infection and Immunity, 2019.
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Figure 6: Effect of EPS on S. aureus Burden in Organs During Systemic
Infection. S. aureus burden in organs were assessed by determining CFU S. aureus in
organ homogenates by dilution plating, from PBS- and EPS-treated mice following
systemic infection. A. CFU S. aureus at 1 d.p.i. Data pooled from 2 independent
experiments. N = 8. B. CFU S. aureus at 3 d.p.i. Data pooled from 2 (spleen) or 6 (liver
and kidney) independent experiments. N = 8 (spleen), 18 (liver), 17 (kidney). C. CFU S.
aureus in blood at 6 h.p.i. Each triangle represents one mouse. Bars represent mean.
Data pooled from 2 independent experiments. N = 9 (PBS), 10 (EPS). *P<0.05.
**P<0.01. ****P<0.0001. Adopted from Paik and colleagues, Infection and Immunity,
2019.
While EPS did not alter pathogen colonization in the C. rodentium-induced colitis
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model (Jones et al., 2014), we still tested if EPS alters S. aureus colonization during
infection by assessing bacterial load within organs. To our surprise, EPS-treated mice
had 8-fold reduced CFU S. aureus in the spleen and 3-fold reduced CFU S. aureus in the
liver at 1 d.p.i. (Figure 6A), suggesting that EPS reduces bacterial burden. A 3-fold
decrease in CFU S. aureus was noted in the liver at 3 d.p.i., although not statistically
significant (Figure 6B). No difference in the bacterial load was observed in the spleen
at 3 d.p.i., and in the kidney at all time points assessed (Figure 6A and B). Since the
beneficial effect of EPS was noted as early as 1 d.p.i., we tested if EPS-treated mice have
reduced bacterial burden at an earlier time point by assessing the circulating numbers of
S. aureus. We found that EPS-treated mice had 3-fold lower CFU S. aureus in the blood
as early as 6 hours post infection (h.p.i.) (Figure 6C). Together, these data suggest that
EPS reduces bacterial burden early during systemic infection by S. aureus.
EPS Protection from S. aureus Bloodstream Infection Through TLR4
EPS protects mice from C. rodentium-induced colitis through the inhibition of T
cell activation that drives disease, and any changes in pathogen colonization could not
be observed in that model (Jones et al., 2014). In S. aureus bloodstream infection, EPStreated mice had reduced bacterial burden in multiple organs (Figure 6), indicating
that in this model, EPS had an antimicrobial effect. B. subtilis has been demonstrated to
produce bacteriocins, including those with antimicrobial activity against Gram-positive
pathogens like L. monocytogenes and S. aureus (Liu et al., 2015; Shelburne et al., 2007).
Therefore, one possibility for the reduced bacterial load in EPS-treated mice is that our
EPS preparations contain antimicrobial properties. We tested this by culturing S. aureus
in the presence of EPS in vitro and found that EPS did not affect S. aureus growth
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(Figure 7), suggesting that the EPS preparation does not have direct antimicrobial
activity against S. aureus.

Figure 7: Effect of EPS on S. aureus Growth In Vitro. Overnight culture of S.
aureus AH1263 was subcultured 1:100 in TSB containing noted concentrations of EPS
and growth was monitored over time. Error bars represent SD. N = 3.
The other possible explanation for EPS reducing pathogen burden during
infection is through indirect mechanisms, by modulating the host immune system, for
example. The protection from C. rodentium-induced colitis by EPS requires TLR4 and
MyD88 (Jones et al., 2014; Paynich et al., 2017), suggesting that EPS modulates host
immunity through TLR4-MyD88 signaling. To test if protection from S. aureus
bloodstream infection by EPS occurs through immune modulation, we asked whether
TLR4 is required for EPS protection using TLR4-deficient mice. We treated wild-type
and TLR4 KO mice with EPS one day prior to systemic infection with S. aureus and
found that while EPS-treated wild-type mice lost less weight compared to PBS-treated
mice at 1 d.p.i., this difference was not observed between PBS- and EPS-treated TLR4
KO mice (Figure 8A).
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Figure 8: Role of TLR4 on EPS Protection from S. aureus Bloodstream
Infection. Wild-type (WT) or TLR4 KO mice were treated with PBS or EPS one day
before S. aureus bloodstream infection. A. % body weight at 1 d.p.i. Data pooled from 4
independent experiments. N = 13 (TLR4 KO PBS), 14 (all groups). B. CFU S. aureus in
organ homogenates at 1 d.p.i. Each triangle represents data from one mouse. Bars
represent mean. Data pooled from 2 independent experiments. N = 8 (WT), 7 (TLR4 KO
PBS), 9 (TLR4 KO EPS). *P<0.05. **P<0.01.
We also assessed the bacterial burden within organs and found that while EPS-treated
WT mice had reduced CFU S. aureus in spleen and liver at 1 d.p.i., EPS-treated TLR4
KO mice did not have such a reduction in splenic bacterial burden and no difference in
hepatic CFU S. aureus compared to PBS-treated TLR4 KO mice (Figure 8B). As before,
we did not see any difference in CFU S. aureus in kidney between all groups (Figure
8B). These data suggest that the reduction of the bacterial burden during systemic S.
aureus infection depends on the modulation of host immunity by EPS through TLR4.
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Figure 9: Role of TLR4 on EPS Inhibition of Early Systemic Inflammation
During S. aureus Bloodstream Infection. WT or TLR4 KO mice were treated with
EPS 1 day prior to systemic S. aureus bloodstream infection. Serum levels of cytokines
and chemokines were determined using CBA. Each triangle represents data from one
mouse. Bars represent mean. Data pooled from 3 independent experiments. N = 8
(TLR4 KO PBS, IL-12p70), 9 (all groups, IL-12p70), 11 (TLR4 KO PBS, all groups), 12
(all groups). *P>0.05. **P>0.01. ***P>0.001. ****P>0.0001.
We also tested if EPS affects inflammation during disease in a TLR4-dependent manner
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by measuring serum levels of cytokines and chemokines from the infected mice in
Figure 8. The levels of pro-inflammatory cytokines and chemokines IL-12p70, IFN-γ,
KC, and TNF were reduced in EPS-treated WT mice, but not in EPS-treated TLR4 KO
mice (Figure 9), indicating that the reduction in systemic inflammation by EPS during
systemic S. aureus infection requires TLR4. Together, these data indicate that EPS
protects hosts from systemic S. aureus infection by modulating the host immune
response through TLR4, resulting in both reduced bacterial burden and systemic
inflammation.
Anti-Bacterial Activity of EPS-Induced Peritoneal Macrophages
The initial host response to S. aureus infection is characterized by an influx of
innate immune cells, particularly neutrophils and MΦs, designed for phagocytosis of
invading pathogens and intracellular killing. EPS protects mice from systemic S. aureus
infection, reducing bacterial load early during disease through modulation of host
immunity through TLR4. In addition, EPS is known to exert its functions through MΦs
in C. rodentium-induced colitis, albeit through the anti-inflammatory polarization of
MΦs (Paynich et al., 2017). Therefore, we hypothesized that EPS might reduce bacterial
burden during infection by bolstering the two primary antimicrobial functions of innate
immune cells: by increasing bacterial uptake or by increasing intracellular killing. We
first incubated total peritoneal cells from PBS- and EPS-treated mice with opsonized S.
aureus for 30 min to assess bacterial uptake and found no difference between the
number of S. aureus CFU taken up by cells (Figure 10), indicating that EPS did not
affect bacterial uptake by immune cells.
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Figure 10: Effect of EPS on Peritoneal Cell Restriction of S. aureus Growth.
Peritoneal cells (106) from PBS- or EPS-treated Balb/cJ mice were infected ex vivo with
opsonized S. aureus at MOI 1. CFU internalized S. aureus was assessed at 30 min after
washing cells of free bacterium (left). Washed cells were further cultured and CFU S.
aureus was assessed at 4 hr (right). Each triangle represents data from one mouse. Bar
represents mean. N = 4 (PBS), 5 (EPS). ****P>0.0001.
To test if EPS enhances immune cell-mediated killing of internalized S. aureus, we
continued to culture washed cells and found that by 4 hr, cells from EPS-treated mice
had less CFU S. aureus then PBS-treated mice (Figure 10), suggesting that EPS
enhances immune cell restriction of S. aureus growth.
The two principal immune cells that mediate phagocytic killing of bacteria are
neutrophils and MΦs. Protection from C. rodentium-induced colitis by EPS requires
MΦs, since i.p. administration of clodronate-loaded liposomes to deplete MΦs negated
the protective effects of EPS (Paynich et al., 2017). Therefore, we took the same
approach to test if MΦs were responsible for the restriction of S. aureus growth in EPStreated mice. We administered clodronate-loaded liposomes to mice prior to PBS or EPS
treatment which resulted in a reduction in percent peritoneal CD11b+F4/80+ cells (MΦs)
in both PBS- and EPS-treated mice (Figure 11). We also observed an increase in the
percent CD11b+Ly6G+F4/80- cells (PMNs) in EPS-treated mice and in both clodronate-
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loaded liposome treated mice (Figure 11). We infected these cells with opsonized S.
aureus to test their capacity to restrict S. aureus growth as before and found that while
cells from mice treated with EPS and control liposomes had lower CFU S. aureus by 5 hr,
cells from mice with EPS and clodronate-loaded liposomes did not (Figure 12),
indicating that peritoneal MΦs are required for restriction of S. aureus growth in vitro.

Figure 11: In Vivo Depletion of Peritoneal Macrophages Using Clodronate-Loaded Liposomes. ND4 Swiss
Webster mice were given 200 μL PBS- or clodronate-loaded liposomes by i.p. injection 1 day prior to i.p. EPS injection.
Peritoneal cells were harvested 1 day later and analyzed by flow cytometry. Representative data from 2 experiments.
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Figure 12: Effect of EPS on Restriction of S. aureus Growth in the Absence
of MΦs. Peritoneal cells (106) were harvested from EPS-treated ND4 Swiss Webster
mice, depleted of MΦs by pre-treatment with clodronate-loaded liposomes 1 day before
treatment with EPS, 1 day after EPS and were infected with opsonized S. aureus at MOI
1. After washing, growth of internalized S. aureus was monitored over time. Error bars
represent SD. Data pooled from 4 independent experiments. N = 4. *P<0.05.

EPS is thought to polarize MΦs into the anti-inflammatory M2 phenotype, which
in turn limits the activation of T cells to protect hosts from inflammatory diseases such
as C. rodentium-induced colitis (Paynich et al., 2017). Generally, M2 MΦs are not
associated with antimicrobial functions. In fact, Arg-1-expressing MΦs have been found
associated with S. aureus persistence in a murine model of catheter-associated biofilm
infection (Thurlow et al., 2011). Therefore, we hypothesized that two reasons underlie
the apparent anomaly of EPS-induced MΦs restricting S. aureus growth ex vivo. For one,
EPS-induced M2 MΦs are typically detectable 3 days after i.p. EPS injection (Paynich et
al., 2017), so at earlier time points, the MΦs may take on pro-inflammatory
characteristics like antimicrobial activity. The other is that since MΦs modulate their
functions in response to environmental cues, the EPS-induced M2 MΦs may increase
their antimicrobial activity in response to infection by S. aureus. To test this, we isolated
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peritoneal F4/80+ MΦs from PBS- or EPS-treated mice at 3 days after i.p. EPS injection
and tested their capacity to restrict S. aureus growth ex vivo. We found that whereas
peritoneal F4/80+ cells from EPS-treated mice had lower CFU S. aureus than F4/80+
cells from PBS-treated mice by 5 hr, F4/80- cells from PBS- and EPS-treated mice did
not show any difference in CFU S. aureus (Figure 13), confirming that EPS-induced
peritoneal MΦs, previously demonstrated to be anti-inflammatory M2 MΦs (Paynich et
al., 2017), restrict S. aureus growth.

Figure 13: Effect of EPS on Peritoneal MΦ-Mediated Restriction of S. aureus
Growth. Peritoneal F4/80+ and F4/80- cells (5 x 105) harvested from PBS- or EPStreated mice 3 days after EPS injection were infected with opsonized S. aureus at MOI 1.
After washing, growth of internalized S. aureus was assessed over time. Error bars
represent SD. Data pooled from 4 independent experiments. N = 7 (F4/80+ PBS), 8
(F4/80+ EPS), 5 (F4/80- PBS), 6 (F4/80- EPS). *P<0.05. **P<0.01. Adopted from Paik
and colleagues, Infection and Immunity, 2019.
A classic mechanism by which phagocyte kill bacteria or restrict their growth
internally is the production of ROS and RNS. After uptake, phagocytes use NADPH
oxidase that catalyzes the reaction of NADPH and O2 to generate O2-, which is then used
to generate a variety of reactive oxidants that damage microbial processes (Sbarra and
Karnovsky, 1959; Segal, 1987; Xie et al., 1992).
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Figure 14: Effect of EPS on Peritoneal MΦ Production of ROS. Peritoneal cells
were harvested from PBS- or EPS-treated mice 3 days after EPS injection. Cells (106)s
were incubated with A. CellROX Green or B. MitoSOX Red ROS indicators in the
presence of absence of infection with opsonized S. aureus at MOI 1. MFI of ROS
indicators on CD11bhighF4/80high cells were assessed by flow cytometry. Each triangle
represents data from one mouse. Bars represent mean. Data pooled from 5 (CellROX) or
2 (MitoSOX) independent experiments. N = 9 (CellROX), 5 (MitoSOX, PBS), 6
(MitoSOX, EPS). *P<0.05. **P<0.01. ****P<0.0001. Adopted from Paik and colleagues,
Infection and Immunity, 2019.
To determine if EPS-induced MΦs use ROS to restrict the growth of internalized S.
aureus, we measured ROS levels in EPS-induced MΦs after infection with opsonized S.
aureus ex vivo using a fluorescent ROS indicator, CellROX Green. There was no
difference in CellROX Green staining between CD11bhighF4/80high MΦs from PBS- and
EPS-treated mice freshly isolated, but upon infection with S. aureus ex vivo, MΦs from
EPS-treated mice had increased CellROX Green staining compared to MΦs from PBStreated mice, which failed to increase CellROX staining (Figure 14A). This suggests
that EPS-induced MΦs, while not increased in ROS levels at baseline, can increase ROS
during infection. Another source of ROS is the mitochondria, thought to be produced
through mitochondrial respiratory metabolic processes (Boveris et al., 1976; Turrens
and Boveris, 1980).
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Figure 15: Restriction of S. aureus Growth by EPS-Induced Peritoneal MΦs
and ROS Production. Peritoneal F4/80+ cells (5 x 105) from PBS- or EPS-treated
mice were harvested 3 days after i.p. EPS. Cells were infected with opsonized S. aureus
at MOI 1, then monitored for S. aureus growth after washing in the presence or absence
of 2 μM DPI in the medium. Error bars represent SD. Data pooled from 4 independent
experiments. N = 6. *P<0.05. **P<0.01. Adopted from Paik and colleagues, Infection
and Immunity, 2019.
This mtROS can be used to augment phagocyte antibacterial activity (West et al., 2011),
and mtROS was recently reported to play a role in MΦ responses against S. aureus
(Abuaita et al., 2018). M2 MΦs are associated with mitochondrial metabolic processes
compared to M1 MΦs that rely more on glycolysis (Huang et al., 2014; 2016; RodríguezPrados et al., 2010), and tissue-derived mtROS was demonstrated to promote
differentiation of M2 MΦs in vivo (Formentini et al., 2017). Given this, we hypothesized
that EPS-induced peritoneal MΦs might harbor increased levels of mtROS. To test this,
we stained the peritoneal cells as in Figure 14A with MitoSOX Red mtROS indicator
and found that CD11bhighF4/80high LPMs from EPS-treated mice had higher levels
MitoSOX Red staining compared to PBS-treated mice at baseline (Figure 14B),
indicating that EPS-induced MΦs have increased mtROS.
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Figure 16: Effect of EPS on MΦ Production of RNS. F4/80+ cells (105) from
PBS- and EPS-treated mice were stimulated with 10% S. aureus culture supernatant
and RNS levels were determined using the Griess test. Each triangle represents data
from one mouse. Bars represent mean. Data pooled from 2 independent experiments.
N = 4.
Both cells had increased MitoSOX Red staining upon infection with S. aureus beyond
baseline levels, and EPS-induced MΦs had mtROS levels that were even higher (Figure
14B), consistent with the previous reports that mtROS plays a role in MΦ responses to S.
aureus infection. To confirm that this increase in ROS production was responsible for
restriction of S. aureus growth by EPS-induced MΦs, we repeated the restriction assay
as in Figure 13 in the presence of DPI, a general ROS inhibitor (Cross and Jones, 1986).
We found that in the presence of DPI, restriction of S. aureus growth by EPS-induced
MΦs was abrogated (Figure 15). We also measured RNS production from EPS-induced
MΦs using the Griess test. However, supernatants from the MΦ cultures from S. aureus
infection ex vivo from Figure 13 did not have detectable RNS levels (data not shown).
We then stimulated F4/80+ peritoneal cells from PBS- and EPS-treated mice with
culture supernatants of S. aureus to compare their RNS-producing capacity and found
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no difference in RNS production (Figure 16), suggesting that an increase in RNS
production is likely not responsible for increased restriction of S. aureus growth ex vivo.
Together, these data suggest that EPS reduces bacterial burden by inducing MΦs that
restrict S. aureus growth through ROS.
Effect of EPS-Induced Macrophages on S. aureus Superantigen-Induced
Activation of T Cells
EPS was previously demonstrated to induce anti-inflammatory M2 MΦs that
limit T cell activation (Paynich et al., 2017). Here, we found that these MΦs restrict S.
aureus growth through ROS production, a feature classically associated with proinflammatory M1 MΦs. We reasoned that this apparent paradox could be explained by
the flexible nature of MΦs, constantly modulating their functions according to
environmental cues (Gautier et al., 2012; Murray et al., 1985). If this is the case, we
hypothesized that EPS-induced M2 MΦs, when infected with S. aureus, may convert to
pro-inflammatory M1 MΦs to deal with the bacterial infection. It is thought that M1 and
M2 MΦ polarization is mutually exclusive because of the competition of the two M1- and
M2-defining enzymes, iNOS and Arg-1, for the same substrate (Munder et al., 1998). To
test this idea, we took advantage of the fact that S. aureus secretes both lipopeptides
that trigger pro-inflammatory responses through TLR2 (Hashimoto et al., 2006) and
SAgs that drive polyclonal activation of T cells (Peavy et al., 1970). We first tested a
system for SAg-driven splenic T cell activation in vitro using culture supernatants from
S. aureus AH1263. When C57BL/6J splenocytes were stimulated with 33% S. aureus
AH1263 culture supernatants for 4 days, we found that both CD4+ and CD8a+ T cell
proliferated, as measured by the dilution of CellTrace Violet proliferation tracking dye
(Figure 17). S. aureus LAC makes three SAgs: SEl-K, SEl-Q, and SEl-X encoded by sek,
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seq, and sex, respectively. It also harbors a gene annotated as a putative type A
enterotoxin, USA300_1559. We also stimulated the splenocytes with culture
supernatants from transposon mutants deficient in each one of these SAgs and found
that while the wild-type (JE2) stimulated proliferation of both CD4+ and CD8a+
splenocytes, mutant deficient in SEl-Q failed to stimulate proliferation (Figure 17).
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Figure 17: Effect of S. aureus SAg on Splenic T Cell Proliferation In Vitro.
Splenocytes (3.5 x 105) from mice were stimulated with 33% culture supernatant from S.
aureus for 4 days. Proliferation of CD4+ and CD8a+ splenocytes were assessed by CTV
dilution by flow cytometry. Proliferative index = % events within the “proliferated” gate.
A. Representative flow cytometry plots showing CD4+ splenocytes. B. Error bars
represent SD. Data pooled from 4 independent experiments. N = 4 (NT), 6 (all others).
Data analyzed using 1-way ANOVA with Bonferroni’s multiple comparisons test.
***P<0.001. Adopted from Paik and colleagues, Infection and Immunity, 2019.
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Figure 18: Effect of EPS-Induced Peritoneal MΦs on S. aureus SEl-Q-Mediated Proliferation and
Activation of T Cells. Splenocytes (3.5 x 105) from naïve mice were co-cultured with peritoneal F4/80+ cells (5 x 104)
from PBS- or EPS-treated mice 3 days after i.p. EPS. Cultures were stimulated with 33% S. aureus culture supernatant for
4 days. A and B. Representative flow cytometry plots showing CD8a+ splenocytes. C. T cell proliferation. D. %
CD25+CD44+ activated T cells. Each triangle represents data from individual mouse. Bars represent mean. Data pooled
from 3 independent experiments. N = 8. *P<0.05. **P<0.01. Adopted from Paik and colleagues, Infection and Immunity,
2019.
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All other mutants tested caused proliferation of T cells (Figure 17), indicating that in
the C57Bl/6J mouse background, S. aureus culture supernatants drive SEl-Q-dependent
T cell proliferation. To test if EPS-induced MΦs retain their ability to inhibit T cell
activation during S. aureus infection, we co-cultured F4/80+ cells from PBS- or EPStreated mice with splenocytes from naïve mice and stimulated them with S. aureus
culture supernatant as in Figure 17. While co-culture with F4/80+ cells from PBStreated mice had proliferated and CD25+CD44+ activated CD4+ and CD8a+ T cells, coculture with F4/80+ cells from EPS-treated mice had reduced T cell proliferation and
activation (Figure 18C and D), suggesting that even in the presence of proinflammatory conditions, EPS-induced peritoneal MΦs retain the ability to limit T cell
activation induced by S. aureus SEl-Q. To test if EPS also affects the activity of SAg in
vivo, we stimulated splenocytes from EPS-treated mice 3 days after i.p. EPS injection
with S. aureus culture supernatant ex vivo.

Figure 19: Effect of EPS In Vivo on Splenic T Cell Proliferation Induced by
S. aureus SEl-Q. Mice were treated with PBS or EPS by i.p. injection and splenocytes
were harvested 3 days later and labeled with CTV. CTV-labeled splenocytes were
stimulated with 33% S. aureus culture supernatant for 4 days and assessed for
proliferation by flow cytometry. Proliferative index = % events within “proliferated”
gate. Each triangle represents data from 1 mouse. Bars represent mean. Data pooled
from 3 independent experiments. N = 7. *P<0.05. ****P<0.0001. Adopted from Paik
and colleagues, Infection and Immunity, 2019.

94

We found that splenocytes from EPS-treated mice had reduced proliferation of both
CD4+ and CD8a+ splenocytes (Figure 19), indicating that EPS limits the activation of T
cells by SEl-Q in vivo. Together, these data suggest that EPS induced MΦs, while they
have enhanced antimicrobial capacities like that of M1 MΦs, retain their ability to limit
T cell activation like that of M2 MΦs.
Induction of Hybrid M1-M2 Macrophages by EPS
MΦs have been classically described in two polarized states: pro-inflammatory
M1 MΦs that mediate antibacterial immunity and anti-inflammatory M2 MΦs that
mediate wound healing (Murray et al., 2014). EPS-induced peritoneal MΦs have
previously been reported to be M2 MΦ (Paynich et al., 2017), but our data indicate that
these MΦs also have enhanced antibacterial capacities like that of M1 MΦs. In reality,
MΦs are flexible in nature, and their phenotypes depend on the signals they receive
from the environment (Gautier et al., 2012; Murray et al., 2014). Recently, hybrid states
of MΦs have been reported (O’Carroll et al., 2014). We hypothesized that EPS-induced
MΦs might represent such a hybrid-type, displaying both M1- and M2-like qualities. To
test this, we assessed the expression of the classical M1 marker, iNOS, and the M2
markers, CD206 and Arg-1, on EPS-induced MΦs. We found that, as previously reported,
CD11bhighF4/80high LPMs from EPS-treated mice had increased expression of CD206
and Arg-1 than LPMs from PBS- or ΔEPS-treated mice (Figure 20). In addition, LPMs
from EPS-treated mice had increased expression of iNOS than LPMs from PBS- or
ΔEPS-treated mice (Figure 20), indicating that the EPS-induced peritoneal MΦs are
hybrid MΦs that express both M1 and M2 markers.
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Figure 20: Phenotype of EPS-Induced Peritoneal MΦs. Peritoneal
CD11bhighF4/80high cells from PBS-, ΔEPS, and EPS-treated mice were analyzed 3 days
after i.p. EPS injection by flow cytometry for M1 and M2 marker expression. A.
Representative flow cytometry plots. Solid line (PBS), dotted line (ΔEPS), dashed line
(EPS). B. MFI normalized to cells from PBS-treated mice. Each triangle represents data
from one mouse. Data pooled from 3 independent experiments. N = 10 (PBS), 5 (ΔEPS),
8 (EPS). Data analyzed using 1-way ANOVA with Bonferroni’s multiple comparisons
test. **P<0.01. ***P<0.001. Adopted from Paik and colleagues, Infection and
Immunity, 2019.
Effect of EPS on S. aureus-Induced Local Inflammation In Vivo
Upon entering the bloodstream, S. aureus disseminates to and seeds virtually all
organs, setting off a complex cascade of events thought to lead to inflammation, tissue
damage, and organ failure. We demonstrated that EPS might protect hosts from
systemic S. aureus infection in part by MΦs that better control S. aureus growth and
also limit inappropriate activation of T cells by S. aureus SAg, but many other
mechanisms of protection may be at play given the complex pathophysiology of S.
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aureus bloodstream infection. We first focused on the observation that EPS-treated
mice had reduced serum levels of IFN-γ at 1 d.p.i. (Figure 4). IFN-γ is the classic
defining cytokine of type I immunity (Cher and Mosmann, 1987; Mosmann et al., 1986),
and is associated with enhancing immunity against intracellular pathogens such as L.
monocytogenes and Mycobacterium tuberculosis (Buchmeier and Schreiber, 1985;
Flynn et al., 1993). Therefore, the observation that EPS-treated mice had reduced
disease burden and reduced serum levels of IFN-γ during S. aureus infection seemed
paradoxical, given the apparent importance of IFN-γ in antimicrobial immunity.
However, neutralization of IFN-γ during S. aureus bloodstream infection was reported
to improve survival in mice (Nakane et al., 1995), and infection of IFN-γ-deficient mice
also results in improved survival compared to wild-type mice (Sasaki et al., 2000),
suggesting that under certain circumstances including S. aureus bloodstream infection,
IFN-γ has a role in promoting pathogenesis. A significant producer of IFN-γ is the T
helper 1 (TH1) cell (Cher and Mosmann, 1987; Mosmann et al., 1986), and a major S.
aureus factor that can stimulate T cells is SAgs (Peavy et al., 1970). Since EPS-induced
MΦs limit activation of T cells by SEl-Q in vitro (Figure 18), and splenocytes from
EPS-treated mice proliferate less in response to SEl-Q (Figure 19), we hypothesized
that a principal mechanism underlying protection by EPS in this model is the inhibition
of IFN-γ induced by S. aureus SAgs.
To assess the extent of the effects of EPS on limiting inflammation during S.
aureus bloodstream infection in vivo, including the induction of IFN-γ, we measured
the levels of cytokines and chemokines in the organ homogenates from PBS- and EPStreated mice. In the spleen, EPS-treated mice had reduced levels of IL-1α, IL-6, IFN-γ,
MCP-1, and TNF, and increased levels of RANTES than PBS-treated mice (Figure 21).
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Figure 21: Effect of EPS on Splenic Cytokines and Chemokine Levels
During S. aureus Bloodstream Infection at 1 d.p.i. Levels of cytokines and
chemokines were determined from spleen homogenates from PBS- or EPS-treated mice
systemically infected with S. aureus at 1 d.p.i. by CBA. Each triangle represents data
from one mouse. Bars represent mean. Data pooled from 2 independent experiments.
N = 8. **P<0.01. ****P<0.0001.
IL-2 levels were low in both PBS- and EPS-treated mice and no differences were
observed between the two groups (Figure 21). In the liver, levels of IFN-γ and MCP-1
were reduced in EPS-treated mice compared to PBS-treated mice while RANTES levels
were increased (Figure 22). A small decrease, though not statistically significant, in IL1α levels were observed in the liver of EPS-treated mice compared to PBS-treated mice
(Figure 22).

98

Figure 22: Effect of EPS on Hepatic Cytokine and Chemokine Levels During
S. aureus Bloodstream Infection at 1 d.p.i. Levels of cytokines and chemokines
were determined from liver homogenates from PBS- or EPS-treated mice systemically
infected with S. aureus at 1 d.p.i. by CBA. Each triangle represents data from one mouse.
Bars represent mean. Data pooled from 2 independent experiments. **P<0.01.
***P<0.001.
No differences in IL-6 and TNF levels were observed between the two groups, and IL-2
levels were equally low in both groups. In the kidney, the only molecule showing a
difference between the two groups was RANTES, which was increased in EPS-treated
mice compared to PBS-treated mice (Figure 23).
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Figure 23: Effect of EPS on Renal Cytokines and Chemokines Levels During
S. aureus Bloodstream Infection at 1 d.p.i. Levels of cytokines and chemokines
were determined from kidney homogenates from PBS- or EPS-treated mice systemically
infected with S. aureus at 1 d.p.i. by CBA. Each triangle represents data from one mouse.
Bars represent mean. Data pooled from 2 independent experiments. **P<0.01.
A small decrease in MCP-1 levels in EPS-treated mice compared to PBS-treated mice
was observed, although it did not reach statistical significance (Figure 23). IFN-γ and
IL-2 levels in the kidney in both groups were deficient, and no differences were observed
between the two groups (Figure 23). A much higher level of IL-6, compared to the
spleen and liver, was observed in both groups in the kidney (Figure 23). Across the
three organs, no differences in IL-1β, IL-10, IL-12p70, IL-17A, KC, MIP-1α, MIP-1β, and
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G-CSF were observed between PBS- and EPS-treated mice (data not shown).
Together, these data suggest that EPS alters local inflammation during systemic S.
aureus infection, reducing levels of cytokines and chemokines in the spleen and liver but
not in the kidney. We also confirmed that EPS reduced IFN-γ levels in the spleen and
liver but not in the kidney.
Effect of Superantigen on the Pathogenesis of Systemic S. aureus Infection
EPS limits the induction of IFN-γ both systemically and locally during S. aureus
infection, and IFN-γ-deficient mice have improved survival upon systemic infection with
S. aureus (Sasaki et al., 2000). S. aureus SAgs are major virulence factors thought to
drive polyclonal activation of T cells (Peavy et al., 1970), the significant producers of
IFN-γ (Cher and Mosmann, 1987; Mosmann et al., 1986). This ability to induce
inappropriate activation of T cells have been the focus of studies on SAgs (Bonventre et
al., 1984), and the role of SAgs in S. aureus pathogenesis have not been extensively
studied. One study assessed the role of SAg using S. aureus Newman, that encodes SEA
(Baba et al., 2008). In this study, Xu and colleagues infected mice C57Bl/6Crl (Charles
River strain) mice with sea-deficient mutant S. aureus and found that levels of IFN-γ
and IL-12 were reduced in both in the serum and liver at 8 h.p.i. compared to mice
infected with wild-type S. aureus (Xu et al., 2014). In addition, CFU S. aureus in the
liver and heart, but not the kidney and the lung, were reduced in sea mutant infected
mice compared to wild-type infected mice at 8 h.p.i. (Xu et al., 2014). We noticed that
this pattern of reduced IFN-γ levels early during infection, in the serum and the liver but
not in the kidney, along with reduced bacterial burden in the liver but not in the kidney,
was strikingly similar to that we observed in EPS-treated, S. aureus-LAC infected mice.

101

Figure 24: Role of SEl-Q on Systemic and Local Cytokine and Chemokine
Levels During S. aureus Bloodstream Infection at 1 d.p.i. Mice were infected
with wild-type (JE2) or SEl-Q-deficient mutant (selq::erm) S. aureus and levels of
cytokines and chemokines in the serum (A) and spleen (B), liver (C), and kidney (D)
homogenates collected on 1 d.p.i. were determined by CBA. Each triangle represents data
from one mouse. Bars represent mean. Data pooled from 3 independent experiments. N
= 11 (A), 7 (B-D).
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Figure 25: Role of SEl-Q on Bacterial Burden During S. aureus Bloodstream
Infection at 1 d.p.i. Mice were infected with wild-type (JE2) or SEl-Q-deficient
(seq::erm) S. aureus and CFU S. aureus in organ homogenates were determined at 1
d.p.i. Each triangle represents data from one mouse. Data pooled from 3 independent
experiments. N = 11.
We reasoned that given our hypothesis that EPS functions in part by limiting SAginduced activation of T cells in vivo, the protective phenotype of EPS should be
reproduced by infecting mice with a SAg-deficient mutant in our system as well.
We found that in the C57Bl/6J background, only SEl-Q is the active SAg at least under
in vitro conditions (Figure 17), so we tested this idea by infecting C57Bl/6J mice with
the JE2 strain (wild-type for the transposon library mutants) or the seq-deficient library
mutant (seq::erm) we used previously. However, we found that the levels of IFN-γ and
IL-12p70 were not different in all tissues tested between JE2-infected and seq::erminfected mice (Figure 24), inconsistent with the sea-deficient mutant as reported by
Xu and colleagues (Xu et al., 2014). While EPS-treated mice had reduced levels of MCP1 in the serum, spleen, and liver, the SEl-Q-deficient mutant-infected mice did not have
reduced MCP-1 levels in all tissues tested compared to wild-type-infected mice (Figure
24). IL-2 levels were low in all tissues in both groups (Figure 24). We also assessed the
bacterial load in the organ homogenates at 1 d.p.i. and found no difference in CFU S.
aureus between wild-type- and SEl-Q-deficient mutant-infected mice in all tissues
tested (Figure 25), another discrepancy compared to sea mutants described by Xu and
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colleagues and EPS-treated mice that had reduced CFU S. aureus in the spleen and liver.
Together, these data suggest that during infection with S. aureus LAC in the C57Bl/6J
mouse background, SEl-Q does not drive IFN-γ production and does not promote
bacterial survival early during infection.
Superantigen-Independent Induction of Interferon Gamma by S. aureus
We hypothesized that two possibilities could explain why the SEl-Q-deficient
mutant did not show reduced IFN-γ production as predicted based on a past study on
SEA (Xu et al., 2014). The first possibility stems from the differences in the two strains
of S. aureus used between the SEA study and our study. S. aureus Newman encodes
SEA and SEl-X (Baba et al., 2008; Wilson et al., 2011), but only SEA is responsible for
driving T cell activation in this strain (Xu et al., 2014). In contrast, S. aureus LAC
encodes SEl-K, -Q, and -X along with USA300_1559, a putative type A enterotoxin,
though only SEl-Q was responsible for T cell proliferation in vitro in the C57Bl/6J
background (Figure 17). Still, the other three SAgs could be active in vivo, which would
explain why the SEl-Q single-deficient mutant was able to induce IFN-γ during infection
(Figure 24). However, only SEl-Q had activity in vitro in S. aureus LAC just as only
SEA had activity in S. aureus Newman, making it somewhat unlikely that the other SAgs
could function in vivo at least in the C57Bl/6J background.
Another possibility is that S. aureus has a SAg-independent mechanism for
inducing host IFN-γ responses. One thing we noticed was that in vivo, IL-2 levels were
not elevated during infection with S. aureus across our experiments. IL-2 is the T cell
growth factor produced by T cells upon activation to support its proliferation (Mier and
Gallo, 1980), so the lack of IL-2 elevation during infection at 1 d.p.i. seemed to suggest
that the production of IFN-γ at this point may not be driven by T cells. Another relevant
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observation was made in a study that looked for endotoxin-induced IFN-γ responses in
mouse splenocytes. In this study, Varma and colleagues stimulated splenocytes from
BALB/c mice in vitro with LPS and a few different heat-killed bacteria, including S.
aureus, which resulted in the production of IFN-γ (Varma et al., 2002). The way in
which heat-killed S. aureus was prepared was not described by the authors, but SAgs are
not expected to be produced by heat-killed S. aureus, though there may have been some
residual SAgs in the preparation.
To confirm that heat-killed S. aureus can induce IFN-γ from splenocytes, we
isolated splenocytes from naïve C57Bl/6J mice and stimulated them with either 33% S.
aureus culture supernatant as previously for SEl-Q-based stimulation, or heat-killed S.
aureus, prepared after washing any secreted proteins away, at MOI 10 and measured
the levels of cytokines and chemokines in the culture supernatants. At 24 hr, we found
that cultures stimulated with S. aureus culture supernatant from AH1263 or JE2 had
detectable IL-2 levels while the supernatant from SEl-Q deficient mutant did not
(Figure 26A). Low levels of IFN-γ were also detectable in the wild-type supernatantstimulated cultures (Figure 26A), indicating that at 24 hr, S. aureus culture
supernatant causes a SEl-Q-dependent induction of IL-2 and a little IFN-γ, presumably
from T cells. T cell proliferation induced by S. aureus culture supernatant can be
detected by 4 days after stimulation in vitro (Figure 17), so we also measured cytokines
from the supernatant-stimulated cultures at 96 hr. At this time point, high levels of IFNγ could be detected in cultures stimulated with the two wild-type S. aureus supernatants
but not in the SEl-Q-deficient mutant (Figure 26B). At this time point, IL-2 levels in
the stimulated wells did not differ from the untreated cultures (Figure 26B), indicating
that IL-2 was no longer produced by 96 hr post stimulation. In contrast, the cultures
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stimulated with heat-killed S. aureus produced IFN-γ levels at 24 hr, and this effect was
also observed using heat-killed SEl-Q-deficient mutant S. aureus (Figure 26C),
indicating that SEl-Q was not required for IFN-γ production in response to heat-killed S.
aureus.
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Figure 26: Role of SEl-Q on S. aureus Culture Supernatant- or Heat-Killed
S. aureus-Induced Stimulation of Mouse Splenocytes. Splenocytes from mice
were stimulated with 33% S. aureus culture supernatant (A and B) or heat-killed S.
aureus at MOI 10 (C). Levels of cytokines in culture supernatant at 24 hr (A and C) and
96 hr (B) were assessed by CBA. Error bars represent SD. Representative data from 3 (A
and B) or 4 (C) independent experiments. N = 3. Data assessed using 1-way ANOVA
with Bonferroni’s multiple comparisons test. **P<0.01. ***P<0.001.
With the heat-killed S. aureus, a small increase in IL-2, although not statistically
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significant, was observed with all strains tested (Figure 26C). Together, these data
suggest that S. aureus harbors an alternative, SAg-independent mechanism to induce
IFN-γ from mouse splenocytes in vitro.
Mechanism of SAg-Independent Induction of IFN-γ by S. aureus
To elucidate the underlying mechanism by which heat-killed S. aureus induces
IFN-γ, we first tested for the cell types required for the production of IFN-γ in vitro. The
major producers of IFN-γ that can be found in the spleen are T cells, NKT cells, NK cells,
and myeloid cells, though the latter is considered a minor contribution (Emoto et al.,
1999; Fukao et al., 2000; Mosmann et al., 1986; Scharton and Scott, 1993; Yeaman et al.,
1998).

Figure 27: Splenic Cell Types Required for the Induction of IFN-γ by
Heat-Killed S. aureus. Total, CD3-, NK1.1-, or CD11b-depleted splenocytes from
mice (3.5 x 105) were stimulated with heat-killed S. aureus at MOI 10 for 24 hr. IFN-γ
levels in culture supernatants were assessed by CBA. Each triangle represents data
from one mouse. Bars represent mean. Data pooled from 4 independent experiments.
N = 7 (total splenocytes), 5 (CD3-), 4 (other groups). Data were analyzed using 1-way
ANOVA with Bonferroni’s multiple comparisons test. **P<0.01.
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To test if these cells are required for heat-killed S. aureus-induced IFN-γ, we depleted
splenocytes of CD3+ (T and NKT cells), NK1.1+ (NK and NKT cells), or CD11b+ (myeloid
cells) cells and stimulated them with heat-killed S. aureus in vitro. We found that while
depletion of CD3+ cells resulted in only a minor reduction in IFN-γ levels, depletion of
NK1.1+ or CD11b+ cells completely abrogated IFN-γ production (Figure 27), suggesting
that NK cells and myeloid cells are required.
Given that NK cells are a typical IFN-γ-producing cell type while myeloid cells
are thought to be minor contributors (Fukao et al., 2000; Scharton and Scott, 1993;
Yeaman et al., 1998) , we reasoned that the myeloid cells might be playing a supportive
role in NK cell-mediated production of IFN-γ.

Figure 28: Role of MyD88 on Induction of IFN-γ by Heat-Killed S.
aureus. Splenocytes from MyD88-deficient mice were stimulated with heat-killed
S. aureus at MOI 10 for 24 hr. IFN-γ levels were assessed by CBA. Each triangle
represents data from one mouse. Bars represent mean. Data for wild-type group
was pooled from at least 6 independent experiments including historical data for
comparison. MyD88 data pooled from 3 independent experiments. N = 4. Data
analyzed using Mann Whitney U-test. **P<0.01.
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We hypothesized that for its supportive functions, myeloid cells would interact with S.
aureus through its PRRs, mainly TLR2, to cause IFN-γ production. To test this, we
isolated splenocytes from MyD88-deficient mice and stimulated them with heat-killed S.
aureus. Here, we found that the levels of IFN-γ induced by heat-killed S. aureus were
completely abrogated in MyD88-deficient mice compared to historic data on IFN-γ
induction in wild-type splenocytes (Figure 28), suggesting that recognition of S.
aureus through PRRs was required.

Figure 29: Role of IL-12 on Heat-Killed S. aureus-Induced IFN-γ
Production by Splenocytes. Splenocytes from mice were stimulated with heatkilled S. aureus at MOI 10 in the presence of neutralizing anti-IL12p40, anti-IL-18, or
isotype control antibodies for 24 hr. Levels of IFN-γ in culture supernatants were
determined by CBA. Error bars represent SD. Representative data from 3 independent
experiments. N = 3. Data analyzed using 1-way ANOVA with Bonferroni’s multiple
comparisons test. **P<0.01.
The finding that the induction of IFN-γ requires both NK cells and myeloid cell
activation by S. aureus through PRRs could result from cytokine-dependent activation
of IFN-γ production, as previously reported for NK cells (Chan et al., 1991). To test if
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IFN-γ induction by heat-killed S. aureus occurs through cytokine-dependent activation
of NK cells, we neutralized the two known IFN-γ-inducing cytokines IL-12 and IL-18
using antibodies when stimulating splenocytes with heat-killed S. aureus. We found that
neutralization of IL-12p40 but not IL-18 or the addition of irrelevant antibody (isotype)
reduced IFN-γ levels in cells stimulated with heat-killed S. aureus (Figure 29).
Together, these data suggest that S. aureus can induce IFN-γ through a SAgindependent mechanism, by activating NK cells to produce IFN-γ through IL-12.
Effect of EPS on SAg-Independent Induction of IFN-γ by S. aureus
Our data suggest that EPS reduces IFN-γ levels during systemic S. aureus
infection, and that this IFN-γ is induced likely through both SAg-dependent and SAgindependent processes. This indicates that EPS interferes with IL-12-dependent
activation of NK cells by S. aureus, but no evidence to date exists to support the idea
that EPS affects NK cell functions. To test this, we treated mice with EPS by i.p. injection
and isolated the total splenocytes the next day. We stimulated these splenocytes ex vivo
with heat-killed S. aureus to see if EPS reduces NK cell-derived IFN-γ production. While
splenocytes from PBS-treated mice produced IFN-γ in response to heat-killed S. aureus,
splenocytes from EPS-treated mice essentially did not produce IFN-γ (Figure 30). In
addition, splenocytes from EPS-treated mice produced reduced levels of the proinflammatory cytokine IL-6 and higher levels of the anti-inflammatory cytokine IL-10
compared to cells from PBS-treated mice (Figure 30). No differences in IL-2
production were observed (Figure 30).
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Figure 30: Effect of EPS on Heat-Killed S. aureus-Induced Splenic Cytokine
Response in Wild-Type and TLR4-Deficient Mice. Splenocytes from PBS- or
EPS-treated wild-type or TLR4 KO mice were stimulated with heat-killed S. aureus 1
day after i.p. EPS injection. At 24 hr, levels of cytokines in the culture supernatants were
determined by CBA. Each triangle represents data from one mouse. Bars represent
mean. Data pooled from 6 (WT) and 3 (TLR4 KO) independent experiments. N = 14-15
(WT), 4-6 (TLR4 KO). *P<0.05. ***P<0.001. ****P<0.0001.
We then asked if this alteration of splenic cytokine response, especially the reduction in
IFN-γ, requires TLR4 by performing the same experiment with TLR4-deficient mice.
We found that in TLR4 KO mice, the reduction in IFN-γ and IL-6, along with the
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increase in IL-10 production by EPS in response to heat-killed S. aureus was abrogated
(Figure 30). These data suggest that EPS reduces NK cell production of IFN-γ in
response to S. aureus through TLR4. In addition, EPS imprints an anti-inflammatory
signature on splenic cytokine response to S. aureus through TLR4, reducing proinflammatory IL-6 production and increasing anti-inflammatory IL-10 production.
Immunostimulatory Properties of EPS
EPS bolsters antimicrobial immunity and reduces inflammation by limiting SAg
stimulation of T cells and by limiting IFN-γ production by NK cells. This “EPS-primed”
immunity results in reduced bacterial burden and limited inflammation during S.
aureus bloodstream infection, improving host survival. However, the mechanism by
which EPS is able to prime host immunity is not clear. To elucidate this mechanism, we
sought to characterize the basic immunologic properties of EPS. One observation we
focused on was that the effects of EPS, both from previous studies and from this study,
required TLR4 (Jones et al., 2014; Paynich et al., 2017). TLR4 is best characterized as
the signaling receptor for LPS, driving activation of NF-κB and subsequent production
of pro-inflammatory mediators (Hoshino et al., 1999; Kawai et al., 1999). Given that the
induction of peritoneal M2 MΦs is TLR4-dependent (Paynich et al., 2017), we
hypothesized that EPS could be activating TLR4 signaling in peritoneal MΦs. To test
this, we stimulated peritoneal F4/80+ cells with EPS in vitro and measured the levels of
cytokines and chemokines in the culture supernatant. We found that EPS treatment
resulted in induction of many pro-inflammatory cytokines and chemokines as did LPS,
including IL-6, KC, MIP-1α, MIP-1β, and TNF (Figure 31).
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Figure 31: Effect of EPS on Production of Cytokines and Chemokines by
Peritoneal MΦs. Peritoneal F4/80+ cells (105) from naïve Balb/cJ mice were
stimulated with EPS or LPS and the levels of cytokines and chemokines in culture
supernatants were measured at 24 hr using CBA. Error bars represent SD.
Representative data from 4 independent experiments. N = 3. Data analyzed using 1-way
ANOVA with Bonferroni’s multiple comparisons test. **P<0.01. ***P<0.001.
We also found that EPS stimulated the production of IL-1α, IL-1β, and MCP-1 while LPS
failed to do so (Figure 31), at least at the concentrations we tested. We also observed
that the anti-inflammatory cytokine IL-10 was produced by cells stimulated with EPS
and LPS, though the levels were higher in EPS-treated cells (Figure 31). Paynich and
colleagues previously reported that the peritoneal F4/80+ cells increased intracellular
levels of IL-4 and IL-13 upon stimulation using intracellular flow cytometry (Paynich et
al., 2017), but we did not detect any increase in IL-4 or IL-13 levels in the supernatant of
these cultures (Figure 31). We also observed that while EPS or LPS did not increase the
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expression, some baseline level of IL-12p70 production by these cells was detected
(Figure 31).
We next tested if EPS activates NF-κB activation. Paynich and colleagues
previously reported that treatment of RAW 264.7 cells increases their expression of M2
MΦ markers(Paynich et al., 2017) , suggesting that EPS also activates RAW 264.7 cells.
To test if EPS activates NF-κB, we utilized RAW 264.7 cells with a chromosomal
integration of a secreted embryonic alkaline phosphatase (SEAP) gene whose expression
is driven by NF-κB or activator protein 1 (AP-1), allowing estimation of NF-κB or AP-1
activation by measuring SEAP activity levels. We stimulated these reporter cells with
EPS for 24 hr and measured the activity of SEAP in culture supernatants.

Figure 32: Effect of EPS on NF-κB Activation. RAW-SEAP cells were stimulated
with either LPS, EPS, or ΔEPS for 24 hr and the activity of NF-κB reporter, SEAP, was
measured in culture supernatants using a colorimetric assay. Error bars represent SD.
Representative data from 4 independent experiments. N = 3. Data analyzed using 1way ANOVA with Dunnett’s multiple comparisons test. ***P<0.001.
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We found that like LPS, EPS induced SEAP activity from these cells in a dose-dependent
manner (Figure 32), suggesting that EPS activates NF-κB. ΔEPS was not able to induce
NF-κB activity at any concentrations tested (Figure 32). Together, these data suggest
that EPS harbors TLR agonistic properties in vitro.
Mechanism of EPS-Induced IL-4 Receptor Expression
EPS induces the expression of M2 MΦ markers both in vitro and in vivo
(Paynich et al., 2017). One key molecule associated with this effect has been the IL-4
receptor alpha chain (IL-4Rα), whose expression is increased in EPS-induced peritoneal
LPMs and also in EPS-treated peritoneal MΦs in vitro (Paynich et al., 2017). IL-4Rα
forms the IL-4R in complex with the common gamma chain (γc) (Russell et al., 1993),
and signaling through the IL-4R on MΦs is the best characterized method for alternative
activation (Stein et al., 1992). Two major cytokines have been demonstrated in the
literature to increase the expression of IL-4Rα on MΦs, IL-6 and IL-10 (Hutchins et al.,
2012; Mauer et al., 2014), both of which were stimulated from peritoneal MΦs by EPS in
vitro (Figure 31). To test which of these cytokines drives the increase in IL-4Rα
expression on MΦs by EPS, we neutralized IL-6 and IL-10 during EPS stimulation of
peritoneal cells using neutralizing antibodies. In a preliminary experiment, we found
that neutralization of IL-6 did not affect the increase in IL-4Rα expression by peritoneal
CD11bhighF4/80high LPMs in vitro (data not shown). However, in the presence of
neutralizing anti-IL-10 antibodies, EPS did not increase IL-4Rα expression by LPMs
(Figure 33), indicating that the EPS-driven increase in expression of IL-4Rα and in
vitro initiation of the M2 polarization requires IL-10.
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Figure 33: Requirement for IL-10 on EPS-Induced Expression of IL-4Rα
by Peritoneal MΦs. Total peritoneal cells (3 x 105) were stimulated with EPS or
ΔEPS in the presence or absence of neutralizing anti-IL-10 antibody or isotype control.
Expression of IL-4Rα on CD11bhighF4/80high cells was assessed 24 hr later by flow
cytometry. A. Representative flow cytometry data. B. Each symbol represents data
from one mouse. Bars represent mean. Data pooled from 3 independent experiments.
N = 4 (ΔEPS), 6 (all others). Data analyzed using 1-way ANOVA with Bonferroni’s
multiple comparisons test. *P<0.05. ***P<0.001.
Addition of irrelevant antibody (isotype) to EPS-treated cultures resulted in only a small
reduction in IL-4Rα expression (Figure 33).
Mechanism of EPS-Induced Suppression of NK cell IFN-γ Response to S.
aureus
We also sought to elucidate the underlying mechanisms by which EPS limits
IFN-γ production during S. aureus infection. Paynich and colleagues had previously
reported that EPS-induced M2 MΦs inhibit T cell activation through TGF-β and PD-L1
(Paynich et al., 2017). However, the mechanism by which EPS limits IFN-γ induced by
heat-killed S. aureus, which we found is driven by cytokine-dependent activation of NK
cells, is not clear. Given that TLR4 was required for EPS inhibition of NK cell IFN-γ
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response to heat-killed S. aureus, we reasoned that some of the effector molecules EPS
induces through TLR4 activation could also be required for this inhibition. We noticed
that one cytokine induced by EPS treatment of peritoneal MΦs was IL-10 (Figure 31),
an anti-inflammatory cytokine discovered because of its ability to inhibit IFN-γ
production in T cells (Fiorentino et al., 1989). We also noticed that splenocytes from
EPS-treated mice produced increased levels of IL-10 when stimulated with heat-killed S.
aureus (Figure 30). We tested if EPS requires IL-10 to suppress IFN-γ responses to
heat-killed S. aureus by administering neutralizing anti-IL-10 antibodies to mice one
day prior to EPS treatment. Our preliminary results showed that splenocytes from mice
treated with both EPS and the neutralizing anti-IL-10 antibody had reduced IFN-γ levels
just like splenocytes from EPS-treated mice (data not shown), suggesting that IL-10
was not likely the suppressive factor.
We then sought for other potential mediators by which EPS limits IFN-γ
production and focused on TNF-α that was also induced by EPS (Figure 31). TNF-α
was originally discovered as a factor induced in serum after stimulation with endotoxin
(Aggarwal et al., 1985; Carswell et al., 1975). TNF-α is generally associated with potent
pro-inflammatory activity (Osborn et al., 1989b), and is a clinically relevant target in
many inflammatory diseases. However, TNF-α has also been implicated in
immunosuppression, especially against T cells (Speiser et al., 1996), and its activity is
recognized to be more complex.
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Figure 34: Requirement of TNF-α for EPS Inhibition of IFN-γ Induced by
Heat-Killed S. aureus. Mice were treated with neutralizing anti-TNF-α antibody 1
day prior to i.p. treatment with PBS or EPS. At 24 hr, splenocytes were harvested and
stimulated with heat-killed S. aureus at MOI 10. Levels of IFN-γ were determined
from culture supernatants at 24 hr by CBA. Each triangle represents data from one
mouse. Bars represent mean. Data pooled from 2 independent experiments. N = 3.
****P<0.0001.
To test if TNF-α was required for the inhibitory effects of EPS on heat-killed S. aureusinduced IFN-γ, we administered neutralizing anti-TNF-α antibody to mice 1 day prior to
EPS treatment. Splenocytes from these mice were stimulated with heat-killed S. aureus,
and the levels of IFN-γ were measured in the culture supernatants 24 hr later. While
cells from EPS-treated mice produced less IFN-γ compared to PBS-treated mice as we
observed before, cells from EPS- and anti-TNF-α antibody treated mice did not produce
less IFN-γ than PBS- and anti-TNF-α-treated mice (Figure 34), suggesting that EPS
limits IFN-γ induced by heat-killed S. aureus, driven by NK cells, through TNF-α.
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Recruitment and Activation of Immune Cells by EPS
Another aspect of EPS we noticed was that EPS-treated peritoneal MΦs
produced high levels of chemokines KC, MCP-1, MIP-1α, and MIP-1β (Figure 31).
Chemokines are known to be responsible for the recruitment of various immune cells to
the tissue (Anisowicz et al., 1987; Martins-Green and Feugate, 1998), and since EPS
induces the production of chemokines, we hypothesized that EPS could promote
immune cell recruitment into tissues in vivo.

Figure 35: Effect of EPS on Neutrophil Recruitment to the Spleen. WT or
TLR4-deficient mice were treated i.p. with PBS or EPS. The splenic myeloid
compartment was assessed by flow cytometry 1 day later. A. Representative flow
cytometry plots showing CD11b+CD11c- splenic myeloid compartment. B. Pooled
quantification of % Ly6C+Ly6G+ PMNs and % Ly6C+Ly6C- monocytes from the
CD11b+CD11c- compartment. Each triangle represents data from one mouse. Bars
represent mean. Data pooled from 4 independent experiments. N = 9 (WT), 7 (TLR4
KO). ****P<0.0001.
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In fact, recruitment of CD11b+Ly6C+Ly6G- monocytes and CD11b+Ly6C+Ly6G+ PMNs
has been observed in the peritoneal cavity 1 day following i.p. EPS injection (Paynich,
unpublished data). EPS-treated mice have reduced bacterial load in the spleen and liver
during systemic S. aureus infection, so we tested if EPS can recruit immune cells to the
spleen in vivo 1 day after i.p. EPS treatment. We found that while neutrophils
represented about 50% of the splenic CD11b+CD11c- myeloid compartment in PBStreated mice, more than 75% of this compartment was neutrophils in EPS-treated mice
(Figure 35), suggesting that EPS induces neutrophil recruitment in the spleen. We also
observed that while in PBS-treated mice 40% of the CD11b+CD11c- myeloid cells were
Ly6C+Ly6G- monocytes, this compartment was reduced to about 15% in EPS-treated
mice (Figure 35). We also tested if this recruitment depends on EPS activation of TLR4
using TLR4-deficient mice. We found that EPS-treated TLR4-deficient mice did not
have increased percentages of Ly6C+Ly6G+PMNs compared to PBS-treated TLR4deficient mice (Figure 35), suggesting that EPS recruits neutrophils to the tissue
through TLR4 signaling. The reduction in % Ly6C+Ly6G- monocytes by EPS did not
occur in TLR4-deficient mice as well (Figure 35).
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Figure 36: Effect of EPS on Cytokine and Chemokine Production by
Neutrophils. Bone marrow neutrophils (105) isolated from WT or TLR4 KO mice were
stimulated with 5 μg/mL EPS or ΔEPS, or 10 ng/mL LPS for 24 hr. Levels of cytokines
and chemokines in culture supernatants were determined by CBA. Error bars represent
SD. Representative data from 2 independent experiments. N = 3. Data analyzed using 1way ANOVA with Bonferroni’s multiple comparisons test. ***P<0.001.
Given that EPS activates MΦs to produce cytokines and chemokines (Figure
31), and that EPS recruits neutrophils to tissues (Figure 35), we wondered if EPS could
also activate neutrophils for the production of cytokines and chemokines. We tested this
by isolating bone marrow neutrophils (BM-PMNs) using gradient centrifugation and
stimulating them with EPS in vitro. We found that stimulation with EPS and LPS, but
not ΔEPS, of BM-PMNs led to the production of IL-6, MIP-1α, and TNF (Figure 36). In
addition, production of these molecules required TLR4, as shown by the observation
that treatment of TLR4-deficient BM-PMNs with EPS and LPS did not induce the
production of these cytokines (Figure 36). Together, these data suggest that EPS can
recruit and activate neutrophils through TLR4.

CHAPTER FOUR
DISCUSSION
How Probiotics can Become Therapies
Barriers to Probiotic Therapy
Microbes are gaining an appreciation for their ability to influence many host
physiologic processes, especially the immune system. The use of microbes in order to
benefit the host is a concept first characterized by Metchnikoff more than 100 years ago
(Metchnikoff, 1908), and the practice of this is represented today by the large probiotic
industry. It is relatively easy for the general public to access an array of probiotic
products, but the majority of these products are food supplements, and only a limited
number of probiotics have been approved for use in clinical settings for specific therapy.
In 2010, the Panel on Dietetic Products, Nutrition and Allergies of the European Food
Safety Authority gave negative opinions to all health claim submissions related to
probiotics (Rijkers et al., 2011).
The reasons behind the difficulty of getting probiotics to the mainstream clinical
settings are many and complex, including things such as the discrepancy in the field on
how to measure health benefits. Still, the primary barrier is that the mechanistic basis
for how probiotics, and microbes for that matter, confer health benefits are poorly
understood. Especially concerning is the lack of knowledge on the molecular mediators
that microbes produce to confer its benefits. Getting new drugs into the bedside relies
on understanding their pharmacokinetic
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properties, which allow for the prediction of drug efficacy, tissue distribution, adverse
effects, and clearance; all are critical parameters required for clinicians to consider when
tailoring their therapeutic approach to patients. Without identification of the molecules
that microbes use to benefit hosts, characterization of the pharmacokinetic parameters
of the probiotic is difficult, and so is predicting its efficacy and the adverse effects. There
are reports of detrimental traits such as metabolic syndrome that can be conferred by
the transfer of microbiota from one individual to another in animal models (Ridaura et
al., 2013), demonstrating a need to understand the underlying mechanisms by which
microbes affect host physiology.
However, this is not to downplay the prospect of microbial therapies. In fact,
penicillin, the most famous and arguably the most successful medical therapy, is derived
from a microbe (Fleming, 1929). Given the full range of physiologic systems that
microbes are being demonstrated to affect, we suspect that studying microbes’ probiotic
benefits will reveal many novel therapeutic targets and agents that, if their mechanisms
are elucidated, could be used to improve patient care in many disciplines.
In this study, we characterized the use of an EPS molecule derived from the
probiotic bacterium, B. subtilis, in a model of systemic infection by S. aureus, to prevent
hosts from succumbing to the disease. We found that EPS does this by stimulating the
immune system through TLR4, which results in bolstering antimicrobial immunity
while limiting specific aspects of host inflammatory processes, ultimately reducing
disease burden and improving survival. However, the structure of EPS is yet unknown,
and means to detect EPS reliably in vivo do not exist. Therefore, it is currently not
possible to tract the levels of EPS after administration to hosts in vivo, preventing
studies from elucidating its pharmacokinetic properties. Developing the tools to reliably
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detect EPS in vivo would significantly advance our goal of developing EPS into a novel
therapy for clinical use, since we will be able to understand better the tissue distribution
of EPS, which will help us predict how EPS affects different host tissue sites, and
clearance of EPS from the hosts, which will help avoid potential adverse effects of EPS.
Clinical Considerations for EPS Therapy in Sepsis
We demonstrated that pre-treatment of mice with EPS improved outcomes from
S. aureus bloodstream infection that occurred one day later. In the C. rodentiuminduced colitis model, Jones and colleagues demonstrated that B. subtilis spores could
be administered to mice as late as 3 days post exposure to C. rodentium (Jones and
colleagues, unpublished data), suggesting that B. subtilis could potentially be used as a
treatment for infectious colitis. However, we did not test if EPS could be administered to
mice after exposure to S. aureus for protection. In this model, EPS-treated mice had
signs of protection that could be detected as early as 6 h.p.i. (Figure 6C), and immune
cells isolated from EPS-treated mice respond differently to S. aureus ex vivo by 1 day
after EPS treatment (Figure 10 and 30), suggesting that EPS primes the host
immunity in a way better suited for survival when challenged by S. aureus. In addition,
the peak disease symptoms occur 10 d.p.i. in C. rodentium-induced colitis, so the
administration of B. subtilis spores at 3 d.p.i. in this is still prior to the development of
disease symptoms. Sepsis patients often present to the healthcare setting after the
development of symptoms which rapidly deteriorate, making it a challenge for clinicians
to identify patients rapidly and to immediately treat them (Rhodes et al., 2017; Singer et
al., 2016). Therefore, testing if EPS could be used as a treatment for patients with an
established bloodstream infection is clinically relevant.
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Still, the pre-treatment model can be a successful therapy in many situations
regarding sepsis. One major risk factor for developing bloodstream infections is invasive
procedures. S. aureus is a major concern for these patients since S. aureus is normally
found on patients on the skin and anterior nares (Gorwitz et al., 2008). During invasive
procedures, S. aureus on the skin can get access into the bloodstream, a concern that is
managed by antimicrobial prophylaxis (Bratzler et al., 2013).
Invasive procedures are performed on a daily basis, close to 40 million episodes
reported between 2009-2014 in the UK (Abbott et al., 2017). We reason that EPS could
be used prior to an invasive procedure, to prime the patient’s immune system against
potential systemic S. aureus infection and improve outcomes. As it will be discussed
later, this approach with EPS may have some limitations given that we have not tested
EPS against other potential bloodstream pathogens; the protective mechanism of EPS
on S. aureus infection may not work, or even be detrimental, in infections by other
causes. Once again, a better understanding of the mechanisms underlying EPS
protection from S. aureus, and potentially from other etiologic agents, will help develop
EPS into specific therapies that ultimately benefit humanity.
EPS Protection from S. aureus Bloodstream Infection: Role of IFN-γ
The Duality of IFN-γ: Initial Observations
Systemic infection is a complex challenge for the host. The host must mount
aggressive pro-inflammatory immune responses to remove the invading pathogen, but
in doing so, limit overt inflammation. As we discussed previously, S. aureus harbors
numerous mechanisms to subvert host immunity, rendering the pro-inflammatory
responses ineffective. This persistence inflammation damages the surrounding tissue
and impedes organ functions, causing severe conditions such as sepsis.
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We initiated this study under the premise that EPS, through its antiinflammatory properties, could reduce inflammation during S. aureus infection to
improve disease outcomes. However, we found that the effects of EPS are more complex,
inducing hybrid MΦs that perform both pro- and anti-inflammatory functions. In
addition, EPS prevented the induction of IFN-γ during disease, a paradoxical result
given the canonical view of IFN-γ as a cytokine that enhances antimicrobial functions of
phagocytes (Held et al., 1999). Consistent with our observation, some studies
demonstrated that in S. aureus bloodstream infection, IFN-γ plays a detrimental role for
the host since neutralization of IFN-γ using antibodies or the infection of IFN-γdeficient mice led to improved survival and reduced bacterial load (Nakane et al., 1995;
Sasaki et al., 2000). EPS-treated mice had reduced IFN-γ levels both in the serum and
in organs after infection with S. aureus, leading us to conclude that by limiting IFN-γ
production, EPS reduces the detrimental effects of IFN-γ during pathogenesis, reducing
disease burden. However, the specific reason as to how the reduction in IFN-γ levels
correlates with improved disease outcomes in systemic S. aureus infection is not
apparent.
Since its discovery, IFN-γ has been characterized as a molecule driving immune
response against intracellular pathogens (Wheelock, 1965). IFN-γ mediates its effects
through its receptor, which is a heterodimer of IFN-γ receptor 1 (IFN-γR1) and IFN-γR2
(Basu et al., 1988; Hemmi et al., 1989; 1994; Soh et al., 1994). The activation of the IFNγR activates the Janus kinase-signal transducer and activator of transcription (JAKSTAT) pathway that stimulates the expression of various genes involved in immune
responses (Igarashi et al., 1994; Sakatsume et al., 1995). In spite of the studies showing
that the absence of IFN-γ led to improved survival and reduced bacterial load (Nakane
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et al., 1995; Sasaki et al., 2000), the general consensus is that IFN-γ plays a protective
role during S. aureus infection. This is because the treatment of MΦs with IFN-γ in vitro
augments their activation (Held et al., 1999; Murray et al., 1985), and treatment of
neutrophils with IFN-γ in vitro enhances their capacity to kill S. aureus (Edwards et al.,
1988). In vivo, immunization of mice through primary infection with a low inoculum of
S. aureus protects mice from subsequent re-challenge with S. aureus 8 weeks later, and
this protection is abrogated in IFN-γ-deficient mice (Sasaki et al., 2006), suggesting that
IFN-γ mediates protection in vivo. In addition, systemic administration of recombinant
IFN-γ to mice reduces mortality during S. aureus bloodstream infection (Zhao et al.,
1998), consistent with the consensus view that IFN-γ plays a protective role.
However, a closer look into the studies of S. aureus infection involving IFN-γ
reveals a more complicated story. Zhao and colleagues initially reported that the
administration of recombinant IFN-γ protected mice from S. aureus bloodstream
infection (Zhao et al., 1998). In contrast, this group previously reported that IFN-γRdeficient mice have increased arthritis severity during systemic infection by S. aureus,
but also noted that at later points of infection, fewer IFN-γR-deficient mice succumbed
to disease compared to WT mice, suggesting a pathological role of IFN-γ signaling (Zhao
and Tarkowski, 1995). These results were corroborated by another group that
administered neutralizing anti-IFN-γ antibodies to C57Bl/6 mice during infection and
found improved survival (Nakane et al., 1995). Also, Sasaki and colleagues used IFN-γdeficient mice and showed improved survival and reduced bacterial load during S.
aureus bloodstream infection (Sasaki et al., 2000), providing a view that contradicts the
general view that IFN-γ is protective.
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The Duality of IFN-γ: Role of Neutrophils
There is an apparent paradox regarding the protective and pathogenic roles of
IFN-γ during S. aureus bloodstream infection. Although the underlying reason for this
duality of IFN-γ remains unclear, one hypothesis to explain this can be derived from a
critical observation made in IFN-γ-deficient mice. When Sasaki and colleagues assessed
the kidney of infected IFN-γ-deficient mice for histopathology, they noticed smaller and
fewer abscesses, with neutrophils present but the borders unclear (Sasaki et al., 2000).
Usually, abscess from S. aureus infections show a necrotic focus containing viable
bacteria with neutrophils surrounded by a fibrous capsule. Under the premise that
abscess is a host mechanism to contain the bacterial infection, such finding of an
abscess with unclear borders would implicate incomplete control of bacterial
dissemination. However, this is not the case, since these mice had improved survival. In
addition, abscess formation is also promoted by the bacteria as well, since bacterial
factors from S. aureus are required (Cheng et al., 2009; Lam et al., 1963). This suggests
that S. aureus might utilize the abscess as a way to promote its own pathogenic program.
One target of S. aureus manipulation of host response is the neutrophil. The
infected site becomes concentrated with neutrophils as they are recruited to clear the
pathogen. These neutrophils augment their antimicrobial functions through NETosis
(Brinkmann et al., 2004). Ironically, NETosis has been implicated in S. aureus immune
evasion. Thammavongsa and colleagues assessed renal abscesses from S. aureusinfected mice using immunohistochemical staining and found that the inner parts of the
abscess only contained Ly6G+ neutrophils. In contrast, F4/80+ MΦs were concentrated
around the periphery of the abscess, excluded from the central infected foci
(Thammavongsa et al., 2013). These investigators also observed that in mice infected
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with mutants deficient in nuclease (Nuc) and adenosine synthase A (AdsA), F4/80+ cells
were found within the abscess, indicating that this mutant S. aureus failed to exclude
MΦs from the abscess. This was mediated by S. aureus converting host DNA released
from neutrophils during NETosis into deoxyadenosine, known to be toxic to MΦs
(Thammavongsa et al., 2013). Not surprisingly, infection with one of these mutants,
adsA, resulted in reduced CFU S. aureus in the kidney (Thammavongsa et al., 2009). It
should be noted that NETosis is probably not required for S. aureus to obtain DNA from
neutrophils since S. aureus can also use the pore-forming toxin LukED to directly kill
neutrophils (Alonzo III et al., 2012a) and release DNA from neutrophils. Therefore, it
can be inferred that while neutrophils play a critical role in containing the initial
infection by S. aureus, they also serve as a pool of materials that S. aureus have adapted
to utilize for immune evasion.
This view that the neutrophils are utilized by S. aureus during pathogenesis is
supported by the studies assessing the role of neutrophils in systemic S. aureus infection.
The initial studies utilized in vivo depletion of neutrophils using anti-Gr-1 antibodies
that demonstrated that 10 of 13 neutrophil-depleted mice had died from bloodstream
infection by S. aureus by 2 d.p.i. compared to 0 of 14 deaths in control mice (Verdrengh
and Tarkowski, 1997). It should be noted here that the extreme sensitivity of neutrophildepleted mice in the study by Verdrengh and Tarkowski may be due to the fact the
authors likely depleted both monocytes and neutrophils since anti-Gr-1 antibody (RB68C5) targets both Ly6C+ monocytes and Ly6G+ neutrophils. Still, another study has used
anti-Ly6G antibody (1A8) to specifically deplete neutrophils in vivo, which also
rendered mice more prone to death during S. aureus bloodstream infection (Alonzo III
et al., 2012a). The presumed protective role of neutrophils in S. aureus infection came
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into question when investigators unexpectedly observed that an influx of neutrophils
correlated with increased CFU S. aureus (Lowrance et al., 1994). In a study using an
anti-Gr-1 antibody to limit, but not deplete, neutrophils in vivo, Gresham and colleagues
found a decrease in bacterial burden during systemic S. aureus infection (Gresham et al.,
2000). Combined with the observation that S. aureus readily survives within leukocytes
(Rogers and Tompsett, 1952), these data indicate that neutrophils, while required for
host survival during S. aureus disease, also serve as a niche for S. aureus survival.
The Duality of IFN-γ: Linking IFN-γ with Neutrophils
The observation linking the alteration of abscesses in IFN-γ-deficient mice and
neutrophils came from a study in which McLoughlin and colleagues observed that
TCRα/β-deficient mice had reduced numbers of S. aureus within abscesses and reduced
local levels of CXC motif chemokines such as KC (CXCL1) and MIP-2 (CXCL8), which
correlated with reduced myeloperoxidase (MPO) activity in tissues (McLoughlin et al.,
2006). They also observed that IFN-γ-deficient mice had slightly reduced levels of KC at
6 h.p.i. and MIP-2 at 48 h.p.i., with reduced MPO activity (McLoughlin et al., 2008),
suggesting that IFN-γ promotes neutrophil recruitment through local production of
CXC motif chemokines, leading to increased bacterial burden within the abscess.
Similarly, the study of sea mutant demonstrated that sea-infected mice had reduced
levels of IFN-γ in the liver, which correlated with a reduced number of hepatic abscesses
(Xu et al., 2014). This study also reported that the number of CD11b+Ly6G+ neutrophils
was reduced in the liver by 96 h.p.i., consistent with the view that IFN-γ promotes
neutrophil recruitment (Xu et al., 2014). These data indicate that IFN-γ contributes to
recruitment of neutrophils during S. aureus infection, thereby increasing the cells S.
aureus can target for its own survival within the infected site.
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The Duality of IFN-γ: Role of Macrophages
While the studies of neutrophils reveal the nature of S. aureus-induced abscess
as a potential survival mechanism, they only reported a reduction in the number and
size of abscesses during infection. As yet, there are no data to directly explain how in
IFN-γ-deficient mice, the abscess structure was less organized, and the borders
obscured (Sasaki et al., 2000). The periphery of the abscess is described by a fibrous
capsule that surrounds the necrotic region (Kobayashi et al., 2011), and the excluded
MΦ are located just outside the periphery of the abscess (Thammavongsa et al., 2013).
MΦs are known to express a variety of matrix metalloproteinases (MMP) upon both
classical and alternative activation (Huang et al., 2012), and these MMPs mediate
breakdown of extracellular matrix components (Gross and Lapiere, 1962; Wart and
Birkedal-Hansen, 1990). We suggest that in IFN-γ-deficient mice, the reduction in
neutrophil numbers in the abscess leads to reduced S. aureus-induced toxicity against
MΦs, thereby increasing MΦ presence around the abscess. These MΦs could utilize their
MMPs to break down the fibrous capsule surrounding the abscess to gain access to the
abscess; indeed, a corresponding increase in F4/80+ cells within abscesses can be
observed when S. aureus cannot produce deoxyadenosine to exclude MΦs
(Thammavongsa et al., 2013). This MMP-mediated breakdown of the abscess border
may explain why the abscess borders are obscure in IFN-γ-deficient mice, and may also
signify that in these mice, the abscess is more accessible by immune cells, further
enhancing host responses to S. aureus. Assessing the status of extracellular matrix
components in IFN-γ-deficient mice during S. aureus infection could reveal if the
breakdown in the fibrous capsule is responsible for the obscure borders.
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Proposed Model of the Role of IFN-γ During S. aureus Pathogenesis
In conclusion, abscess formation, and the role of IFN-γ during S. aureus
infection are complex processes that require further studies to elucidate. At present, we
propose the following model (Figure 37) for the role of IFN-γ in S. aureus pathogenesis.
S. aureus induces an early IFN-γ response from T or NK cells that leads to the local
production of CXC motif chemokines such as KC (CXCL1) in the tissues, which
promotes neutrophil recruitment and initiates abscess formation (Figure 37A). The
source of CXCL1 is not known (Figure 37A). Within the abscess, PMNs take up S.
aureus for killing, but S. aureus survives within PMNs. The more PMNs take up the
bacteria, the more S. aureus survives within the PMNs, increasing the CFU S. aureus
within the abscess (Figure 37B). PMNs augment their antimicrobial functions through
NETosis, which releases chromatin to trap the invading bacteria, but S. aureus utilizes
this DNA for its own survival, killing MΦs that are additionally recruited (Figure 37B).
S. aureus also uses leukotoxins to kill neutrophils, releasing more DNA to kill MΦs
(Figure 37B).
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Figure 37: Proposed Model for the Role of IFN-γ and Abscess Formation
During S. aureus Pathogenesis. A. S. aureus stimulates IFN-γ production which
promotes PMN recruitment through chemokine production. Dashed arrow indicates
that the source of CXCL1 is not known. B. S. aureus readily survives within PMNs after
phagocytosis. S. aureus utilizes DNA from PMNs to evade MΦ-mediated immunity. C.
S. aureus excludes MΦs from the abscess outside the fibrous capsule, creating an
immune-privileged site for bacterial persistence.
These processes, stemming from the initial IFN-γ production, form an abscess that
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restricts access by immune cells, allowing S. aureus an immune-privileged environment
to persist within the host (Figure 37C).
Proposed Effect of EPS Suppression of IFN-γ on S. aureus Infection
We demonstrated that EPS prevents the production of IFN-γ during S. aureus
infection in vivo. Based on the proposed role of IFN-γ in S. aureus pathogenesis
(Figure 37), we suggest that EPS disrupts the formation of abscesses, thereby reducing
bacterial load (Figure 38). With the reduction in IFN-γ levels, the recruitment of
neutrophils to the site of infection would be disrupted, and there would be a
corresponding decrease in CFU S. aureus persisting within neutrophils (Figure 38A).

Figure 38: Proposed Model of the Effect of EPS on S. aureus within
Abscesses. A. EPS inhibits IFN-γ during S. aureus infection, disrupting neutrophilmediated abscess formation. B. Reduced neutrophil recruitment to abscesses reduces
MΦ toxicity and subsequent exclusion by S. aureus. C. EPS-induced hybrid MΦs
penetrate abscesses through MMPs, disrupting the abscess capsule to render it more
accessible by other MΦs. D. EPS-induced hybrid MΦs restrict S. aureus growth within
the abscess through increased ROS levels. Dashed arrows indicate disruption of process
by EPS. Yellow circles represent S. aureus.
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Furthermore, there would be a decrease in the amount of deoxyadenosine produced by S.
aureus using neutrophil DNA due to a reduction in neutrophil recruitment, which would
reduce toxicity against MΦs (Figure 38B). This, in turn, could increase MΦ access into
the abscess where bacteria are present, reducing S. aureus numbers (Figure 38B).
Since activated MΦs express MMPs (Huang et al., 2012), EPS-activated MΦs may also
have increased MMP expression to penetrate the abscess better (Figure 38C). We also
demonstrated that EPS-induced MΦs had increased antimicrobial activity through ROS
production (Figure 13-15), which would contribute to better pathogen control once the
cell takes up S. aureus within the abscess (Figure 38D). Visualization of the abscesses
in EPS-treated mice during S. aureus infection, particularly the periphery of the
abscesses and the surrounding extracellular matrix components, will help test the
validity of this model.
How IFN-γ Can Contribute to Protection from S. aureus
There is one key observation we made that creates a discrepancy for the
proposed model for EPS-mediated protection from S. aureus infection. We proposed
that the reduction in IFN-γ levels in EPS-treated mice disrupted the recruitment of
neutrophils to the abscess, which would then correlate with reduced CFU S. aureus
(Figure 38A). However, we observed that EPS recruits neutrophils to tissues (Paynich,
unpublished data and Figure 35). One explanation for this apparent discrepancy can
be found in yet another discrepancy, the finding that mice treated with recombinant
IFN-γ are protected from S. aureus bloodstream infection (Zhao et al., 1998). In this
case, recombinant IFN-γ was administered to mice systemically (Zhao et al., 1998),
which would theoretically activate all cells expressing the IFN-γR. While S. aureus
survives within neutrophils, and the literature suggests that neutrophils contribute to S.
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aureus persistence, IFN-γ-activated neutrophils readily kill S. aureus (Edwards et al.,
1988). Enhancing the bactericidal capacity of individual neutrophils in vivo, e.g., by
systemic administration of recombinant IFN-γ (Zhao et al., 1998), should reduce the
initial burden of S. aureus at the infected sites, leading to improved outcomes. We
observed that EPS activates BM-PMNs (Figure 36), so EPS could systemically enhance
their antimicrobial activities against S. aureus in vivo, which would lead to the better
killing of S. aureus by PMNs, thereby reducing overall bacterial burden independent of
the effects of EPS on IFN-γ and abscess formation.
The Source of IFN-γ During S. aureus Infection In Vivo
Perhaps reflective of the important role IFN-γ plays during S. aureus
pathogenesis, S. aureus harbors two classical and two alternative mechanisms to induce
host IFN-γ production. The two classical mechanisms are Ag-mediated activation of
cognate T cells and SAg-mediated polyclonal activation of T cells. In both cases, T cells
are activated and undergo proliferation and produce effector cytokines. Experimentally,
the activation of mouse T cells with CP8, a capsular polysaccharide Ag of S. aureus,
resulted in IFN-γ production 72 hr post stimulation (McLoughlin et al., 2008). In our
studies, high levels of IFN-γ were detected 96 hr after stimulation with SEl-Q containing
culture supernatants (Figure 26B). However, the in vitro kinetics of IFN-γ do not
match the kinetics of IFN-γ levels during S. aureus bloodstream infection in vivo.
Nakane and colleagues reported that during systemic S. aureus infection, serum IFN-γ
was detectable at low levels at 1 d.p.i., undetectable in the following couple days, and
then peaked at much higher levels by 5 d.p.i (Nakane et al., 1995). We also detected IFNγ in the serum at 1 d.p.i. (Figure 4), but IFN-γ was not detectable at 3 d.p.i. (data not
shown), confirming that IFN-γ is produced in a biphasic manner during S. aureus
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bloodstream infection: an early low-level response at 1 d.p.i. and a surge in levels later in
infection, between 3 and 5 d.p.i. SAg-induced IFN-γ in vitro was detected at 96 hr post
stimulation (Figure 26A and B), more in line with the timing of the in vivo surge later
in infection. In contrast, the level of IFN-γ at 24 hr after stimulation with SAg was
relatively low (Figure 26A), so it is not likely that the activation of T cells through the
two classic mechanisms is responsible for the early IFN-γ response observed at 1 d.p.i.
in vivo.
Mice infected with the SEA-deficient mutant, compared to WT, reportedly had
lower IFN-γ levels during infection (Xu et al., 2014), but we did not observe this with
our SEl-Q-deficient mutant (Figure 24). One possible explanation for this is that
because each SAg has specificities for a specific TCR Vβ sequence, the activation profile
of the SEA and SEl-Q would be different. Therefore, SEA could activate resident cells in
the liver that bear the TCR Vβ that SEA recognizes, while SEl-Q would not. Xu and
colleagues also observed that in the Newman strain, sea is encoded in the same immune
evasion cluster of β-hemolysin converting phage that encodes other immune evasion
molecules, especially those involved in evading neutrophil-mediated immunity (Xu et al.,
2014). This suggests that sea may be co-regulated in a way that promotes expression
during neutrophil influx early in the disease. In contrast, the seq gene is only neighbored
by the sek gene, so SEl-Q may not be expressed in the manner sea is expressed in vivo.
Still, the decrease in IFN-γ level in the sea-infected mice was only partial (Xu et al.,
2014), consistent with the view that S. aureus can induce IFN-γ through other means.
S. aureus has alternative mechanisms to induce IFN-γ responses that are more
rapid. We found that the stimulation of splenocytes with heat-killed S. aureus-induced
IFN-γ that was in low but detectable levels at 24 hr post stimulation (Figure 26C). The
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production of IFN-γ through this method required NK1.1+ cells, CD11b+ cells, MyD88
signaling, and IL-12 (Figure 27-29), suggesting that S. aureus activates myeloid cell
production of IL-12 that activates NK cells for the production of IFN-γ. Another pathway
may involve a specific subset of T cells. Ag-experienced CD8+ T cells were demonstrated
to produce IFN-γ within 6 hr of stimulation with Pam3CSK4 or resiquimod (R-848),
TLR1/2 and TLR7 agonists, respectively (Salerno et al., 2016). Since S. aureus
stimulates immune cells though TLR2, it is possible that these CD8+ T cells could be
activated by S. aureus directly through TLR2, leading to rapid production of IFN-γ. In
our hands, depletion of NK1.1+ cells (NK and NKT cells) resulted in complete abrogation
of IFN-γ production, but depletion of CD3+ cells (T and NKT cells) resulted in only a
slight decrease that was not statistically significant (Figure 27). Based on these data,
we suggest that NK cells are the primary mediators of the early IFN-γ response to S.
aureus infection. We cannot rule out the possibility that NKT cells and T cells, especially
certain subsets of CD8+ T cells, make a minor contribution to the rapid IFN-γ response
to S. aureus, and studies utilizing NK cell-depleted mice would allow us to determine if
non-NK cells contribute. However, we favor the idea that the NK cells are the major
contributors since in mice infected with L. monocytogenes, another Gram positive
pathogen, NK1.1+ cells were the dominant IFN-γ-producing compartment at 19 h.p.i., an
early time point in infection (Thäle and Kiderlen, 2005).
EPS Suppression of IFN-γ Production Through TNF-α
EPS suppressed splenic IFN-γ production in response to heat-killed S. aureus
(Figure 30), and this required TNF-α (Figure 34). TNF-α has been classified as a proinflammatory cytokine since its discovery as an endotoxin-induced serum factor
(Carswell et al., 1975). However, TNF-α has a much more complex set of functions,
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mediated through TNF receptor 1 and 2 (TNFR1/2). When activated, TNFR1 recruits an
adaptor protein called TNFR type 1-associated death domain protein (TRADD) which
mediates two seemingly counteractive signaling pathways: Fas-associated death domain
protein (FADD)-mediated caspase activation leading to apoptosis and TNFR-associated
factor 2 (TRAF2)-mediated NF-κB and AP-1 activation leading to pro-inflammatory
gene expression and cell survival (Hsu et al., 1995; 1996). However, most cells are
resistant to apoptosis when stimulated with TNF-α alone (Sugarman et al., 1985),
though the reason for this is still not understood. Therefore, the general view is that
TNFR1 mediates pro-inflammatory activation and survival of cells. However, a study
showed that TNFR1-deficient mice had increased percentages of CD8+ T cells after
immunization (Speiser et al., 1996), indicating that TNFR1 promotes peripheral deletion
of cytotoxic T cells. In addition, TNFR1 signaling was demonstrated to induce myeloidderived suppressor cells (MDSC) that induced T cell anergy during S. aureus peritonitis
(Ledo et al., 2018), indicating an immunosuppressive role. TNFR2 differs from TNFR1
in that it lacks the death domain. Because of this, TNFR2 was initially thought to only
mediate cell survival (Tartaglia et al., 1991). However, a later study showed that TNFR2
could also mediate cell death (Holler et al., 1992), indicating that the signals induced by
TNFR2 are also complicated. While TNFR1 is expressed ubiquitously, TNFR2
expression is more limited, generally to the immune system and the nervous system
(Ware et al., 1991; Yang et al., 2002). Predominant expression of TNFR2 is found on the
maximally suppressive subset of Treg cells (Chen et al., 2008), and TNF is thought to
increase survival and expansion of this Treg cell compartment to promote
immunoregulation in response to inflammation (Grinberg-Bleyer et al., 2010). Since
EPS induces TNF-α production, we think that some of the immunosuppressive effects of
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EPS, especially the increase in Treg cells (Paynich et al., 2017) and the reduced response
to S. aureus SEl-Q (Figure 19), may be mediated in part through TNFRs. TNF-α is also
crucial for survival during S. aureus bloodstream infection (Nakane et al., 1995),
suggesting that TNF-α-mediated effects of EPS likely play a role in protection from S.
aureus infection. Studies using TNFR1- and TNFR2-deficient mice will help us test this
hypothesis.
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Figure 39: Proposed Model for the Role of TNF-α in EPS Suppression of
NK Cell IFN-γ Production. A. EPS-induced TNF-α directly inhibits myeloid IL-12
production in response to S. aureus, reducing NK cell activation. B. EPS-induced
TNF-α indirectly inhibits myeloid production of IL-12 in response to S. aureus,
through a yet unidentified mediator cell. C. EPS-induced IFN-γ inhibits NK cell
sensitivity to IL-12, likely through a yet unidentified mediator cell. The mediator could
consist of multiple cell types and signaling pathways.
TNFR1 and TNFR2 are both expressed on NK cells, but there is no explanation
as to why EPS would require TNF-α to suppress IFN-γ production by the NK cells. This
is because TNF-α was shown to mediate the opposite for NK cells, as the addition of
TNF-α or a TNFR2 agonist enhances IFN-γ production stimulated by IL-2 and IL-12 in
human NK cells (Almishri et al., 2016). Therefore, we suggest that EPS-induced TNF-α
does not directly act on the NK cell itself. We think that there are three possible
mechanisms by which EPS-induced TNF-α limits IL-12-dependent activation of NK cells
in response to S. aureus. First, TNF-α could act on the myeloid compartment to limit
their IL-12 production in response to S. aureus (Figure 39A), leading to reduced
activation of NK cells and their IFN-γ production. While we could not detect differences
in IL-12p70 levels in spleen, liver, and kidney of PBS- and EPS-treated mice during S.

142

aureus infection (Figure 21-23), we did observe reduced serum levels of IL-12p70 in
EPS-treated mice at 1 d.p.i. (Figure 4), suggesting that EPS has the capacity to limit IL12 production. Another possibility is that EPS-induced TNF-α acts on a yet unidentified
mediator cell, perhaps an MDSC, that then inhibits the production of IL-12 in response
to S. aureus, leading to reduced NK cell activation (Figure 39B). It could also be that
this mediator cell act on NK cells to reduce their sensitivity to IL-12, such as
downregulating IL-12R levels on NK cells (Figure 39C), leading to reduced NK cell
activation by IL-12. Identifying the source of IL-12 during S. aureus infection in vivo
that is responsible for the activation of NK cells and assessing the expression of IL-12R
on NK cells will help elucidate this mechanism further.
EPS Protection from S. aureus Bloodstream Infection: Role of Macrophages
Antimicrobial Mechanisms of Hybrid Macrophages: ROS
EPS-induced MΦs were previously characterized as anti-inflammatory M2 MΦs
that limit T cell activation (Paynich et al., 2017). Our results showed that EPS-induced
MΦs are hybrid MΦs with both M1- and M2-like qualities, able to restrict S. aureus
growth through ROS and limit T cell activation by S. aureus SEl-Q. In mediating
opsonophagocytic killing, MΦs use a variety of mechanisms to kill bacteria; the two
major mechanisms are RNS and ROS production. While RNS did not explain the
enhanced restriction of S. aureus by EPS-induced MΦs, RNS was produced by these
MΦs, suggesting that RNS contributes to the restriction of S. aureus growth (Figure
16). In demonstrating that ROS was responsible for the enhanced restriction, we used
DPI, an irreversible inhibitor of NADPH oxidase (Cross and Jones, 1986). However, DPI
is known to have off-target effects that lead to inhibition of mtROS production as well
(Li and Trush, 1998), so we cannot identify the source of ROS responsible for restriction
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of S. aureus growth. However, recent studies have highlighted the close relationship
between mtROS, M2 MΦs, and killing of S. aureus, leading us to think that mtROS play
a vital role in the restriction of S. aureus growth.
ROS production from the mitochondria is thought to occur as a byproduct of
mitochondrial metabolic processes since increasing mitochondrial respiration increases
MΦ ROS levels (Arsenijevic et al., 2000). One key feature of M2 MΦ differentiation is
fatty acid oxidation (Huang et al., 2014), a mitochondrial metabolic process. Therefore,
M2 MΦs are expected to produce higher levels of mtROS, and indeed, EPS-induced
MΦs had higher mtROS levels (Figure 14B). A recent study showed that during S.
aureus infection, MΦs recruit mtROS-containing vesicles derived from the
mitochondria to the S. aureus-containing phagosomes (Abuaita et al., 2018), suggesting
that mtROS are involved in the MΦ response to internalized S. aureus. The importance
of the mitochondria in MΦ-mediated immunity is further highlighted by the discovery
that S. aureus alpha-toxin drives the mitochondria away from S. aureus-containing
phagosomes (Cohen et al., 2018), indicating that S. aureus evades the mitochondria to
promote its survival within the MΦ. While EPS-induced MΦs also increase their mtROS
levels upon infection with S. aureus, we do not know if EPS-induced MΦs utilize mtROS
to restrict S. aureus growth, Examination of the mtROS and their recruitment within
EPS-induced MΦs will help us determine if EPS-induced MΦs use mtROS for restriction
of S. aureus growth.
Antimicrobial Mechanisms of Hybrid Macrophages: Other Potential
Mechanisms
While ROS was required for restriction of S. aureus growth by EPS-induced
MΦs, we cannot rule out the possibility that other mechanisms also contribute. One
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particular way MΦs can capture intracellular pathogens for killing is through autophagy,
but it is not clear if autophagy benefits MΦs in their response to internalized S. aureus.
In fact, accumulation of autophagosomes was associated with enhanced survival of S.
aureus in BMDCs (O’Keeffe et al., 2015), suggesting that autophagy may be detrimental
for the host. However, this result is in part due to S. aureus manipulating the autophagic
processes. S. aureus is known to activate the mammalian target of rapamycin (mTOR)
through to transit into autophagosomes which prevents its maturation to promote
persistence (Schnaith et al., 2007). M2 MΦ differentiation involves the activation of the
mTOR pathway, which drives cells to rely on mitochondrial metabolism (Huang et al.,
2016). Therefore, we hypothesize that EPS-induced MΦs may have an altered state of
mTOR activation, which could alter the autophagic response to S. aureus infection. In
addition, EPS-induced MΦs could promote maturation of the autophagosomes, leading
to enhanced restriction of S. aureus within the cells. Consistent with this model, TLR4
has been implicated in promoting autophagy through Toll-IL-1R domain-containing
adaptor-inducing IFN-β (TRIF) signaling, so we think that EPS could also do this
through TLR4-TRIF signaling. We will need further studies utilizing S. aureus mutants
that cannot induce autophagy or autophagy-deficient MΦs to test if this process is
involved in EPS-mediated protection.
Induction of Hybrid Macrophages by EPS
Unlike the effector functions of EPS-induced hybrid MΦs, the mechanisms
underlying the induction of these cells by EPS is poorly understood. Paynich and
colleagues previously demonstrated that treatment of peritoneal MΦs with EPS in vitro
results in increased expression of M2 MΦ markers (Paynich et al., 2017), but these MΦs
do not recapitulate all of the functions of MΦs isolated from EPS-treated mice (data
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not shown). To understand why these in vitro-stimulated MΦs did not function like
EPS-induced MΦs in vivo, we need to consider the dynamic nature of peritoneal MΦ
subsets. The majority of peritoneal cavity MΦs at steady state are CD11bhighF4/80high
LPMs (Ghosn et al., 2010). Therefore, in vitro experiments assessing the effect of EPS
on MΦs were performed on LPMs. However, the peritoneal cavity becomes dominated
by CD11b+F4/80+/low SPMs after EPS treatment in vivo (Paynich, unpublished data),
and there is a corresponding decrease in the LPM compartment. By 3 days after EPS
treatment, the LPM compartment is restored, and the MΦ compartment then consists of
functional hybrid MΦs. While we do not know the mechanism underlying the induction
of hybrid MΦs in vivo, we propose a model that potentially explains the process
considering the dynamics of peritoneal cavity MΦs.
Ontogeny of Peritoneal Macrophages
A hint for the origins of EPS-induced hybrid MΦs can be found in the study of
peritoneal LPMs and SPMs. Ghosn and colleagues compared the LPMs and SPMs in
their ability to produce the antimicrobial molecule, RNS, and found that when isolated
20 hr after i.p. LPS treatment, SPMs increase NO levels higher than that of LPMs; SPMs
also had higher levels of MHCII (Ghosn et al., 2010). SPMs were shown to be derived
from the infiltrating CD11b+Ly6C+ monocytes (Ghosn et al., 2010), so it is thought that
these are cells recruited to mediate antimicrobial responses against invading pathogens.
EPS induces the infiltration of CD11b+Ly6C+ monocytes into the peritoneal cavity
(Paynich, unpublished data), so we hypothesize that EPS-induced hybrid MΦs may
originate from the recruited monocytes like SPMs, which could explain the enhanced
antimicrobial capacities of these cells. Consistent with this view is that EPS induces the
production of a variety of chemokines by the peritoneal F4/80+ cells (Figure 31), which
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would recruit SPMs. It should be noted that in comparing LPMs and SPMs, Ghosn and
colleagues did not assess ROS production, so we will need to confirm that SPMs have
increased ROS levels like in EPS-induced MΦs. Also, we will need to confirm if EPSinduced MΦs are derived from cells in the circulation using fate mapping or adoptive
transfer approaches.
Signals Governing EPS-Induced Macrophage Differentiation
If EPS-induced MΦs originate from the infiltrating monocytes that are classically
characterized to mediate pro-inflammatory responses, how is it that these MΦs mediate
anti-inflammatory functions as well? We think that the answer lies in the signaling
events that occur after recruitment. Paynich and colleagues demonstrated that
treatment of peritoneal MΦs increases their expression of IL-4Rα (Paynich et al., 2017),
indicating that EPS sensitizes cells to activation by IL-4 or IL-13. While we have not
assessed if this also occurs on the recruited SPMs, the increase in IL-4Rα depends on
IL-10 (Figure 33), a cytokine produced by type I IFNs, resulting from TLR4-TRIF
signaling (Chang et al., 2007). Since EPS activates NF-κB through TLR4 (Figure 32)
and induces cytokine production multiple cell types (Figure 31 and 36), we think that
EPS could be activating IL-10 production from the recruited SPMs as well, thus
increasing their IL-4Rα expression. If not, IL-10 produced by the LPMs within the
peritoneal cavity could act on the recruited SPMs to increase their IL-4Rα expression.
Signaling through the IL-4R is the classic mechanism for alternative activation of MΦs
(Murray et al., 2014), so we think that by increasing IL-4Rα expression on the SPMs,
EPS makes the SPMs prone to alternative activation, leading to their immunoregulatory
functions.
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Paynich and colleagues demonstrated that EPS treatment increases intracellular
levels of IL-4 and IL-13 on LPMs (Paynich et al., 2017), but we could not detect secretion
of IL-4 and IL-13 after treatment of peritoneal LPMs with EPS in vitro (Figure 31). In
addition, i.p. administration of EPS results in the initial disappearance of the LPMs as
the SPMs get recruited (Paynich, unpublished data), leading us to think that a different
cell is the source of IL-4 or IL-13. We do not yet know this source, but a number of
different cell types within the peritoneal cavity are known to produce IL-4 and IL-13,
leading us to think that these cells could be the source by which EPS drives the
induction of hybrid MΦs. Amongst these cells, we think that eosinophils, basophils, type
2 innate lymphoid cells (ILC2), and B cells are the likely cells since they are involved in
type 2 immune responses defined by IL-4 and IL-13. Interestingly, iNKT cells in the liver
were demonstrated to produce IL-4 after a sterile injury to drive M2 differentiation of
the recruited monocytes and promote wound healing (Liew et al., 2017), consistent with
the view that an accessory cell drives M2 differentiation in EPS-treated mice. It should
be noted that we cannot rule out the possibility that signals other than IL-4 and IL-13
drive EPS induction of hybrid MΦs, so we need to consider other signals that could
contribute.
Such an alternative signal to consider for hybrid MΦ differentiation by EPS is
MCP-1 (CCL2). During murine systemic infection, MCP-1 is produced early and is
thought to mediate the recruitment of monocytes through its receptor CCR2 (Kurihara
et al., 1997), thereby promoting inflammation. However, during systemic infection,
MCP-1 was associated with immunosuppression and increased mortality (Tsuda et al.,
2004). Blockade of MCP-1 in MΦs enhanced M1-associated gene expression while it
reduced M2-associated genes, suggesting that MCP-1 promotes M2 polarization of MΦs
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(Sierra-Filardi et al., 2014). EPS induces MCP-1 production by peritoneal LPMs (Figure
31), so MCP-1 could contribute by not only recruiting monocytes to the peritoneal cavity,
but also promote their M2 polarization in vivo. In addition, EPS-treatment results in
abrogated serum MCP-1 levels during S. aureus infection (Figure 4). This reduction in
MCP-1 during infection may promote MΦs to take on antimicrobial capacities rather
than fully adopting M2 polarization as in EPS-treated mice, leading to their hybrid state
capable of both antimicrobial and immunoregulatory functions. In addition, CCR2deficient mice show impaired IFN-γ production in response to immunization with
Mycobacterium bovis (Peters et al., 2000), another parallel observation consistent with
the abrogation of both MCP-1 and IFN-γ during S. aureus infection by EPS.
Proposed Model of the Induction of Hybrid Macrophages by EPS
Taking the above information into account, we propose the following model for
EPS induction of hybrid MΦs in the peritoneal cavity. EPS initially activates TLR4MyD88 signaling on LPMs, inducing the production of chemokines that lead to
recruitment of SPMs that have increased antimicrobial capacities (Figure 40A) (Ghosn
et al., 2010). EPS also activates TLR4-TRIF signaling, which causes IL-10 production,
driving the expression of IL-4Rα on recruited SPMs (Figure 40B). A yet unidentified
accessory cell provides IL-4 and IL-13, activating the SPMs and promoting their M2
differentiation (Figure 40C). Activation through IL-4Rα converts MΦ metabolism to
mitochondria-driven metabolism (Huang et al., 2016), and TLR4 signaling also
increases mtROS (West et al., 2011), which contributes to M2 MΦ differentiation
(Formentini et al., 2017) (Figure 40C). Due to the origin and the differentiation
pathway of EPS-induced MΦs, we propose that they harbor qualities of both M1 and M2
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MΦs, able to restrict S. aureus growth and limit T cell activation, making these hybrid
MΦs (Figure 40D).

Figure 40: Proposed Model for the Induction of Hybrid MΦs by EPS. A. EPS
activation of TLR4-MyD88 on LPMs induce chemokine production, recruiting SPMs
that have increased antimicrobial capacities. B. EPS activation of TLR4-TRIF induces
IL-10 that act on recruited SPMs to increase their IL-4Rα expression. C. An accessory
cell produces IL-4 and IL-13 that activates the SPMs through IL-4/13R, driving M2-like
differentiation. EPS may also increase fatty acid oxidation through IL-4Rα-mTORC2
signaling, and also mtROS through TLR4, promoting M2 differentiation. D. The EPSinduced MΦs have both increased antimicrobial capacities to restrict S. aureus growth
like M1 MΦs and capacity to limit T cell activation like M2 MΦs, a characteristic of
hybrid MΦs.
Mechanism Underlying Inhibition of Superantigen-Mediated T Cell
Activation
EPS-induced MΦs inhibit T cells stimulated through the TCR, using anti-CD3ε
antibodies (Paynich et al., 2017). In this model, EPS-induced MΦs inhibit T cells
through the inhibitory cytokine TGF-β and the co-inhibitory molecule PD-L1 (Paynich et
al., 2017). However, the culture supernatant of S. aureus we used for SEl-Q-mediated
stimulation of T cells contains S. aureus lipoproteins that drive pro-inflammatory
activation of immune cells. In addition, S. aureus is known to subvert adaptive
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immunity by altering the expression of co-stimulatory molecules on Ag-presenting cells
(Sanchez et al., 2017). Therefore, EPS-induced MΦs could use other mechanisms to
inhibit T cells in the presence of S. aureus-derived factors due to the pro-inflammatory
signals they receive. We will need to confirm that TGF-β and PD-L1 mediate this
inhibition or reassess the mechanisms of inhibition to understand inhibition of SAgmediated activation of T cells by EPS-induced MΦs.
Tissue-Specific Protection from S. aureus Infection by EPS
Role of Interferon-Gamma
EPS-treated mice have reduced bacterial burden in the spleen and liver, but not
in the kidney (Figure 6A and B). While we do not understand the mechanism behind
this, we suggest that it may be due to the differences in immune cells among these
tissues. DCs dominate the immune cell population within the kidney (Kaissling and Hir,
1994; Zheng et al., 2006). This is in contrast to the spleen and the liver that harbor
many MΦs and lymphocytes. Nakane and colleagues observed that IFN-γ levels in the
kidney remain at baseline levels throughout the infection (Nakane et al., 1995), and we
observed that renal IFN-γ levels in S. aureus-infected mice at 1 d.p.i. are barely
detectable (Figure 23). Therefore, we think that the inhibitory effect of EPS on T and
NK cells, and the resulting IFN-γ, in the kidney is minimal, since the kidney does not
harbor so many of these cells. Consistent with this view, sea-infected mice had reduced
IFN-γ levels in the liver but not in the kidney (Xu et al., 2014), suggesting that IFN-γ
differentially contributes to pathogenesis among organs, which could explain the lack of
EPS effects in the kidney. It should be noted that IFN-γ-deficient mice had reduced
bacterial load in the kidney, and the observation on abscess formation was made from
the kidney (Sasaki et al., 2000), suggesting that IFN-γ plays an overall pathogenic role
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in the kidney as well. Therefore, we suggest that EPS does not affect kidney
pathophysiology.
Role of Myeloid Cells
Another possibility for the failure of EPS to reduce bacterial load in the kidney
may have to do with the myeloid compartment. As discussed, DCs are the dominant
immune cell in the kidney (Kaissling and Hir, 1994). Renal DCs are thought to rapidly
recruit neutrophils upon recognition of infection such as uropathogenic E. coli (Tittel et
al., 2012). In the case of S. aureus infection, this rapid recruitment of neutrophils may
promote abscess formation, thereby increasing S. aureus survival. In contrast, the liver
harbors Kupffer cells, unique tissue resident MΦs, that clear activated neutrophils and
cellular debris (Brown et al., 2001). Clearance of neutrophils would reduce abscess
formation within the hepatic tissue and not only help clear the bacteria, but also
maintain MΦ access to the invading pathogen. Resident MΦs were recently shown to
cloak pathogens from recognition by neutrophils, preventing the initiation of abscess
formation and subsequent tissue damage (Uderhardt et al., 2019). This process may also
be occurring in the liver through Kupffer cells, reducing abscesses. In addition,
peritoneal LPMs have been demonstrated to be directly recruited to the liver during
sterile injury, where the LPMs mediated uptake of necrotic tissue debris and promoted
wound healing (Wang and Kubes, 2016); this may be another way the liver could recruit
more MΦs during S. aureus infection to clear neutrophils, suppress abscesses, and
promote wound healing. The spleen also contains specialized resident MΦs, some of
them known to mediate immunity against bloodborne pathogens (Geijtenbeek et al.,
2002), and these could also contribute to clearing activated neutrophils and provide
additional immunity against S. aureus. Additionally, EPS could enhance the
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antimicrobial capacities of MΦs in these tissues to further accentuate the difference in
responses in these tissues compared to the kidney.
Activation of TLR4 by EPS
Classic and Modern Views on the Effect of Lipopolysaccharide in Immunity
EPS has broad anti-inflammatory effects that confer host protection against a
variety of diseases where inflammation plays a role, including infectious diarrhea (Jones
et al., 2014; Paynich et al., 2017), allergic eosinophilia (Swartzendruber et al., 2019), and
sepsis. However, we found that EPS also stimulates immune cells through TLR4, leading
to the activation of NF-κB and pro-inflammatory cytokine production. The bestcharacterized ligand for TLR4 is LPS, an inducer of pro-inflammatory responses, and
the model causative agent of sepsis (Hoshino et al., 1999). However, a closer look at the
literature on LPS indicates that TLR4 can mediate immunoregulatory responses in vivo.
The first evidence of this was observed when Uchiyama and colleagues found that while
LPS administration at the time of immunization enhanced antibody responses, preinjecting mice with LPS 3 days prior to immunization reduced antibody responses
(Uchiyama et al., 1984). Since then, this phenomenon of has been studied in the context
of LPS-induced endotoxemia model and has been termed sepsis-induced
immunosuppression or immunoparalysis. Generally, the primary mechanistic focus
from these studies has been the induction of CD11b+Gr-1+ MDSCs in vivo (Greifenberg
et al., 2009; Wilde et al., 2009). Therefore, the underlying mechanism for how LPS
administration results in a suppressed host immunity is poorly understood outside of
the induction of MDSCs. Because EPS also activates TLR4, we think that some of the
immunoregulatory mechanisms of EPS could also explain sepsis-induced
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immunosuppression. This also suggests that the classic view of TLR4 signaling in
mediating pro-inflammatory responses need to be re-examined.
The modern view of immunity is that the immune system, like virtually all other
physiologic systems in the body, is subject to extensive homeostatic mechanisms. Such
an idea has been highlighted in studies of inflammation that claim the need to balance
pro- and anti-inflammatory responses. However, these processes need to be recognized
as part of the same process. We hypothesize that LPS-induced immunosuppression, and
even EPS-primed immunity, demonstrate this phenomenon: an initial proinflammatory response activated through TLR4 that results in host countermeasures to
limit and resolve inflammation. MDSCs would also fit into this view since MDSCs are
known to be induced through inflammatory mediators such as IL-1β (Elkabets et al.,
2010), representing a host response to inflammation that limits or resolves
inflammation.
Clinically, sepsis-induced immunosuppression is a primary concern, since many
patients that survive the initial inflammatory phase are vulnerable to superinfections,
presumably due to the immunosuppressed state that ensues later in the disease.
Therefore, agents that limit inflammation have not been well-accepted by the field, in
part due to concerns of worsening the immunosuppressed state of sepsis patients.
However, we suggest that limiting inflammation during the early phase of sepsis can not
only improve patient survival, but also reduce the ensuing anti-inflammatory response
that occurs in response to the initial inflammation, essentially a reflex response. In
addition, priming the host through TLR4, as shown in our EPS-treated mice, bolsters
antimicrobial immunity, indicating that the immunoregulatory effect of TLR4 does not
impair antimicrobial immunity to S. aureus. Therefore, limiting inflammation during
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the acute phase of sepsis using a TLR4-based immunotherapeutic agent such as EPS
may be a novel strategy to preserve host immunity during the late phase of sepsis. The
effect of EPS treatment on preserving host immunity during the late phase of sepsis will
need to be examined, but EPS limits activation of T cells by S. aureus SAg which
normally results in deletion of certain T cells from the repertoire, thereby providing
some evidence for EPS preserving host immunity.
EPS and LPS
EPS and LPS both activate signaling through TLR4. However, LPS is produced
as a part of the gram negative cell wall while EPS is produced by the gram positive B.
subtilis, as a part of its biofilm matrix. Therefore, the structure of EPS, while not known,
is expected to be quite dissimilar compared to LPS. While the idea of two dissimilar
molecules acting through the same receptor seems unlikely, TLR4 is known to mediate
signaling by a vast array of ligands, many of them endogenous ligands such as
fibrinogen (Smiley et al., 2001), hyaluronan (Jiang et al., 2005), and S100 proteins
(Vogl et al., 2007). The diversity of ligands for TLR4 is possible because TLR4 often
works in conjunction with co-receptors, such as CD14 and MD-2 that mediate LPS
recognition. Therefore, we hypothesize that EPS has a distinct receptor that acts as a coreceptor on TLR4 to initiate EPS-induced TLR4 signaling, a potential difference from
LPS which uses LPS-binding protein, CD14, and MD-2 (Ryu et al., 2017). While the
signal itself induced through TLR4 is very similar between EPS and LPS, there may be
some differences if a different co-receptor is used because this can affect the
downstream adaptors that are recruited or the amount of TLR4 that is endocytosed to
mediate TLR4-TRIF signaling. These differences may lead to EPS being used in
potentially different therapeutic scenarios than other TLR4-targeting agents. The
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elucidation of EPS structure, and the identification of the EPS receptor, will help us
understand the biology of EPS-induced signaling, which may even reveal a novel aspect
of TLR4 biology.
Other Cell Types that Could Mediate Protection by EPS in S. aureus
Infection
Given that EPS activates TLR4 signaling on both MΦs and neutrophils, we
hypothesize that many other cell types contribute to EPS-mediated protection from
sepsis, given that they express the yet unidentified EPS receptor. The following are a
short, incomplete list of cell types that could be affected by EPS during S. aureus
bloodstream infection.
Basophils: Basophils have been demonstrated to protect mice from sepsis induced by
cecal ligation and puncture through TNF, and these cells express TLR4 (Piliponsky et al.,
2019). TNF-α is crucial for survival during S. aureus infection (Nakane et al., 1995), and
we hypothesize that EPS could potentially induce TNF-α production by basophils,
thereby contributing to protection from sepsis.
Eosinophils: Eosinophils have recently been implicated in protection from S. aureus
sepsis, through a mechanism that is poorly understood (Krishack et al., 2019). We have
some evidence that EPS increases the percentage of eosinophils within tissues (Paynich,
Fleming-Trujillo, unpublished data), and we suggest that eosinophils could mediate EPS
protection from sepsis.
Endothelial cells: The major pathologic feature of sepsis, cardiovascular collapse, is
thought to initiate from endothelial dysfunction. Endothelial cells were demonstrated to
be activated by LPS through TLR4, but this does not lead to endothelial dysfunction as
presumed previously (Menghini et al., 2014). Instead, activation of endothelial cells
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leads to protection from sepsis, presumably from efficient recruitment of neutrophils to
the site of infection (Andonegui et al., 2009). We think that EPS could also activate
endothelial cells through TLR4, thereby contributing to protection from sepsis.
Platelets: Platelets have been demonstrated to mediate host defense against S. aureus.
One mechanism that bears uncanny similarity to EPS is the ability to enhance
macrophage uptake and restriction of S. aureus growth, mediated through IL-1β
production by platelets (Ali et al., 2017). Platelets express TLR4 (Andonegui et al., 2005),
and stimulation of platelets with LPS leads to the production of IL-1β (Brown et al.,
2013). Therefore, we think that EPS could enhance antimicrobial activities of MΦs
through TLR4-mediated activation of platelets. In addition, activated platelets have
been shown to directly kill S. aureus by releasing a yet unidentified antimicrobial
product (Ali et al., 2017), which could also be a way EPS could promote antimicrobial
immunity against S. aureus.
Concluding statement
Sepsis is one of the most dramatic manifestations of infection. Patients are
treated immediately and aggressively, but their conditions can rapidly deteriorate,
leading to high mortality rates. S. aureus is the leading cause of sepsis, and it is
incredibly challenging to treat, given its broad antimicrobial resistance profile and an
uncanny ability to subvert the immune system to persist and even promote its own
survival. Therefore, novel agents and strategies to combat systemic S. aureus infection
are critically needed. Probiotics represent a vast potential for developing new therapies,
but the mechanisms by which they benefit hosts are not known.
In this study, we demonstrated that EPS derived from the probiotic, B. subtilis,
can protect hosts from S. aureus bloodstream infection. EPS does this by priming host
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immunity through TLR4, which improves antimicrobial functions of MΦs, and limits
inflammation induced during infection. This EPS-primed immunity prevents S. aureus
from optimally subverting the host processes for its own pathogenic program, leading to
reduced disease burden and improved host survival. By priming high-risk patients with
EPS, we suggest that we can benefit patients undergoing invasive procedures by limiting
severity during subsequent infection that occurs in high frequency. Still, EPS has the
potential to affect many other aspects of host physiology beyond the few cell types we
presented here, so there could be other scenarios in which EPS could be beneficial. By
increasing our understanding of the structure, host receptor, and the molecular
pathways of EPS, we will be able to bring EPS, and more broadly TLR4-targeting
therapy, to the healthcare industry. In addition, we will be able to open the door to
microbial therapy, a novel sector of therapeutics with a vast potential to benefit
humanity.
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